

Swaziland Country Operational Plan FY 2017



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Summary of Flammed Funding by Agency and Funding Source							
		Funding Source				Total All	
						Funding	
Agency				Funding	Applied	Sources and	
Agency	GAP	GHP-State	GHP-USAID	Source Total	Pipeline	Applied	
						Pipeline	
						Amount	
State		769,642		769,642	269,468	1,039,110	
USAID		32,970,062	6,900,000	39,870,062	3,998,640	43,868,702	
DOD		0		0	717,776	717,776	
PC		1,120,000		1,120,000	0	1,120,000	
HHS/CDC	487,500	16,795,493		17,282,993	4,781,114	22,064,107	
Total	487,500	51,655,197	6,900,000	59,042,697	9,766,998	68,809,695	

Summary of Planned Funding by Budget Code and Agency

			Agency			On Hold	
Budget Code	State	DOD	HHS/CDC	PC	USAID	Amount	Total
CIRC	2,223				3,977,595	0	3,979,818
нвнс	43,648	0	5,345,806	14	5,954,108	0	11,343,576
HKID	13,808		0	863,937	6,144,005	0	7,021,750
HLAB	0		143,629		6,946	0	150,575
HMBL	0		304,971			0	304,971
HMIN	0					0	0
HTXD	4,682				5,537,490	0	5,542,172
HTXS	81,446	0	4,685,012		3,335,760	0	8,102,218
HVAB	58			0	610,301	0	610,359
HVCT	31,712	0	2,861,686		2,066,767	0	4,960,165
HVMS	468,961	0	644,698	256,007	1,531,019	0	2,900,685
HVOP	18,607	0	0	14	5,837,754	0	5,856,375
HVSI	26,972	0	557,192	0	544,487	0	1,128,651



	769,642	0	17,282,993	1,120,000	39,870,062	0	59,042,697
PDTX	4,740		246,381		212,059	0	463,180
PDCS	29,195		771,285	14	1,664,658	0	2,465,152
OHSS	7,431		221,811	14	1,452,466	0	1,681,722
МТСТ	31,419		170,557		596,158	0	798,134
IDUP	0					0	0
HVTB	4,740	0	1,329,965		398,489	0	1,733,194



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
НВНС	10,965,009	0
HKID	6,124,626	0
HVTB	1,595,081	0
PDCS	2,388,141	0
Total Technical Area Planned Funding:	21,072,857	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	100,711	0
HVSI	934,615	0
OHSS	1,471,010	0
Total Technical Area Planned Funding:	2,506,336	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	3,961,604	0
HMBL	300,000	0
HVAB	610,301	0
HVCT	4,788,206	0
HVOP	5,790,612	0
мтст	734,658	0
Total Technical Area Planned Funding:	16,185,381	0



Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXD	5,505,810	0
HTXS	7,305,447	0
PDTX	419,116	0
Total Technical Area Planned Funding:	13,230,373	0



Technical Area Summary Indicators and Targets

Indicator Number	Label	2018
	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	25,355
	Number of new ANC and L&D clients	
	By Age (Denominator): Unknown Age	0
	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	495
	By Age (Denominator): <15-19	4,040
	By Age (Denominator): 20-24	6,992
	By Age (Denominator): 25-49	15,168
	By Age (Denominator): 50+	6
	By Number of known positives: Unknown Age	0
	By Number of known positives: <10	0
	By Number of known positives: 10-14	98
	By Number of known positives: 15-19	838
	By Number of known positives: 20-24	1,486
	By Number of known positives:	3,756



	25-49	
	By Number of known positives: 50+	0
	By Number of new positives:	0
	Unknown Age	
	By Number of new positives: <10	0
	By Number of new positives: 10-14	24
	By Number of new positives: 15-19	451
	By Number of new positives: 20-24	951
	By Number of new positives: 25-49	1,695
	By Number of new positives: 50+	0
	By Number of new negative: Unknown Age	0
	By Number of new negative: <10	2
	By Number of new negative: 10-14	386
By Number of new negative: 15-19		3,023
	By Number of new negative: 20-24	
By Number of new negative: 25-49 By Number of new negative: 50+		8,714
		3
	By Age (Numerator): Unknown Age	0
	By Age (Numerator): <10	0
By Age (Numerator): 10-14		473
	By Age (Numerator): 15-19	4,120
	By Age (Numerator): 20-24	6,839
	By Age (Numerator): 25-49	14,088
	By Age (Numerator): 50+	5
	PMTCT_STAT_TA Number and	
	percentage of pregnant women	
PMTCT_STAT_TA	with known status (includes women	n/a
	who were tested for HIV and	
	received their results) (TA)	
	Number of pregnant women with	
	known HIV status (includes women	1,704
	who were tested for HIV and	_



0
0
63
288
456
1,031
110
0
0
9
64
99
245
16
0
0
1
27
44
114
7
0
0
46
174
273
574



	By new negatives: 50+	81
	By Age (Numerator): Unknown Age	0
	By Age (Numerator): <10	0
	By Age (Numerator): 10-14	56
By Age (Numerator): : 15-19		265
	By Age (Numerator): 20-24	468
	By Age (Numerator): 25-49	933
	By Age (Numerator): 50+	100
	PMTCT_ART_DSD Percentage of	
	HIV-positive pregnant women who	
	received ART to reduce risk of	34 %
	mother-to-child-transmission	
	(MTCT) during pregnancy	
	Number of HIV-positive pregnant	
	women who received ART to	
	reduce risk of	8,560
PMTCT_ART_DSD	mother-to-child-transmission	
	(MTCT) during pregnancy	
	Number of pregnant women with	
	known HIV status (includes women	25,355
	who were tested for HIV and	20,000
	received their results)	
	New on ART	2,863
	Already on ART at beginning of	F 607
	current pregnancy	5,697
	PMTCT_ART_TA Percentage of	
	HIV-positive pregnant women who	
	received ART to reduce risk of	40 %
	mother-to-child-transmission	
PMTCT_ART_TA	(MTCT) during pregnancy	
	Number of HIV-positive pregnant	
	women who received ART to	678
	reduce risk of	
	mother-to-child-transmission	



	(MTCT) during pregnancy	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,704
	New on ART	217
	Already on ART at beginning of current pregnancy	461
	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	22,051
	By Age: 0-60 days	0
	By Age: 2 months - 9 years	0
	By Age: 10-14	7,762
	By Age: 15-19	10,364
	By Age: 20-24	2,038
	By Age: 25-29	994
	By Age: 30-49	813
VMMC_CIRC_DSD	By Age: 50+	80
VIVIIVIO_GIITO_DGD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	
	By circumcision technique: Surgical VMMC	22,051
	By circumcision technique:	0



	Device-based VMMC	
	By follow-up status: Number of	
	surgically circumcised clients who returned at least once for follow-up	
	care within 14 days of circumcision	
	surgery	
	By follow-up status: Number of	
	device based circumcision clients	
	who returned at least once for	
	follow-up care within 14 days of	
	device placement	
	PrEP_NEW_DSD Number of	
	individuals who have received	
	antiretroviral pre-exposure	n/a
	prophylaxis (PrEP) to prevent HIV	
	infection in the reporting period.	
	Number of individuals who have	
	been newly enrolled on oral	
	antiretroviral pre-exposure	1,300
	prophylaxis (PrEP) in the reporting	
	period to prevent HIV infection	
	Male 10-14	
D-ED NEW DCD	Male 15-19	22
PrEP_NEW_DSD	Male 20-24	66
	Male 25-49	132
	Male 50+	0
	Female 10-14	
	Female 15-19	140
	Female 20-24	282
	Female 25-49	658
	Female 50+	0
	(15-19)	
	(20-24)	
	FSW	



MSM	
TG	
PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period. Total number of people in the	115,385
target population	
Age/sex: 10-14 Male	200
Age/sex: 15-19 Male	1,270
Age/sex: 20-24 Male	16,026
Age/sex: 25-49 Male	31,375
Age/sex: 50+ Male	335
Age/sex: 10-14 Female	5,722
Age/sex: 15-19 Female	30,342
Age/sex: 20-24 Female	16,803
Age/sex: 25-49 Female	13,110
Age/sex: 50+ Female	200
Aggregated Age/sex: <15 Male	
Aggregated Age/sex: 15+ Male	
Aggregated Age/sex: <15 Female	
Aggregated Age/sex: 15+ Female	
KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are	n/a
	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD) Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period. Total number of people in the target population Age/sex: 10-14 Male Age/sex: 15-19 Male Age/sex: 20-24 Male Age/sex: 25-49 Male Age/sex: 50+ Male Age/sex: 15-19 Female Age/sex: 20-24 Female Age/sex: 25-49 Female Age/sex: 25-49 Female Age/sex: 50+ Female Age/sex: 50+ Female Aggregated Age/sex: <15 Male Aggregated Age/sex: <15 Male Aggregated Age/sex: <15 Female Aggregated Age/sex: <15 Female KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV



, ,	
minimum standards required (DSD)	
Number of key populations reached	
with individual and/or small group	
level HIV preventive interventions	40.777
that are based on evidence and/or	10,777
meet the minimum standards	
required	
Total estimated number of key	
population in the catchment area	
By key population type: Men who	
have sex with men who are sex	
workers (Numerator: Number of	
key populations reached with	2.422
individual and/or small group level	3,432
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Men who	
have sex with men who are NOT	
sex workers (Numerator: Number	
of key populations reached with	
individual and/or small group level	
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type:	
Transgender who are sex workers	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type:	
Transgender who are NOT sex	
workers (Numerator: Number of	



key populations reached with	
individual and/or small group leve	el
HIV preventive interventions that	
are based on evidence and/or me	eet
the minimum standards required)	1
By key population type: Female	
sex workers (FSW) (Numerator:	
Number of key populations reach	ed
with individual and/or small group	7 245
level HIV preventive interventions	7,345
that are based on evidence and/o	or
meet the minimum standards	
required)	
By key population type: Males wh	no
inject drugs (Male PWID)	
(Numerator: Number of key	
populations reached with individu	ıal
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet t	he
minimum standards required)	
By key population type: Females	
who inject drugs (Female PWID)	
(Numerator: Number of key	
populations reached with individu	ıal
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet t	he
minimum standards required)	
By key population type: People ir	1
prisons and enclosed settings	
(Numerator: Number of key	
populations reached with individu	ıal
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet t	he



Y	
minimum standards required)	
By key population type: Female	
sex workers (FSW) (Denominator:	
Total estimated number of key	
population in the catchment area)	
By key population type: People in	
prisons and enclosed settings	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type: Men who	
have sex with men who are sex	
workers (Denominator: Total	
estimated number of key	
population in the catchment area	
By key population type: Men who	
have sex with men who are NOT	
sex workers (Denominator: Total	
estimated number of key	
population in the catchment area)	
By key population type:	
Transgender who are sex workers	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type:	
Transgender who are NOT sex	
workers (Denominator: Total	
estimated number of key	
population in the catchment area)	
By key population type: Males who	
inject drugs (Male PWID)	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
· · · · · · · · · · · · · · · · · · ·	



	By key population type: Females	
	who inject drugs (Female PWID)	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By key population type: Men who	
	have sex with men/Transgender	
	(MSM/TG) (Denominator: Total	
	estimated number of key	
	population in the catchment area)	
	By key population type: MSM/TG	
	who are male sex workers (subset	
	MSM/TG) (Denominator: Total	
	estimated number of key	
	population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part	
	of the program and/or KP was	
	referred for testing as part of the	
	program	
	By New Client Status: New	
	beneficiary	
	By New Client Status: Returning	
	beneficiary within the current report	
	period	
	Number of individuals who received	
	T&C services for HIV and received	7,213
	their test results during the past 12	1,210
	months	
HTC_TST_TA	By Test Result: Positive	754
110_131_17	Service Delivery Point (Community)	
	Homebased testing: 10-14,	
	Female, Negative	
	Service Delivery Point (Community)	
	Homebased testing: 10-14,	



Female, Positive	
Service Delivery Point (Community)	
Homebased testing: 10-14, Male,	
Negative	
Service Delivery Point (Community)	
Homebased testing: 10-14, Male,	
Positive	
Service Delivery Point (Community)	
Homebased testing: 15-19,	
Female, Negative	
Service Delivery Point (Community)	
Homebased testing: 15-19,	
Female, Positive	
Service Delivery Point (Community)	
Homebased testing: 15-19, Male,	
Negative	
Service Delivery Point (Community)	
Homebased testing: 15-19, Male,	
Positive	
Service Delivery Point (Community)	
Homebased testing: 20-24,	
Female, Negative	
Service Delivery Point (Community)	
Homebased testing: 20-24,	
Female, Positive	
Service Delivery Point (Community)	
Homebased testing: 20-24, Male,	
Negative	
Service Delivery Point (Community)	
Homebased testing: 20-24, Male,	
Positive	
Service Delivery Point (Community)	
Homebased testing: 25-49,	
Female, Negative	
Service Delivery Point (Community)	



Homebased testing: 25-49,	
Female, Positive	
Service Delivery Point (Community)	
Homebased testing: 25-49, Male,	
Negative	
Service Delivery Point (Community)	
Homebased testing: 25-49, Male,	
Positive	
Service Delivery Point (Community)	
Homebased testing: 50+, Female,	
Negative	
Service Delivery Point (Community)	
Homebased testing: 50+, Female,	
Positive	
Service Delivery Point (Community)	
Homebased testing: 50+, Male,	
Negative	
Service Delivery Point (Community)	
Homebased testing: 50+, Male,	
Positive	
Service Delivery Point (Community)	
Homebased testing: Unknown Age,	
Female, Negative	
Service Delivery Point (Community)	
Homebased testing: Unknown Age,	
Female, Positive	
Service Delivery Point (Community)	
Homebased testing: Unknown Age,	
Male, Negative	
Service Delivery Point (Community)	
Homebased testing: Unknown Age,	
Male, Positive	
Service Delivery Point (Community)	
Homebased testing: <1, Negative	
Service Delivery Point (Community)	
Co. v.oc Donvery 1 onit (Community)	



Homebased testing: <1, Positive	
Service Delivery Point (Community)	
Homebased testing: 1-9, Negative	
Service Delivery Point (Community)	
Homebased testing: 1-9, Positive	
Service Delivery Point Agg Age	
(Community) Homebased testing:	
<15, Female, Negative	
Service Delivery Point Agg Age	
(Community) Homebased testing:	
<15, Female, Positive	
Service Delivery Point Agg Age	
(Community) Homebased testing:	
<15, Male, Negative	
Service Delivery Point Agg Age	
(Community) Homebased testing:	
<15, Male, Positive	
Service Delivery Point Agg Age	
(Community) Homebased testing:	
15+, Female, Negative	
Service Delivery Point Agg Age	
(Community) Homebased testing:	
15+, Female, Positive	
Service Delivery Point Agg Age	
(Community) Homebased testing:	
15+, Male, Negative	
Service Delivery Point Agg Age	
(Community) Homebased testing:	
15+, Male, Positive	
Service Delivery Point Agg Age	
(Community) Homebased testing:	
Unknown Age, Female, Negative	
Service Delivery Point Agg Age	
(Community) Homebased testing:	
Unknown Age, Female, Positive	



	Service Delivery Point Agg Age	
	(Community) Homebased testing:	
	Unknown Age, Male, Negative	
	Service Delivery Point Agg Age	
	(Community) Homebased testing:	
	Unknown Age, Male, Positive	
	Service Delivery Point (Facility)	
	Inpatient: 10-14, Female, Negative	0
	Service Delivery Point (Facility)	_
	Inpatient: 10-14, Female, Positive	0
	Service Delivery Point (Facility)	_
	Inpatient: 10-14, Male, Negative	0
	Service Delivery Point (Facility)	
	Inpatient: 10-14, Male, Positive	0
	Service Delivery Point (Facility)	
	Inpatient: 15-19, Female, Negative	0
	Service Delivery Point (Facility)	
	Inpatient: 15-19, Female, Positive	0
	Service Delivery Point (Facility)	
	Inpatient: 15-19, Male, Negative	0
	Service Delivery Point (Facility)	_
	Inpatient: 15-19, Male, Positive	0
	Service Delivery Point (Facility)	
	Inpatient: 20-24, Female, Negative	0
	Service Delivery Point (Facility)	_
	Inpatient: 20-24, Female, Positive	0
	Service Delivery Point (Facility)	_
	Inpatient: 20-24, Male, Negative	0
	Service Delivery Point (Facility)	
	Inpatient: 20-24, Male, Positive	0
	Service Delivery Point (Facility)	
	Inpatient: 25-49, Female, Negative	0
	Service Delivery Point (Facility)	
	Inpatient: 25-49, Female, Positive	0
_		



Service Delivery Point (Facility)	0
Inpatient: 25-49, Male, Negative	-
Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	0
Service Delivery Point (Facility)	0
Inpatient: 50+, Female, Negative	
Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	0
Service Delivery Point (Facility)	0
Inpatient: 50+, Male, Negative Service Delivery Point (Facility)	0
Inpatient: 50+, Male, Positive	-
Service Delivery Point (Facility) Inpatient: Unknown Age, Female,	0
Negative	
Service Delivery Point (Facility) Inpatient: Unknown Age, Female,	0
Positive	Ü
Service Delivery Point (Facility)	
Inpatient: Unknown Age, Male,	0
Negative	
Service Delivery Point (Facility)	
Inpatient: Unknown Age, Male,	0
Positive	
Service Delivery Point (Facility)	0
Inpatient: <1, Negative	0
Service Delivery Point (Facility)	0
Inpatient: <1, Positive	<u> </u>
Service Delivery Point (Facility) Inpatient: 1-9, Negative	0
Service Delivery Point (Facility)	0
Inpatient: 1-9, Positive	
Service Delivery Point Agg Age (Facility) Inpatient: <15, Female,	



Negative	
Service Delivery Point Agg Age (Facility) Inpatient: <15, Female, Positive	
Service Delivery Point Agg Age (Facility) Inpatient: <15, Male, Negative	
Service Delivery Point Agg Age (Facility) Inpatient: <15, Male, Positive	
Service Delivery Point Agg Age (Facility) Inpatient: 15+, Female, Negative	
Service Delivery Point Agg Age (Facility) Inpatient: 15+, Female, Positive	
Service Delivery Point Agg Age (Facility) Inpatient: 15+, Male, Negative	
Service Delivery Point Agg Age (Facility) Inpatient: 15+, Male, Positive	
Service Delivery Point Agg Age (Facility) Inpatient: Unknown Age, Female, Negative	
Service Delivery Point Agg Age (Facility) Inpatient: Unknown Age, Female, Positive	
Service Delivery Point Agg Age (Facility) Inpatient: Unknown Age, Male, Negative	
Service Delivery Point Agg Age (Facility) Inpatient: Unknown Age, Male, Positive	
Service Delivery Point (Facility)	0



Malnutrition: Negative	
Service Delivery Point (Facility)	0
Malnutrition: Positive	0
Service Delivery Point (Community)	
Mobile Testing: 10-14, Female,	
Negative	
Service Delivery Point (Community)	
Mobile Testing: 10-14, Female,	
Positive	
Service Delivery Point (Community)	
Mobile Testing: 10-14, Male,	
Negative	
Service Delivery Point (Community)	
Mobile Testing: 10-14, Male,	
Positive	
Service Delivery Point (Community)	
Mobile Testing: 15-19, Female, Negative	
Service Delivery Point (Community)	
Mobile Testing: 15-19, Female,	
Positive	
Service Delivery Point (Community)	
Mobile Testing: 15-19, Male,	
Negative	
Service Delivery Point (Community)	
Mobile Testing: 15-19, Male,	
Positive	
Service Delivery Point (Community)	
Mobile Testing: 20-24, Female,	
Negative	
Service Delivery Point (Community)	
Mobile Testing: 20-24, Female,	
Positive	
Service Delivery Point (Community)	
Mobile Testing: 20-24, Male,	
iviodile i coung. 20-24, ividie,	



Negative	
Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	
Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	
Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	
Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	
Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	
Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	
Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	
Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	
Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	
Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Negative	
Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Positive	
Service Delivery Point (Community) Mobile Testing: Unknown Age,	



Male, Negative	
Service Delivery Point (Community)	
Mobile Testing: Unknown Age,	
Male, Positive	
Service Delivery Point (Community)	
Mobile Testing: <1, Negative	
Service Delivery Point (Community)	
Mobile Testing: <1, Positive	
Service Delivery Point (Community)	
Mobile Testing: 1-9, Negative	
Service Delivery Point (Community)	
Mobile Testing: 1-9, Positive	
Service Delivery Point Agg Age	
(Community) Mobile Testing: <15,	
Female, Negative	
Service Delivery Point Agg Age	
(Community) Mobile Testing: <15,	
Female, Positive	
Service Delivery Point Agg Age	
(Community) Mobile Testing: <15,	
Male, Negative	
Service Delivery Point Agg Age	
(Community) Mobile Testing: <15,	
Male, Positive	
Service Delivery Point Agg Age	
(Community) Mobile Testing: 15+,	
Female, Negative	
Service Delivery Point Agg Age	
(Community) Mobile Testing: 15+,	
Female, Positive	
Service Delivery Point Agg Age	
(Community) Mobile Testing: 15+,	
Male, Negative	
Service Delivery Point Agg Age	
(Community) Mobile Testing: 15+,	



1	
Male, Positive	
Service Delivery Point Agg Age	
(Community) Mobile Testing:	
Unknown Age, Female, Negative	
Service Delivery Point Agg Age	
(Community) Mobile Testing:	
Unknown Age, Female, Positive	
Service Delivery Point Agg Age	
(Community) Mobile Testing:	
Unknown Age, Male, Negative	
Service Delivery Point Agg Age	
(Community) Mobile Testing:	
Unknown Age, Male, Positive	
Service Delivery Point (Facility)	
Other PITC: 10-14, Female,	152
Negative	
Service Delivery Point (Facility)	
Other PITC: 10-14, Female,	4
Positive	
Service Delivery Point (Facility)	74
Other PITC: 10-14, Male, Negative	74
Service Delivery Point (Facility)	0
Other PITC: 10-14, Male, Positive	2
Service Delivery Point (Facility)	
Other PITC: 15-19, Female,	86
Negative	
Service Delivery Point (Facility)	
Other PITC: 15-19, Female,	0
Positive	
Service Delivery Point (Facility)	220
Other PITC: 15-19, Male, Negative	320
Service Delivery Point (Facility)	0
Other PITC: 15-19, Male, Positive	8
Service Delivery Point (Facility)	4.45
Other PITC: 20-24, Female,	145



Negative	
Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	4
Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	703
Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	22
Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	661
Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	39
Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	1,632
Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	80
Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	280
Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	16
Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	144
Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	8
Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	0
Service Delivery Point (Facility) Other PITC: Unknown Age, Male,	0



Negative	
Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	0
Service Delivery Point (Facility) Other PITC: <1, Negative	23
Service Delivery Point (Facility) Other PITC: <1, Positive	0
Service Delivery Point (Facility) Other PITC: 1-9, Negative	93
Service Delivery Point (Facility) Other PITC: 1-9, Positive	0
Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Negative	
Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Positive	
Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Negative	
Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Positive	
Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Negative	
Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Positive	
Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Negative	
Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male,	



Docitivo	
Positive	
Service Delivery Point Agg Age	
(Facility) Other PITC: Unknown	
Age, Female, Negative	
Service Delivery Point Agg Age	
(Facility) Other PITC: Unknown	
Age, Female, Positive	
Service Delivery Point Agg Age	
(Facility) Other PITC: Unknown	
Age, Male, Negative	
Service Delivery Point Agg Age	
(Facility) Other PITC: Unknown	
Age, Male, Positive	
Service Delivery Point (Community)	
Other: 10-14, Female, Negative	
Service Delivery Point (Community)	
Other: 10-14, Female, Positive	
Service Delivery Point (Community)	
Other: 10-14, Male, Negative	
Service Delivery Point (Community)	
Other: 10-14, Male, Positive	
Service Delivery Point (Community)	
Other: 15-19, Female, Negative	
Other: 15-19, Female, Negative Service Delivery Point (Community) Other: 15-19, Female, Positive	
Service Delivery Point (Community)	
Service Delivery Point (Community) Other: 15-19, Female, Positive	
Service Delivery Point (Community) Other: 15-19, Female, Positive Service Delivery Point (Community) Other: 15-19, Male, Negative	
Service Delivery Point (Community) Other: 15-19, Female, Positive Service Delivery Point (Community)	
Service Delivery Point (Community) Other: 15-19, Female, Positive Service Delivery Point (Community) Other: 15-19, Male, Negative Service Delivery Point (Community) Other: 15-19, Male, Positive	
Service Delivery Point (Community) Other: 15-19, Female, Positive Service Delivery Point (Community) Other: 15-19, Male, Negative Service Delivery Point (Community) Other: 15-19, Male, Positive Service Delivery Point (Community)	
Service Delivery Point (Community) Other: 15-19, Female, Positive Service Delivery Point (Community) Other: 15-19, Male, Negative Service Delivery Point (Community) Other: 15-19, Male, Positive Service Delivery Point (Community) Other: 20-24, Female, Negative	
Service Delivery Point (Community) Other: 15-19, Female, Positive Service Delivery Point (Community) Other: 15-19, Male, Negative Service Delivery Point (Community) Other: 15-19, Male, Positive Service Delivery Point (Community) Other: 20-24, Female, Negative Service Delivery Point (Community)	
Service Delivery Point (Community) Other: 15-19, Female, Positive Service Delivery Point (Community) Other: 15-19, Male, Negative Service Delivery Point (Community) Other: 15-19, Male, Positive Service Delivery Point (Community) Other: 20-24, Female, Negative	



Other: 20-24, Male, Negative	
Service Delivery Point (Community)	
Other: 20-24, Male, Positive	
Service Delivery Point (Community)	
Other: 25-49, Female, Negative	
Service Delivery Point (Community)	
Other: 25-49, Female, Positive	
Service Delivery Point (Community)	
Other: 25-49, Male, Negative	
Service Delivery Point (Community)	
Other: 25-49, Male, Positive	
Service Delivery Point (Community)	
Other: 50+, Female, Negative	
Service Delivery Point (Community)	
Other: 50+, Female, Positive	
Service Delivery Point (Community)	
Other: 50+, Male, Negative	
Service Delivery Point (Community)	
Other: 50+, Male, Positive	
Service Delivery Point (Community)	
Other: Unknown Age, Female,	
Negative	
Service Delivery Point (Community)	
Other: Unknown Age, Female,	
Positive	
Service Delivery Point (Community)	
Other: Unknown Age, Male,	
Negative	
Service Delivery Point (Community)	
Other: Unknown Age, Male,	
Positive	
Service Delivery Point (Community)	
Other: <1, Negative	
Service Delivery Point (Community)	



Other: <1, Positive	
Service Delivery Point (Community)	
Other: 1-9, Negative	
Service Delivery Point (Community)	
Other: 1-9, Positive	
Service Delivery Point Agg Age	
(Community) Other: <15, Female,	
Negative	
Service Delivery Point Agg Age	
(Community) Other: <15, Female,	
Positive	
Service Delivery Point Agg Age	
(Community) Other: <15, Male,	
Negative	
Service Delivery Point Agg Age	
(Community) Other: <15, Male,	
Positive	
Service Delivery Point Agg Age	
(Community) Other: 15+, Female,	
Negative	
Service Delivery Point Agg Age	
(Community) Other: 15+, Female,	
Positive	
Service Delivery Point Agg Age	
(Community) Other: 15+, Male,	
Negative	
Service Delivery Point Agg Age	
(Community) Other: 15+, Male,	
Positive	
Service Delivery Point Agg Age	
(Community) Other: Unknown Age,	
Female, Negative	
Service Delivery Point Agg Age	
(Community) Other: Unknown Age,	
Female, Positive	



Service Delivery Point Agg Age	
(Community) Other: Unknown Age,	
Male, Negative	
Service Delivery Point Agg Age	
(Community) Other: Unknown Age,	
Male, Positive	
Service Delivery Point (Facility)	0.40
Pediatric : <5 Negative	343
Service Delivery Point (Facility)	
Pediatric : <5 Positive	15
Service Delivery Point (Facility) TB:	
10-14, Female, Negative	6
Service Delivery Point (Facility) TB:	
10-14, Female, Positive	0
Service Delivery Point (Facility) TB:	
10-14, Male, Negative	0
Service Delivery Point (Facility) TB:	
10-14, Male, Positive	0
Service Delivery Point (Facility) TB:	_
15-19, Female, Negative	2
Service Delivery Point (Facility) TB:	0
15-19, Female, Positive	0
Service Delivery Point (Facility) TB:	40
15-19, Male, Negative	10
Service Delivery Point (Facility) TB:	0
15-19, Male, Positive	0
Service Delivery Point (Facility) TB:	0
20-24, Female, Negative	6
Service Delivery Point (Facility) TB:	0
20-24, Female, Positive	0
Service Delivery Point (Facility) TB:	00
20-24, Male, Negative	26
Service Delivery Point (Facility) TB:	
20-24, Male, Positive	1



Service Delivery Point (Facility) TB: 25-49, Female, Negative	11
Service Delivery Point (Facility) TB: 25-49, Female, Positive	0
Service Delivery Point (Facility) TB: 25-49, Male, Negative	42
Service Delivery Point (Facility) TB: 25-49, Male, Positive	3
Service Delivery Point (Facility) TB: 50+, Female, Negative	1
Service Delivery Point (Facility) TB: 50+, Female, Positive	0
Service Delivery Point (Facility) TB: 50+, Male, Negative	1
Service Delivery Point (Facility) TB: 50+, Male, Positive	0
Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0
Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
Service Delivery Point (Facility) TB: <1, Negative	0
Service Delivery Point (Facility) TB: <1, Positive	0
Service Delivery Point (Facility) TB: 1-9, Negative	2
Service Delivery Point (Facility) TB: 1-9, Positive	0
Service Delivery Point Agg Age (Facility) TB: <15, Female,	



Negative	
Service Delivery Point Agg Age	
(Facility) TB: <15, Female, Positive	
Service Delivery Point Agg Age	
(Facility) TB: <15, Male, Negative	
Service Delivery Point Agg Age	
(Facility) TB: <15, Male, Positive	
Service Delivery Point Agg Age	
(Facility) TB: 15+, Female,	
Negative	
Service Delivery Point Agg Age	
(Facility) TB: 15+, Female, Positive	
Service Delivery Point Agg Age	
(Facility) TB: 15+, Male, Negative	
Service Delivery Point Agg Age	
(Facility) TB: 15+, Male, Positive	
Service Delivery Point Agg Age	
(Facility) TB: Unknown Age,	
Female, Negative	
Service Delivery Point Agg Age	
(Facility) TB: Unknown Age, Female, Positive	
Service Delivery Point Agg Age	
(Facility) TB: Unknown Age, Male,	
Negative	
Service Delivery Point Agg Age	
(Facility) TB: Unknown Age, Male,	
Positive	
Service Delivery Point (Facility)	
VMMC: <1, Negative	
Service Delivery Point (Facility)	
VMMC: <1, Positive	
Service Delivery Point (Facility)	
VMMC: 10-14, Negative	



Service Delivery Point (Fac	ility)
VMMC: 10-14, Positive	
Service Delivery Point (Factorium VMMC: 15-19, Negative	ility)
Service Delivery Point (Factorium VMMC: 15-19, Positive	ility)
Service Delivery Point (Fac	ility)
Service Delivery Point (Fac	ility)
Service Delivery Point (Fac VMMC: 20-24, Negative	ility)
Service Delivery Point (Fac VMMC: 20-24, Positive	ility)
Service Delivery Point (Fac VMMC: 25-49, Negative	ility)
Service Delivery Point (Fac VMMC: 25-49, Positive	ility)
Service Delivery Point (Fac VMMC: 50+, Negative	ility)
Service Delivery Point (Fac VMMC: 50+, Positive	ility)
Service Delivery Point (Fac VMMC: Unknown Age, Neg	
Service Delivery Point (Fac VMMC: Unknown Age, Pos	• •
Service Delivery Point Agg (Facility) VMMC: <15, Nega	9
Service Delivery Point Agg (Facility) VMMC: <15, Posi	
Service Delivery Point Agg (Facility) VMMC: 15+, Nega	-
Service Delivery Point Agg (Facility) VMMC: 15+, Posi	



Service Delivery Point Agg Age		
(Facility) VMMC: Unknown Age,		
Negative		
Service Delivery Point Agg Age		
(Facility) VMMC: Unknown Age,		
Positive		
Service Delivery Point (Facility)		
Index: 10-14, Female, Negative	22	
Service Delivery Point (Facility)	_	
Index: 10-14, Female, Positive	7	
Service Delivery Point (Facility)		
Index: 10-14, Male, Negative	18	
Service Delivery Point (Facility)		
Index: 10-14, Male, Positive	4	
Service Delivery Point (Facility)		
Index: 15-19, Female, Negative	17	
Service Delivery Point (Facility)	57	
Index: 15-19, Female, Positive		
Service Delivery Point (Facility)		
Index: 15-19, Male, Negative	55	
Service Delivery Point (Facility)		
Index: 15-19, Male, Positive	15	
Service Delivery Point (Facility)		
Index: 20-24, Female, Negative	46	
Service Delivery Point (Facility)		
Index: 20-24, Female, Positive	9	
Service Delivery Point (Facility)		
Index: 20-24, Male, Negative	180	
Service Delivery Point (Facility)		
Index: 20-24, Male, Positive	34	
Service Delivery Point (Facility)		
Index: 25-49, Female, Negative	169	
Service Delivery Point (Facility)	Delivery Point (Facility)	
Index: 25-49, Female, Positive		
		



	Service Delivery Point (Facility) Index: 25-49, Male, Negative	313
	Service Delivery Point (Facility) Index: 25-49, Male, Positive	155
	Service Delivery Point (Facility) Index: 50+, Female, Negative	57
	Service Delivery Point (Facility) Index: 50+, Female, Positive	42
	Service Delivery Point (Facility) Index: 50+, Male, Negative	37
	Service Delivery Point (Facility) Index: 50+, Male, Positive	17
ı	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
ı	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	0
ı	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0
ı	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
	Service Delivery Point (Facility) Index: <1, Negative	2
	Service Delivery Point (Facility) Index: <1, Positive	0
	Service Delivery Point (Facility)	17
	Service Delivery Point (Facility)	2
	Service Delivery Point Agg Age (Facility) Index: <15, Female,	



ļ	Negative	
	Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive	
	Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative	
l	Service Delivery Point Agg Age (Facility) Index: <15, Male, Positive	
	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	
	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	
	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	
	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Positive	
	By Key Population: FSW, Negative	
	By Key Population: FSW, Positive	



By Key Population: MSM, Negative	
By Key Population: MSM, Positive	
By Key Population: People in	
prisons and other enclosed	
settings, Negative	
By Key Population: People in	
prisons and other enclosed	
settings, Positive	
By Key Population: PWID,	
Negative	
By Key Population: PWID, Positive	
By Key Population: TG, Negative	
By Key Population: TG, Positive	
Service Delivery Point (Community)	
Index Mod: 10-14, Female,	
Negative	
Service Delivery Point (Community)	
Index Mod: 10-14, Female, Positive	
Service Delivery Point (Community)	
Index Mod: 10-14, Male, Negative	
Service Delivery Point (Community)	
Index Mod: 10-14, Male, Positive	
Service Delivery Point (Community)	
Index Mod: 15-19, Female,	
Negative	
Service Delivery Point (Community)	
Index Mod: 15-19, Female, Positive	
Service Delivery Point (Community)	
Index Mod: 15-19, Male, Negative	
Service Delivery Point (Community)	
Index Mod: 15-19, Male, Positive	
Service Delivery Point (Community)	
Index Mod: 20-24, Female,	
Negative	



Service Delivery Point (Community)	
Index Mod: 20-24, Female, Positive	
Service Delivery Point (Community)	
Index Mod: 20-24, Male, Negative	
Service Delivery Point (Community)	
Index Mod: 20-24, Male, Positive	
Service Delivery Point (Community)	
Index Mod: 25-49, Female,	
Negative	
Service Delivery Point (Community)	
Index Mod: 25-49, Female, Positive	
Service Delivery Point (Community)	
Index Mod: 25-49, Male, Negative	
Service Delivery Point (Community)	
Index Mod: 25-49, Male, Positive	
Service Delivery Point (Community)	
Index Mod: 50+, Female, Negative	
Service Delivery Point (Community)	
Index Mod: 50+, Female, Positive	
Service Delivery Point (Community)	
Index Mod: 50+, Male, Negative	
Service Delivery Point (Community)	
Index Mod: 50+, Male, Positive	
Service Delivery Point (Community)	
Index Mod: Unknown Age, Female,	
Negative	
Service Delivery Point (Community)	
Index Mod: Unknown Age, Female,	
Positive	
Service Delivery Point (Community)	
Index Mod: Unknown Age, Male,	
Negative	
Service Delivery Point (Community)	
Index Mod: Unknown Age, Male,	



Positive	
Service Delivery Point (Community) Index Mod: <1, Negative	
Service Delivery Point (Community) Index Mod: <1, Positive	
Service Delivery Point (Community) Index Mod: 1-9, Negative	
Service Delivery Point (Community) Index Mod: 1-9, Positive	
Service Delivery Point Agg Age (Community) Index Mod: <15, Female, Negative	
Service Delivery Point Agg Age (Community) Index Mod: <15, Female, Positive	
Service Delivery Point Agg Age (Community) Index Mod: <15, Male, Negative	
Service Delivery Point Agg Age (Community) Index Mod: <15, Male, Positive	
Service Delivery Point Agg Age (Community) Index Mod: 15+, Female, Negative	
Service Delivery Point Agg Age (Community) Index Mod: 15+, Female, Positive	
Service Delivery Point Agg Age (Community) Index Mod: 15+, Male, Negative	
Service Delivery Point Agg Age (Community) Index Mod: 15+, Male, Positive	
Service Delivery Point Agg Age (Community) Index Mod: Unknown	



Age, Female, Negative	
Service Delivery Point Agg Age (Community) Index Mod: Unknown Age, Female, Positive	
Service Delivery Point Agg Age (Community) Index Mod: Unknown Age, Male, Negative	
Service Delivery Point Agg Age (Community) Index Mod: Unknown Age, Male, Positive	
Service Delivery Point (Facility) ANC: <1, Negative	0
Service Delivery Point (Facility) ANC: <1, Positive	0
Service Delivery Point (Facility) ANC: 10-14, Negative	20
Service Delivery Point (Facility) ANC: 10-14, Positive	1
Service Delivery Point (Facility) ANC: 15-19, Negative	38
Service Delivery Point (Facility) ANC: 15-19, Positive	5
Service Delivery Point (Facility) ANC: 1-9, Negative	7
Service Delivery Point (Facility) ANC: 1-9, Positive	0
Service Delivery Point (Facility) ANC: 20-24, Negative	117
Service Delivery Point (Facility) ANC: 20-24, Positive	22
Service Delivery Point (Facility) ANC: 25-49, Negative	243
Service Delivery Point (Facility) ANC: 25-49, Positive	45



T	
Service Delivery Point (Facility) ANC: 50+, Negative	3
Service Delivery Point (Facility) ANC: 50+, Positive	0
Service Delivery Point (Facility) ANC: Unknown Age, Negative	0
Service Delivery Point (Facility) ANC: Unknown Age, Positive	0
Service Delivery Point Agg Age (Facility) ANC: <15, Negative	
Service Delivery Point Agg Age (Facility) ANC: <15, Positive	
Service Delivery Point Agg Age (Facility) ANC: 15+, Negative	
Service Delivery Point Agg Age (Facility) ANC: 15+, Positive	
Service Delivery Point Agg Age (Facility) ANC: Unknown Age, Negative	
Service Delivery Point Agg Age (Facility) ANC: Unknown Age, Positive	
Service Delivery Point (Facility) VCT: 10-14, Female, Negative	16
Service Delivery Point (Facility) VCT: 10-14, Female, Positive	1
Service Delivery Point (Facility) VCT: 10-14, Male, Negative	8
Service Delivery Point (Facility) VCT: 10-14, Male, Positive	1
Service Delivery Point (Facility) VCT: 15-19, Female, Negative	12
Service Delivery Point (Facility) VCT: 15-19, Female, Positive	6



Service Delivery Point (Facility) VCT: 15-19, Male, Negative	45
Service Delivery Point (Facility) VCT: 15-19, Male, Positive	10
Service Delivery Point (Facility) VCT: 20-24, Female, Negative	26
Service Delivery Point (Facility) VCT: 20-24, Female, Positive	19
Service Delivery Point (Facility) VCT: 20-24, Male, Negative	100
Service Delivery Point (Facility) VCT: 20-24, Male, Positive	40
Service Delivery Point (Facility) VCT: 25-49, Female, Negative	81
Service Delivery Point (Facility) VCT: 25-49, Female, Positive	62
Service Delivery Point (Facility) VCT: 25-49, Male, Negative	216
Service Delivery Point (Facility) VCT: 25-49, Male, Positive	67
Service Delivery Point (Facility) VCT: 50+, Female, Negative	46
Service Delivery Point (Facility) VCT: 50+, Female, Positive	4
Service Delivery Point (Facility) VCT: 50+, Male, Negative	37
Service Delivery Point (Facility) VCT: 50+, Male, Positive	7
Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	0
Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	0



Service Delivery Point (Facility) VCT: Unknown Age, Male,	0
Negative	· ·
Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	0
Service Delivery Point (Facility) VCT: <1, Negative	0
Service Delivery Point (Facility) VCT: <1, Positive	0
Service Delivery Point (Facility) VCT: 1-9, Negative	9
Service Delivery Point (Facility) VCT: 1-9, Positive	0
Service Delivery Point Agg Age (Facility) VCT: <15, Female, Negative	
Service Delivery Point Agg Age (Facility) VCT: <15, Female, Positive	
Service Delivery Point Agg Age (Facility) VCT: <15, Male, Negative	
Service Delivery Point Agg Age (Facility) VCT: <15, Male, Positive	
Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Negative	
Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Positive	
Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Negative	
Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Positive	
Service Delivery Point Agg Age	



(Facility) VCT: Unknown Age,	
Female, Negative	
Service Delivery Point Agg Age	
(Facility) VCT: Unknown Age,	
Female, Positive	
Service Delivery Point Agg Age	
(Facility) VCT: Unknown Age,	
Male, Negative	
Service Delivery Point Agg Age	
(Facility) VCT: Unknown Age,	
Male, Positive	
Service Delivery Point (Community)	
VCT Mod: 10-14, Female, Negative	
Service Delivery Point (Community)	
VCT Mod: 10-14, Female, Positive	
Service Delivery Point (Community)	
VCT Mod: 10-14, Male, Negative	
Service Delivery Point (Community)	
VCT Mod: 10-14, Male, Positive	
Service Delivery Point (Community)	
VCT Mod: 15-19, Female, Negative	
Service Delivery Point (Community)	
VCT Mod: 15-19, Female, Positive	
Service Delivery Point (Community)	
VCT Mod: 15-19, Male, Negative	
Service Delivery Point (Community)	
VCT Mod: 15-19, Male, Positive	
Service Delivery Point (Community)	
VCT Mod: 20-24, Female, Negative	
Service Delivery Point (Community)	
VCT Mod: 20-24, Female, Positive	
Service Delivery Point (Community)	
VCT Mod: 20-24, Male, Negative	
Service Delivery Point (Community)	
·	· · · · · · · · · · · · · · · · · · ·



VCT Mod: 20-24, Male, Positive	
Service Delivery Point (Community)	
VCT Mod: 25-49, Female, Negative	
Service Delivery Point (Community)	
VCT Mod: 25-49, Female, Positive	
Service Delivery Point (Community)	
VCT Mod: 25-49, Male, Negative	
Service Delivery Point (Community)	
VCT Mod: 25-49, Male, Positive	
Service Delivery Point (Community)	
VCT Mod: 50+, Female, Negative	
Service Delivery Point (Community)	
VCT Mod: 50+, Female, Positive	
Service Delivery Point (Community)	
VCT Mod: 50+, Male, Negative	
Service Delivery Point (Community)	
VCT Mod: 50+, Male, Positive	
Service Delivery Point (Community)	
VCT Mod: Unknown Age, Female,	
Negative	
Service Delivery Point (Community)	
VCT Mod: Unknown Age, Female,	
Positive	
Service Delivery Point (Community)	
VCT Mod: Unknown Age, Male,	
Negative	
Service Delivery Point (Community) VCT Mod: Unknown Age, Male,	
Positive	
Service Delivery Point (Community)	
VCT Mod: <1, Negative	
Service Delivery Point (Community)	
VCT Mod: <1, Positive	
Service Delivery Point (Community)	
ocivide Delivery i dirit (Collinatility)	



VCT Mod: 1-9, Negative	
Service Delivery Point (Community)	
VCT Mod: 1-9, Positive	
Service Delivery Point Agg Age	
(Community) VCT Mod: <15,	
Female, Negative	
Service Delivery Point Agg Age	
(Community) VCT Mod: <15,	
Female, Positive	
Service Delivery Point Agg Age	
(Community) VCT Mod: <15, Male,	
Negative	
Service Delivery Point Agg Age	
(Community) VCT Mod: <15, Male,	
Positive	
Service Delivery Point Agg Age	
(Community) VCT Mod: 15+,	
Female, Negative	
Service Delivery Point Agg Age	
(Community) VCT Mod: 15+,	
Female, Positive	
Service Delivery Point Agg Age	
(Community) VCT Mod: 15+, Male,	
Negative	
Service Delivery Point Agg Age	
(Community) VCT Mod: 15+, Male, Positive	
Service Delivery Point Agg Age (Community) VCT Mod: Unknown	
Age, Female, Negative	
Service Delivery Point Agg Age	
(Community) VCT Mod: Unknown	
Age, Female, Positive	
Service Delivery Point Agg Age	
(Community) VCT Mod: Unknown	
National Community of the Community of t	I



	Age, Male, Negative	
	Service Delivery Point Agg Age (Community) VCT Mod: Unknown Age, Male, Positive	
	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	98 %
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	4,426
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	4,538
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator:	



Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 25-49 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 50+ (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 10-14	
(Numerator: Number of registered	
new and relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 15-19	
(Numerator: Number of registered	
new and relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 20-24	
(Numerator: Number of registered	
new and relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 25-49	
(Numerator: Number of registered	
new and relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 50+ (Numerator:	
Number of registered new and	



relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Aggregated Age/Sex: Male <15	
(Numerator: Number of registered	
new and relapsed TB cases with	80
documented HIV status, during the	
reporting period)	
Aggregated Age/Sex: Male 15+	
(Numerator: Number of registered	
new and relapsed TB cases with	1,785
documented HIV status, during the	
reporting period)	
Aggregated Age/Sex: Female <15	
(Numerator: Number of registered	
new and relapsed TB cases with	131
documented HIV status, during the	
reporting period)	
Aggregated Age/Sex: Female 15+	
(Numerator: Number of registered	
new and relapsed TB cases with	2,430
documented HIV status, during the	,
reporting period)	
Result: Known HIV positive at	
service entry	
Result: New HIV positive	
Result: HIV Negative	
Age/Sex: <1 (Denominator: Total	
number of registered new and	
relapsed TB cases, during the	
reporting period.)	
Age/Sex: 1-9 (Denominator: Total	
number of registered new and	
relapsed TB cases, during the	
reporting period.)	



Age/Sex: Male 10-14	
(Denominator: Total number of	
registered new and relapsed TB	
cases, during the reporting period.)	
Age/Sex: Male 15-19	
(Denominator: Total number of	
registered new and relapsed TB	
cases, during the reporting period.)	
Age/Sex: Male 20-24	
(Denominator: Total number of	
registered new and relapsed TB	
cases, during the reporting period.)	
Age/Sex: Male 25-49	
(Denominator: Total number of	
registered new and relapsed TB	
cases, during the reporting period.)	
Age/Sex: Male 50+ (Denominator:	
Total number of registered new and	
relapsed TB cases, during the	
reporting period.)	
Age/Sex: Female 10-14	
(Denominator: Total number of	
registered new and relapsed TB	
cases, during the reporting period.)	
Age/Sex: Female 15-19	
(Denominator: Total number of	
registered new and relapsed TB	
cases, during the reporting period.)	
Age/Sex: Female 20-24	
(Denominator: Total number of	
registered new and relapsed TB	
cases, during the reporting period.)	
Age/Sex: Female 25-49	
(Denominator: Total number of	
registered new and relapsed TB	



	<u></u>	1
	cases, during the reporting period.)	
	Age/Sex: Female 50+	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period.)	
	Aggregated Age/Sex: Male <15	
	(Denominator: Total number of	00
	registered new and relapsed TB	80
	cases, during the reporting period)	
	Aggregated Age/Sex: Male 15+	
	(Denominator: Total number of	4.000
	registered new and relapsed TB	1,832
	cases, during the reporting period)	
	Aggregated Age/Sex: Female <15	
	(Denominator: Total number of	400
	registered new and relapsed TB	132
	cases, during the reporting period)	
	Aggregated Age/Sex: Female 15+	
	(Denominator: Total number of	2.404
	registered new and relapsed TB	2,494
	cases, during the reporting period)	
	TB_STAT_TA Percentage of	
	registered new and relapsed TB	
	cases with documented HIV status.	100 %
	Number of registered new and	
TB_STAT_TA	relapsed TB cases with	72
10_0171_17	documented HIV status, during the	12
	reporting period.	
	Total number of registered new and	
	relapsed TB cases, during the	72
	reporting period.	
	Aggregated Age/Sex: Female <15	0
	(Denominator: Total number of	U



registered new and relapsed TB	
cases, during the reporting period)	
Aggregated Age/Sex: Male <15	
(Denominator: Total number of	0
registered new and relapsed TB	0
cases, during the reporting period)	
Aggregated Age/Sex: Female 15+	
(Denominator: Total number of	_
registered new and relapsed TB	5
cases, during the reporting period)	
Aggregated Age/Sex: Male 15+	
(Denominator: Total number of	67
registered new and relapsed TB	67
cases, during the reporting period)	
Age/Sex: <1 (Numerator: Number	
of registered new and relapsed TB	
cases with documented HIV status,	
during the reporting period)	
Age/Sex: 1-9 (Numerator: Number	
of registered new and relapsed TB	
cases with documented HIV status,	
during the reporting period)	
Age/Sex: Male 10-14 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 15-19 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 20-24 (Numerator:	
Number of registered new and	
relapsed TB cases with	
· L	



documented HIV status, during the	
reporting period)	
Age/Sex: Male 25-49 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 50+ (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 10-14	
(Numerator: Number of registered	
new and relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 15-19	
(Numerator: Number of registered	
new and relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 20-24	
(Numerator: Number of registered	
new and relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 25-49	
(Numerator: Number of registered	
new and relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 50+ (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	



ronouting pouis d)	
reporting period)	
Aggregated Age/Sex: Male <15	
(Numerator: Number of registered	
new and relapsed TB cases with	0
documented HIV status, during the	
reporting period)	
Aggregated Age/Sex: Male 15+	
(Numerator: Number of registered	
new and relapsed TB cases with	67
documented HIV status, during the	
reporting period)	
Aggregated Age/Sex: Female <15	
(Numerator: Number of registered	
new and relapsed TB cases with	0
documented HIV status, during the	
reporting period)	
Aggregated Age/Sex: Female 15+	
(Numerator: Number of registered	
new and relapsed TB cases with	5
documented HIV status, during the	· ·
reporting period)	
Result: Known HIV positive at	
·	
service entry	
Result: New HIV positive	
Result: HIV negative	
Age/Sex: <1 (Denominator: Total	
number of registered new and	
relapsed TB cases, during the	
reporting period)	
Age/Sex: 1-9 (Denominator: Total	
number of registered new and	
relapsed TB cases, during the	
reporting period)	
Age/Sex: Male 10-14	
(Denominator: Total number of	
(Denominator, Total number of	



	<u> </u>	
	registered new and relapsed TB	
	cases, during the reporting period)	
	Age/Sex: Male 15-19	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period)	
	Age/Sex: Male 20-24	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period)	
	Age/Sex: Male 25-49	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period)	
	Age/Sex: Male 50+ (Denominator:	
	Total number of registered new and	
	relapsed TB cases, during the	
	reporting period)	
	Age/Sex: Female 10-14	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period)	
	Age/Sex: Female 15-19	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period)	
	Age/Sex: Female 20-24	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period)	
	Age/Sex: Female 25-49	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period)	
HTC_TST_DSD	Number of individuals who received	338,216



T&C services for HIV and received	
their test results during the past 12	
months	
By Test Result: Positive	35,103
Service Delivery Point (Community)	
Homebased testing: 10-14,	
Female, Negative	
Service Delivery Point (Community)	
Homebased testing: 10-14,	
Female, Positive	
Service Delivery Point (Community)	
Homebased testing: 10-14, Male,	
Negative	
Service Delivery Point (Community)	
Homebased testing: 10-14, Male,	
Positive	
Service Delivery Point (Community)	
Homebased testing: 15-19,	
Female, Negative	
_	
Service Delivery Point (Community)	
Homebased testing: 15-19,	
Female, Positive	
Service Delivery Point (Community)	
Homebased testing: 15-19, Male,	
Negative	
Service Delivery Point (Community)	
Homebased testing: 15-19, Male,	
Positive	
Service Delivery Point (Community)	
Homebased testing: 20-24,	
Female, Negative	
Service Delivery Point (Community)	
Homebased testing: 20-24,	
Female, Positive	
Service Delivery Point (Community)	



Homebased testing: 20-24, Male,
Negative
Service Delivery Point (Community)
Homebased testing: 20-24, Male,
Positive
Service Delivery Point (Community)
Homebased testing: 25-49,
Female, Negative
Service Delivery Point (Community)
Homebased testing: 25-49,
Female, Positive
Service Delivery Point (Community)
Homebased testing: 25-49, Male,
Negative
Service Delivery Point (Community)
Homebased testing: 25-49, Male,
Positive
Service Delivery Point (Community)
Homebased testing: 50+, Female,
Negative
Service Delivery Point (Community)
Homebased testing: 50+, Female,
Positive
Service Delivery Point (Community)
Homebased testing: 50+, Male,
Negative
Service Delivery Point (Community)
Homebased testing: 50+, Male,
Positive
Service Delivery Point (Community)
Homebased testing: Unknown Age,
Female, Negative
Service Delivery Point (Community)
Homebased testing: Unknown Age,
Female, Positive



Service Delivery Point (Community) Homebased testing: Unknown Age, Male, Negative Service Delivery Point (Community) Homebased testing: Unknown Age, Male, Positive Service Delivery Point (Community) Homebased testing: <1, Negative Service Delivery Point (Community) Homebased testing: <1, Positive Service Delivery Point (Community) Homebased testing: 1-9, Negative Service Delivery Point (Community) Homebased testing: 1-9, Positive Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Positive Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Male, Negative		
Male, Negative Service Delivery Point (Community) Homebased testing: Unknown Age, Male, Positive Service Delivery Point (Community) Homebased testing: <1, Negative Service Delivery Point (Community) Homebased testing: <1, Positive Service Delivery Point (Community) Homebased testing: 1-9, Negative Service Delivery Point (Community) Homebased testing: 1-9, Positive Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing:	Service Delivery Point (Community)	
Service Delivery Point (Community) Homebased testing: Unknown Age, Male, Positive Service Delivery Point (Community) Homebased testing: <1, Negative Service Delivery Point (Community) Homebased testing: <1, Positive Service Delivery Point (Community) Homebased testing: 1-9, Negative Service Delivery Point (Community) Homebased testing: 1-9, Positive Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Positive Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Positive Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing:	Homebased testing: Unknown Age,	
Homebased testing: Unknown Age, Male, Positive Service Delivery Point (Community) Homebased testing: <1, Negative Service Delivery Point (Community) Homebased testing: <1, Positive Service Delivery Point (Community) Homebased testing: 1-9, Negative Service Delivery Point (Community) Homebased testing: 1-9, Positive Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing:	Male, Negative	
Male, Positive Service Delivery Point (Community) Homebased testing: <1, Negative Service Delivery Point (Community) Homebased testing: <1, Positive Service Delivery Point (Community) Homebased testing: 1-9, Negative Service Delivery Point (Community) Homebased testing: 1-9, Positive Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing:	Service Delivery Point (Community)	
Service Delivery Point (Community) Homebased testing: <1, Negative Service Delivery Point (Community) Homebased testing: <1, Positive Service Delivery Point (Community) Homebased testing: 1-9, Negative Service Delivery Point (Community) Homebased testing: 1-9, Positive Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing:	Homebased testing: Unknown Age,	
Homebased testing: <1, Negative Service Delivery Point (Community) Homebased testing: <1, Positive Service Delivery Point (Community) Homebased testing: 1-9, Negative Service Delivery Point (Community) Homebased testing: 1-9, Positive Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing:	Male, Positive	
Service Delivery Point (Community) Homebased testing: <1, Positive Service Delivery Point (Community) Homebased testing: 1-9, Negative Service Delivery Point (Community) Homebased testing: 1-9, Positive Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing:	Service Delivery Point (Community)	
Homebased testing: <1, Positive Service Delivery Point (Community) Homebased testing: 1-9, Negative Service Delivery Point (Community) Homebased testing: 1-9, Positive Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Positive Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing:	Homebased testing: <1, Negative	
Service Delivery Point (Community) Homebased testing: 1-9, Negative Service Delivery Point (Community) Homebased testing: 1-9, Positive Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Positive Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing:	Service Delivery Point (Community)	
Homebased testing: 1-9, Negative Service Delivery Point (Community) Homebased testing: 1-9, Positive Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Positive Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing:	Homebased testing: <1, Positive	
Service Delivery Point (Community) Homebased testing: 1-9, Positive Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Positive Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing:	Service Delivery Point (Community)	
Homebased testing: 1-9, Positive Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Positive Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing:	Homebased testing: 1-9, Negative	
Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Positive Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing:	Service Delivery Point (Community)	
(Community) Homebased testing: <15, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Positive Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing:	Homebased testing: 1-9, Positive	
<15, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Positive Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing:	Service Delivery Point by Agg Age	
Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Positive Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing:	(Community) Homebased testing:	
(Community) Homebased testing: <15, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Positive Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing:	<15, Female, Negative	
<15, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Positive Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing:	Service Delivery Point by Agg Age	
Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Positive Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing:	(Community) Homebased testing:	
(Community) Homebased testing: <15, Male, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Positive Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing:	<15, Female, Positive	
<15, Male, Negative Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Positive Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing:	Service Delivery Point by Agg Age	
Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Positive Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing:	(Community) Homebased testing:	
(Community) Homebased testing: <15, Male, Positive Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing:	<15, Male, Negative	
<15, Male, Positive Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing:	Service Delivery Point by Agg Age	
Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing:	(Community) Homebased testing:	
(Community) Homebased testing: 15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing:	<15, Male, Positive	
15+, Female, Negative Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing:	Service Delivery Point by Agg Age	
Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing:	(Community) Homebased testing:	
(Community) Homebased testing: 15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing:	15+, Female, Negative	
15+, Female, Positive Service Delivery Point by Agg Age (Community) Homebased testing:	Service Delivery Point by Agg Age	
Service Delivery Point by Agg Age (Community) Homebased testing:	(Community) Homebased testing:	
(Community) Homebased testing:	15+, Female, Positive	
	Service Delivery Point by Agg Age	
15+, Male, Negative	(Community) Homebased testing:	
	15+, Male, Negative	



Service Delivery Point by Agg Age	
(Community) Homebased testing:	
15+, Male, Positive	
Service Delivery Point by Agg Age	
(Community) Homebased testing:	
Unknown Age, Female, Negative	
Service Delivery Point by Agg Age	
(Community) Homebased testing:	
Unknown Age, Female, Positive	
Service Delivery Point by Agg Age	
(Community) Homebased testing:	
Unknown Age, Male, Negative	
Service Delivery Point by Agg Age	
(Community) by Aggregated Age:	
Homebased testing: Unknown Age,	
Male, Positive	
Service Delivery Point (Facility)	400
Inpatient: 10-14, Female, Negative	183
Service Delivery Point (Facility)	0
Inpatient: 10-14, Female, Positive	9
Service Delivery Point (Facility)	77
Inpatient: 10-14, Male, Negative	77
Service Delivery Point (Facility)	
Inpatient: 10-14, Male, Positive	8
Service Delivery Point (Facility)	
Inpatient: 15-19, Female, Negative	135
Service Delivery Point (Facility)	
Inpatient: 15-19, Female, Positive	13
Service Delivery Point (Facility)	
Inpatient: 15-19, Male, Negative	362
Service Delivery Point (Facility)	
Inpatient: 15-19, Male, Positive	34
Service Delivery Point (Facility)	
Inpatient: 20-24, Female, Negative	183
,	



Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	2
Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	806
Service Delivery Point (Facility)	
Inpatient: 20-24, Male, Positive	79
Service Delivery Point (Facility)	005
Inpatient: 25-49, Female, Negative	835
Service Delivery Point (Facility)	
Inpatient: 25-49, Female, Positive	80
Service Delivery Point (Facility)	
Inpatient: 25-49, Male, Negative	1,744
Service Delivery Point (Facility)	
Inpatient: 25-49, Male, Positive	206
Service Delivery Point (Facility)	005
Inpatient: 50+, Female, Negative	325
Service Delivery Point (Facility)	24
Inpatient: 50+, Female, Positive	34
Service Delivery Point (Facility)	102
Inpatient: 50+, Male, Negative	193
Service Delivery Point (Facility)	29
Inpatient: 50+, Male, Positive	29
Service Delivery Point (Facility)	
Inpatient: Unknown Age, Female,	0
Negative	
Service Delivery Point (Facility)	
Inpatient: Unknown Age, Female,	0
Positive	
Service Delivery Point (Facility)	
Inpatient: Unknown Age, Male,	0
Negative	
Service Delivery Point (Facility)	
Inpatient: Unknown Age, Male,	0
Positive	



Service Delivery Point (Facility) Inpatient: <1, Negative	284
Service Delivery Point (Facility) Inpatient: <1, Positive	3
Service Delivery Point (Facility) Inpatient: 1-9, Negative	364
Service Delivery Point (Facility) Inpatient: 1-9, Positive	7
Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative	
Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Positive	
Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative	
Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Positive	
Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	
Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	
Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	
Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	
Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Negative	



	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Positive	
-	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	178
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	11
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	143
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	12
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	3,837
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	248
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	333
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	28
	Service Delivery Point (Community) Mobile Testing: 20-24, Female,	4,163



1	
Negative	
Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	276
Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	431
Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	39
Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	2,839
Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	230
Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	3,064
Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	263
Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	346
Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	31
Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	763
Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	66
Service Delivery Point (Community) Mobile Testing: Unknown Age,	0



Female, Negative	
Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Positive	0
Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Negative	0
Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Positive	0
Service Delivery Point (Community) Mobile Testing: <1, Negative	0
Service Delivery Point (Community) Mobile Testing: <1, Positive	0
Service Delivery Point (Community) Mobile Testing: 1-9, Negative	72
Service Delivery Point (Community) Mobile Testing: 1-9, Positive	2
Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Negative	273
Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Positive	18
Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Male, Negative	239
Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Male, Positive	19
Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Negative	6,946
Service Delivery Point by Agg Age(Community) Mobile Testing:	558



15+, Female, Positive	
Service Delivery Point by Agg	
Age(Community) Mobile Testing:	6,208
15+, Male, Negative	
Service Delivery Point by Agg	
Age(Community) Mobile Testing:	642
15+, Male, Positive	
Service Delivery Point by Agg	
Age(Community) Mobile Testing:	
Unknown Age, Female, Negative	
Service Delivery Point by Agg	
Age(Community) Mobile Testing:	0
Unknown Age, Female, Positive	
Service Delivery Point by Agg	
Age(Community) Mobile Testing:	
Unknown Age, Male, Negative	
Service Delivery Point by Agg	
Age(Community) Mobile Testing:	0
Unknown Age, Male, Positive	· ·
Service Delivery Point (Facility)	
Other PITC: 10-14, Female,	4,059
Negative	4,000
Service Delivery Point (Facility)	
Other PITC: 10-14, Female,	300
Positive	300
Service Delivery Point (Facility)	
Other PITC: 10-14, Male, Negative	2,343
Service Delivery Point (Facility)	
Other PITC: 10-14, Male, Positive	295
Service Delivery Point (Facility)	0.077
Other PITC: 15-19, Female,	3,377
Negative	
Service Delivery Point (Facility)	
Other PITC: 15-19, Female,	101
Positive	



	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	8,832
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	302
O	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	4,717
0	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	190
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	20,342
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	764
O	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	20,890
0	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	1,066
	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	49,769
	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	2,747
	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	8,008
	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	290
	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	6,473
	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	224
	Service Delivery Point (Facility) Other PITC: Unknown Age,	0



Female, Negative	
Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	0
Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	0
Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	0
Service Delivery Point (Facility)Other PITC: <1, Negative	875
Service Delivery Point (Facility) Other PITC: <1, Positive	35
Service Delivery Point (Facility) Other PITC: 1-9, Negative	2,894
Service Delivery Point (Facility) Other PITC: 1-9, Positive	144
Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	
Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	
Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	
Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	
Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	184
Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female,	114



Positive	
Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	409
Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	253
Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	
Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Female, Positive	
Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Negative	
Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Positive	
Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	
Service Delivery Point (Community) Other: 10-14, Female, Positive	
Service Delivery Point (Community) Other: 10-14, Male, Negative	
Service Delivery Point (Community) Other: 10-14, Male, Positive	
Other: 15-19, Female, Negative	
Other: 15-19, Female, Positive	
Service Delivery Point (Community) Other: 15-19, Male, Negative	



Service Delivery Point (Community)
Other: 15-19, Male, Positive
Service Delivery Point (Community)
Other: 20-24, Female, Negative
Service Delivery Point (Community)
Other: 20-24, Female, Positive
Service Delivery Point (Community)
Other: 20-24, Male, Negative
Service Delivery Point (Community)
Other: 20-24, Male, Positive
Service Delivery Point (Community)
Other: 25-49, Female, Negative
Service Delivery Point (Community)
Other: 25-49, Female, Positive
Service Delivery Point (Community)
Other: 25-49, Male, Negative
Service Delivery Point (Community)
Other: 25-49, Male, Positive
Service Delivery Point (Community)
Other: 50+, Female, Negative
Service Delivery Point (Community)
Other: 50+, Female, Positive
Service Delivery Point (Community)
Other: 50+, Male, Negative
Service Delivery Point (Community)
Other: 50+, Male, Positive
Service Delivery Point (Community)
Other: Unknown Age, Female,
Negative
Service Delivery Point (Community)
Other: Unknown Age, Female,
Positive
Service Delivery Point (Community)
Other: Unknown Age, Male,



Negative	
Service Delivery Point (Community) Other: Unknown Age, Male, Positive	
Service Delivery Point (Community) Other: <1, Negative	
Service Delivery Point (Community) Other: <1, Positive	
Service Delivery Point (Community) Other: 1-9, Negative	
Service Delivery Point (Community) Other: 1-9, Positive	
Service Delivery Point by Agg Age (Community) Other: <15, Female, Negative	
Service Delivery Point by Agg Age (Community) Other: <15, Female, Positive	
Service Delivery Point by Agg Age (Community) Other: <15, Male, Negative	
Service Delivery Point by Agg Age (Community) Other: <15, Male, Positive	
Service Delivery Point by Agg Age (Community) Other: 15+, Female, Negative	
Service Delivery Point by Agg Age (Community) Other: 15+, Female, Positive	
Service Delivery Point by Agg Age (Community) Other: 15+, Male, Negative	
Service Delivery Point by Agg Age (Community) Other: 15+, Male,	



Positive	
Service Delivery Point by Agg Age (Community) Other: Unknown Age, Female, Negative	
Service Delivery Point by Agg Age (Community) Other: Unknown Age, Female, Positive	
Service Delivery Point by Agg Age (Community) Other: Unknown Age, Male, Negative	
Service Delivery Point by Agg Age (Community) Other: Unknown Age, Male, Positive	
Service Delivery Point (Facility) Pediatric : <5 Negative	10,059
Service Delivery Point (Facility) Pediatric : <5 Positive	227
Service Delivery Point (Facility) TB: 10-14, Female, Negative	191
Service Delivery Point (Facility) TB: 10-14, Female, Positive	98
Service Delivery Point (Facility) TB: 10-14, Male, Negative	63
Service Delivery Point (Facility) TB: 10-14, Male, Positive	80
Service Delivery Point (Facility) TB: 15-19, Female, Negative	117
Service Delivery Point (Facility) TB: 15-19, Female, Positive	13
Service Delivery Point (Facility) TB: 15-19, Male, Negative	371
Service Delivery Point (Facility) TB: 15-19, Male, Positive	49
Service Delivery Point (Facility) TB:	192



20-24, Female, Negative	
Service Delivery Point (Facility) TB: 20-24, Female, Positive	23
Service Delivery Point (Facility) TB: 20-24, Male, Negative	844
Service Delivery Point (Facility) TB: 20-24, Male, Positive	127
Service Delivery Point (Facility) TB: 25-49, Female, Negative	592
Service Delivery Point (Facility) TB: 25-49, Female, Positive	78
Service Delivery Point (Facility) TB: 25-49, Male, Negative	1,711
Service Delivery Point (Facility) TB: 25-49, Male, Positive	277
Service Delivery Point (Facility) TB: 50+, Female, Negative	188
Service Delivery Point (Facility) TB: 50+, Female, Positive	27
Service Delivery Point (Facility) TB: 50+, Male, Negative	167
Service Delivery Point (Facility) TB: 50+, Male, Positive	29
Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0
Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
Service Delivery Point (Facility) TB: <1, Negative	23
Service Delivery Point (Facility) TB:	12



<1, Positive	
Service Delivery Point (Facility) TB: 1-9, Negative	113
Service Delivery Point (Facility) TB: 1-9, Positive	49
Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative	
Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive	
Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative	
Service Delivery Point by Agg Age (Facility) TB: <15, Male, Positive	
Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	
Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	
Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	
Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	
Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Negative	98
Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Positive	50
Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Negative	134
Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male,	69



Positive	
Service Delivery Point (Facility) VMMC: <1, Negative	0
Service Delivery Point (Facility) VMMC: <1, Positive	0
Service Delivery Point (Facility) VMMC: 10-14, Negative	3,186
Service Delivery Point (Facility) VMMC: 10-14, Positive	90
Service Delivery Point (Facility) VMMC: 15-19, Negative	4,308
Service Delivery Point (Facility) VMMC: 15-19, Positive	123
Service Delivery Point (Facility) VMMC: 1-9, Negative	0
Service Delivery Point (Facility) VMMC: 1-9, Positive	0
Service Delivery Point (Facility) VMMC: 20-24, Negative	604
Service Delivery Point (Facility) VMMC: 20-24, Positive	17
Service Delivery Point (Facility) VMMC: 25-49, Negative	516
Service Delivery Point (Facility) VMMC: 25-49, Positive	13
Service Delivery Point (Facility) VMMC: 50+, Negative	0
Service Delivery Point (Facility) VMMC: 50+, Positive	0
Service Delivery Point (Facility) VMMC: Unknown Age, Negative	0
Service Delivery Point (Facility) VMMC: Unknown Age, Positive	0
Service Delivery Point (Facility)	1,384



VMMC: <15, Negative	
Service Delivery Point by Agg Age (Facility) VMMC: <15, Positive	38
Service Delivery Point by Agg Age (Facility) VMMC: 15+, Negative	3,114
Service Delivery Point by Agg Age (Facility) VMMC: 15+, Positive	121
Service Delivery Point by Agg Age (Facility) VMMC: Unknown Age, Negative	0
Service Delivery Point by Agg Age (Facility) VMMC: Unknown Age, Positive	0
Service Delivery Point (Facility) Index: 10-14, Female, Negative	936
Service Delivery Point (Facility) Index: 10-14, Female, Positive	202
Service Delivery Point (Facility) Index: 10-14, Male, Negative	739
Service Delivery Point (Facility) Index: 10-14, Male, Positive	198
Service Delivery Point (Facility) Index: 15-19, Female, Negative	902
Service Delivery Point (Facility) Index: 15-19, Female, Positive	234
Service Delivery Point (Facility) Index: 15-19, Male, Negative	2,050
Service Delivery Point (Facility) Index: 15-19, Male, Positive	585
Service Delivery Point (Facility) Index: 20-24, Female, Negative	1,432
Service Delivery Point (Facility) Index: 20-24, Female, Positive	406
Service Delivery Point (Facility)	4,691



Index: 20-24, Male, Negative	
Service Delivery Point (Facility) Index: 20-24, Male, Positive	1,433
Service Delivery Point (Facility) Index: 25-49, Female, Negative	5,691
Service Delivery Point (Facility) Index: 25-49, Female, Positive	2,133
Service Delivery Point (Facility) Index: 25-49, Male, Negative	12,679
Service Delivery Point (Facility) Index: 25-49, Male, Positive	4,303
Service Delivery Point (Facility) Index: 50+, Female, Negative	2,334
Service Delivery Point (Facility) Index: 50+, Female, Positive	784
Service Delivery Point (Facility) Index: 50+, Male, Negative	2,078
Service Delivery Point (Facility) Index: 50+, Male, Positive	615
Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	0
Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0
Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
Service Delivery Point (Facility) Index: <1, Negative	221
Service Delivery Point (Facility)	56



Index: <1, Positive	
Service Delivery Point (Facility) Index: 1-9, Negative	735
Service Delivery Point (Facility) Index: 1-9, Positive	173
Service Delivery Point Agg Age (Facility) Index: <15, Female, Negative	
Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive	
Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative	
Service Delivery Point Agg Age (Facility) Index: <15, Male, Positive	
Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	43
Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	13
Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	126
Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	41
Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Negative	
Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Positive	
Service Delivery Point Agg Age (Facility) Index: Unknown Age,	



Male, Negative	
Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Positive	
By Key Population: FSW, Negative	2,061
By Key Population: FSW, Positive	267
By Key Population: MSM, Negative	899
By Key Population: MSM, Positive	119
By Key Population: People in prisons and other enclosed settings, Negative	0
By Key Population: People in prisons and other enclosed settings, Positive	0
By Key Population: PWID, Negative	0
By Key Population: PWID, Positive	0
By Key Population: TG, Negative	0
By Key Population: TG, Positive	0
Service Delivery Point (Facility) Malnutrition: Negative	0
Service Delivery Point (Facility) Malnutrition: Positive	0
Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	28
Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	8
Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	76
Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	18
Service Delivery Point (Community) Index Mod: 15-19, Female,	71



Negative	
Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	18
Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	170
Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	48
Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	89
Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	27
Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	216
Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	61
Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	650
Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	197
Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	1,547
Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	425
Service Delivery Point (Community) Index Mod: 50+, Female, Negative	163
Service Delivery Point (Community) Index Mod: 50+, Female, Positive	51
Service Delivery Point (Community) Index Mod: 50+, Male, Negative	385
Service Delivery Point (Community) Index Mod: 50+, Male, Positive	103
Service Delivery Point (Community)	0



Index Mod: Unknown Age, Fema	ıle,
Negative	
Service Delivery Point (Commun	ity)
Index Mod: Unknown Age, Fema	ıle, 0
Positive	
Service Delivery Point (Commun	ity)
Index Mod: Unknown Age, Male,	0
Negative	
Service Delivery Point (Commun	ity)
Index Mod: Unknown Age, Male,	0
Positive	
Service Delivery Point (Commun	ity)
Index Mod: <1, Negative	0
Service Delivery Point (Commun	itv)
Index Mod: <1, Positive	0
Service Delivery Point (Commun	ity)
Index Mod: 1-9, Negative	30
Service Delivery Point (Commun	ity)
Index Mod: 1-9, Positive	6
Service Delivery Point by Agg Ag	ge l
(Community) Index Mod: <15,	31
Female, Negative	
Service Delivery Point by Agg Ag	ge
(Community) Index Mod: <15,	6
Female, Positive	
Service Delivery Point by Agg Ag	ge
(Community) Index Mod: <15,	76
Male, Negative	
Service Delivery Point by Agg Ag	ge
(Community) Index Mod: <15,	18
Male, Positive	
Service Delivery Point by Agg Ag	ge
(Community) Index Mod: 15+,	910
Female, Negative	
Service Delivery Point by Agg Ag	je 288
155. VIGO BOILVOLY I OILL BY MGG MG	200



(Community) Index Mod: 15+, Female, Positive	
Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Negative	1,959
Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Positive	607
Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Female, Negative	0
Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Female, Positive	
Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Male, Negative	0
Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Male, Positive	
Service Delivery Point (Facility) ANC: <1, Negative	61
Service Delivery Point (Facility) ANC: <1, Positive	2
Service Delivery Point (Facility) ANC: 10-14, Negative	761
Service Delivery Point (Facility) ANC: 10-14, Positive	104
Service Delivery Point (Facility) ANC: 15-19, Negative	1,718
Service Delivery Point (Facility) ANC: 15-19, Positive	247
Service Delivery Point (Facility) ANC: 1-9, Negative	223



Service Delivery Point (Facility) ANC: 1-9, Positive	23
Service Delivery Point (Facility) ANC: 20-24, Negative	4,913
Service Delivery Point (Facility) ANC: 20-24, Positive	833
Service Delivery Point (Facility) ANC: 25-49, Negative	11,024
Service Delivery Point (Facility) ANC: 25-49, Positive	1,673
Service Delivery Point (Facility) ANC: 50+, Negative	0
Service Delivery Point (Facility) ANC: 50+, Positive	0
Service Delivery Point (Facility) ANC: Unknown Age, Negative	0
Service Delivery Point (Facility) ANC: Unknown Age, Positive	0
Service Delivery Point by Agg Age (Facility) ANC: <15, Negative	
Service Delivery Point by Agg Age (Facility) ANC: <15, Positive	
Service Delivery Point by Agg Age (Facility) ANC: 15+, Negative	
Service Delivery Point by Agg Age (Facility) ANC: 15+, Positive	
Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Negative	
Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Positive	
Service Delivery Point (Facility) VCT: 10-14, Female, Negative	545



Service Delivery Point (Facility) VCT: 10-14, Female, Positive	69
Service Delivery Point (Facility) VCT: 10-14, Male, Negative	496
Service Delivery Point (Facility) VCT: 10-14, Male, Positive	82
Service Delivery Point (Facility) VCT: 15-19, Female, Negative	660
Service Delivery Point (Facility) VCT: 15-19, Female, Positive	85
Service Delivery Point (Facility) VCT: 15-19, Male, Negative	1,288
Service Delivery Point (Facility) VCT: 15-19, Male, Positive	219
Service Delivery Point (Facility) VCT: 20-24, Female, Negative	572
Service Delivery Point (Facility) VCT: 20-24, Female, Positive	95
Service Delivery Point (Facility) VCT: 20-24, Male, Negative	2,976
Service Delivery Point (Facility) VCT: 20-24, Male, Positive	478
Service Delivery Point (Facility) VCT: 25-49, Female, Negative	3,967
Service Delivery Point (Facility) VCT: 25-49, Female, Positive	735
Service Delivery Point (Facility) VCT: 25-49, Male, Negative	9,310
Service Delivery Point (Facility) VCT: 25-49, Male, Positive	1,787
Service Delivery Point (Facility) VCT: 50+, Female, Negative	1,893
Service Delivery Point (Facility) VCT: 50+, Female, Positive	312



Service Delivery Point (Facility) VCT: 50+, Male, Negative	2,011
Service Delivery Point (Facility) VCT: 50+, Male, Positive	378
Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	0
Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	0
Service Delivery Point (Facility) VCT:	0
Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	0
Service Delivery Point (Facility) VCT: <1, Negative	188
Service Delivery Point (Facility) VCT: <1, Positive	13
Service Delivery Point (Facility) VCT: 1-9, Negative	554
Service Delivery Point (Facility) VCT: 1-9, Positive	70
Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	
Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	
Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	
Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	
Service Delivery Point by Agg Age (Facility) VCT: 15+, Female,	524



Negative	
Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	97
Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	1,165
Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	216
Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Negative	
Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Positive	
Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Negative	
Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Positive	
Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	126
Service Delivery Point (Community) VCT Mod: 10-14, Female, Positive	16
Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	234
Service Delivery Point (Community) VCT Mod: 10-14, Male, Positive	47
Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	298
Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	36
Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	541



Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	107
Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	382
Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	48
Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	697
Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	142
Service Delivery Point (Community) VCT Mod: 25-49, Female, Negative	2,726
Service Delivery Point (Community) VCT Mod: 25-49, Female, Positive	349
Service Delivery Point (Community) VCT Mod: 25-49, Male, Negative	4,971
Service Delivery Point (Community) VCT Mod: 25-49, Male, Positive	1,025
Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	678
Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	85
Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	1,240
Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	241
Service Delivery Point (Community) VCT Mod: Unknown Age, Female, Negative	0
Service Delivery Point (Community) VCT Mod: Unknown Age, Female, Positive	0
Service Delivery Point (Community) VCT Mod: Unknown Age, Male,	0



Negative	
Service Delivery Point (Community) VCT Mod: Unknown Age, Male, Positive	0
Service Delivery Point (Community) VCT Mod: <1, Negative	0
Service Delivery Point (Community) VCT Mod: <1, Positive	0
Service Delivery Point (Community) VCT Mod: 1-9, Negative	124
Service Delivery Point (Community) VCT Mod: 1-9, Positive	21
Service Delivery Point by Agg Age (Community) VCT Mod: <15, Female, Negative	141
Service Delivery Point by Agg Age (Community) VCT Mod: <15, Female, Positive	10
Service Delivery Point by Agg Age (Community) VCT Mod: <15, Male, Negative	254
Service Delivery Point by Agg Age (Community) VCT Mod: <15, Male, Positive	16
Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Female, Negative	3,553
Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Female, Positive	316
Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Male, Negative	5,950
Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Male,	462



	Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Male, Positive	
	Number of people receiving post-GBV care	2,465
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,858
	By type of service: Sexual Violence (Post-Rape Care)	602
	By PEP service provision (related to sexual violence services provided)	551
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	60
	<10, Female, Sexual Violence (Post-Rape Care)	17
	<10, Male, Physical and/or Emotional Violence	9
	<10, Male, Sexual Violence (Post-Rape Care)	1
	10-14, Female, Physical and/or Emotional Violence	150
	10-14, Female, Sexual Violence	84



(Post-Rape Care)	
10-14, Male, Physical and/or Emotional Violence	59
10-14, Male, Sexual Violence (Post-Rape Care)	9
15-19, Female, Physical and/or Emotional Violence	243
15-19, Female, Sexual Violence (Post-Rape Care)	94
15-19, Male, Physical and/or Emotional Violence	42
15-19, Male, Sexual Violence (Post-Rape Care)	0
20-24, Female, Physical and/or Emotional Violence	730
20-24, Female, Sexual Violence (Post-Rape Care)	271
20-24, Male, Physical and/or Emotional Violence	246
20-24, Male, Sexual Violence (Post-Rape Care)	76
25-49, Female, Physical and/or Emotional Violence	178
25-49, Female, Sexual Violence (Post-Rape Care)	39
25-49, Male, Physical and/or Emotional Violence	100
25-49, Male, Sexual Violence (Post-Rape Care)	1
50+, Female, Physical and/or Emotional Violence	23
50+, Female, Sexual Violence (Post-Rape Care)	0
50+, Male, Physical and/or	2



	Emotional Violence	
	50+, Male, Sexual Violence	0
	(Post-Rape Care)	
	Unknown Age, Female, Physical	0
	and/or Emotional Violence	
	Unknown Age, Female, Sexual	0
	Violence (Post-Rape Care)	0
	Unknown Age, Male, Physical	0
	and/or Emotional Violence	0
	Unknown Age, Male, Sexual	0
	Violence (Post-Rape Care)	0
	Number of people receiving	878
	post-GBV care	0/0
	By type of service: Physical and/or	
	Emotional Violence (Other	661
	Post-GBV Care)	
	By type of service: Sexual Violence	21.4
	(Post-Rape Care)	214
	By PEP service provision (related	
	to sexual violence services	191
	provided)	
	<10, Female, Physical and/or	24
GEND_GBV_TA	Emotional Violence	24
	<10, Female, Sexual Violence	Λ
	(Post-Rape Care)	4
	<10, Male, Physical and/or	0
	Emotional Violence	2
	<10, Male, Sexual Violence	0
	(Post-Rape Care)	0
	10-14, Female, Physical and/or	00
	Emotional Violence	60
	10-14, Female, Sexual Violence	0.4
	(Post-Rape Care)	24
	10-14, Male, Physical and/or	13



Emotional Violence	
10-14, Male, Sexual Violence (Post-Rape Care)	2
15-19, Female, Physical and/or Emotional Violence	86
15-19, Female, Sexual Violence (Post-Rape Care)	30
15-19, Male, Physical and/or Emotional Violence	0
15-19, Male, Sexual Violence (Post-Rape Care)	0
20-24, Female, Physical and/or Emotional Violence	297
20-24, Female, Sexual Violence (Post-Rape Care)	106
20-24, Male, Physical and/or Emotional Violence	101
20-24, Male, Sexual Violence (Post-Rape Care)	31
25-49, Female, Physical and/or Emotional Violence	30
25-49, Female, Sexual Violence (Post-Rape Care)	4
25-49, Male, Physical and/or Emotional Violence	8
25-49, Male, Sexual Violence (Post-Rape Care)	0
50+, Female, Physical and/or Emotional Violence	0
50+, Female, Sexual Violence (Post-Rape Care)	0
50+, Male, Physical and/or Emotional Violence	0
50+, Male, Sexual Violence	0



	(Post-Rape Care)	
	Unknown Age, Female, Physical and/or Emotional Violence	0
	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
	Unknown Age, Male, Physical and/or Emotional Violence	0
	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	85,349
	Age/Sex: 10-14 Male	10,386
	Age/Sex: 15-17 Male	12,854
	By: Age/sex: Male 18-24	1,552
	By: Age/sex: Male 25+	70
	Age/Sex: 18+ Male	
	Age/Sex: 10-14 Female	11,407
	Age/Sex: 15-17 Female	14,430
	By: Age/sex: 18-24 Female	3,354
OVC_SERV_DSD	By: Age/sex: 25+ Female	830
	Age/Sex: 18+ Female	
	Sum of Age/Sex disaggregates	49,077
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	5,422
	Required only for DREAMS countries - By service, age and sex: Education Support Female	1,855



15-17	
Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	1,241
Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	716
Required only for DREAMS countries - By service, age and sex: Education Support Male <1	
Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	3,460
Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	1,641
Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	691
Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	34
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	4,984
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs	498



E	
Female 15-17	
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	599
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	3,190
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	299
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	399
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	
Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	
Required only for DREAMS countries - By service, age and sex: Social Protection Female	1,085



	10-14	
	Required only for DREAMS	
	countries - By service, age and	000
	sex: Social Protection Female	238
	15-17	
	Required only for DREAMS	
	countries - By service, age and	440
	sex: Social Protection Female	118
	18-24	
	Required only for DREAMS	
	countries - By service, age and	
	sex: Social Protection Female 25+	
	Required only for DREAMS	
	countries - By service, age and	
	sex: Social Protection Male <1	
	Required only for DREAMS	
	countries - By service, age and	679
	sex: Social Protection Male 10-14	
	Required only for DREAMS	
	countries - By service, age and	115
	sex: Social Protection Male 15-17	
	Required only for DREAMS	
	countries - By service, age and	34
	sex: Social Protection Male 18-24	
	Required only for DREAMS	
	countries - By service, age and	
	sex: Social Protection Male 25+	
	Required only for DREAMS	
	countries - By service, age and	
	sex: Economic Strengthening	
	Female <1	
	Required only for DREAMS	
	countries - By service, age and	7.505
	sex: Economic Strengthening	7,535
	Female 10-14	



T		1
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	3,393
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	941
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	3,393
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	2,826
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	753
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	



Required only for DREAMS	
countries - By service, age and	15,507
sex: Other Services Female 10-14	
Required only for DREAMS	
countries - By service, age and	12,675
sex: Other Services Female 15-17	
Required only for DREAMS	
countries - By service, age and	1,948
sex: Other Services Female 18-24	
Required only for DREAMS	
countries - By service, age and	
sex: Other Services Female 25+	
Required only for DREAMS	
countries - By service, age and	
sex: Other Services Male <1	
Required only for DREAMS	
countries - By service, age and	9,989
sex: Other Services Male 10-14	
Required only for DREAMS	
countries - By service, age and	8,836
sex: Other Services Male 15-17	
Required only for DREAMS	
countries - By service, age and	1,650
sex: Other Services Male 18-24	
Required only for DREAMS	
countries - By service, age and	
sex: Other Services Male 25+	
Age/Sex: <1	631
Age/Sex: 1-9	9,168
Required only for DREAMS	
countries - By service, age and	
sex: Education Support 1-9 Male	
Required only for DREAMS	
countries - By service, age and	
sex: Parenting/Caregiver Programs	



Male 1-9	
Required only for DREAMS	
countries - By service, age and	
sex: Social Protection Programs	
Male 1-9	
Required only for DREAMS	
countries - By service, age and	
sex: Economic Strengthening Male	
1-9	
Required only for DREAMS	
countries - By service, age and	
sex: Other Services Male 1-9	
Program Completion: Active	39,522
Program Completion: Graduation	8,397
Program Completion: Transferred	33,630
Program Completion: Exited	2 000
without graduation	3,800
By Aggregated Age/Sex: <18 Male	
By Aggregated Age/Sex: 18+ Male	
By Aggregated Age/Sex: <18	
Female	
By Aggregated Age/Sex: 18+	
Female	
Required only for DREAMS	
countries - By service, age and	
sex: Education Support Female 1-9	
Required only for DREAMS	
countries - By service, age and	
sex: Parenting/Caregiver Programs	
Female 1-9	
Required only for DREAMS	
countries - By service, age and	
sex: Social Protection Programs	
Female 1-9	



<u></u>		
	Required only for DREAMS	
	countries - By service, age and	
	sex: Economic Strengthening	
	Female 1-9	
	Required only for DREAMS	
	countries - By service, age and	
	sex: Other Services Female 1-9	
	TB_ART_DSD Percentage of	
	HIV-positive new and relapsed	400.07
	registered TB cases on ART during	100 %
	TB treatment	
	The number of registered new and	
	relapse TB cases with documented	
	HIV-positive status who are on	3,158
	ART during TB treatment during	·
	the reporting period	
	The number of registered new and	
	relapse TB cases with documented	
	HIV-positive status during TB	3,158
	treatment during the reporting	,
	period	
TB_ART_DSD	Age/Sex: <1 (Numerator: The	
	number of registered new and	
	relapse TB cases with documented	
	HIV-positive status who are on	
	ART during TB treatment during	
	the reporting period)	
	Age/Sex: 1-9 (Numerator: The	
	number of registered new and	
	relapse TB cases with documented	
	HIV-positive status who are on	
	ART during TB treatment during	
	the reporting period)	
	Age/Sex: Male 10-14 (Numerator:	
	,	
	The number of registered new and	I



HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 15-19 (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 20-24 (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 25-49 (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 50+ (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 10-14	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 15-19	
(Numerator: The number of	



registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 20-24	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 25-49	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 50+ (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Aggregated Age/Sex: Male <15	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	39
	39
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Aggregated Age/Sex: Male 15+	
(Numerator: The number of	1,298
registered new and relapse TB	
cases with documented	



HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Aggregated Age/Sex: Female <15	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	67
HIV-positive status who are on	•
ART during TB treatment during	
the reporting period)	
Aggregated Age/Sex: Female 15+	
(Numerator: The number of	
registered new and relapse TB	4.754
cases with documented	1,754
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
On ART: Already on ART	
On ART: New on ART	
Age/Sex: >1 (Denominator: The	
number of registered new and	
relapse TB cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: 1-9 (Denominator: The	
number of registered new and	
relapse TB cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Male 10-14	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	



treatment during the reporting	
period)	
Age/Sex: Male 15-19	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Male 20-24	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Male 25-49	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Male 50+ (Denominator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Female 10-14	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
r -··*/	



Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB	
cases with documented HIV-positive status during TB	
treatment during the reporting period)	
Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting	
period) Age/Sex: Female 25-49	
(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	33
Aggregated Age/Sex: Male 15+	1,300



	1	
	(Denominator: The number of	
	registered new and relapse TB	
	cases with documented	
	HIV-positive status during TB	
	treatment during the reporting	
	period)	
	Aggregated Age/Sex: Female <15	
	(Denominator: The number of	
	registered new and relapse TB	
	cases with documented	67
	HIV-positive status during TB	
	treatment during the reporting	
	period)	
	Aggregated Age/Sex: Female 15+	
	(Denominator: The number of	
	registered new and relapse TB	
	cases with documented	1,758
	HIV-positive status during TB	,
	treatment during the reporting	
	period)	
	TB_ART_TA Percentage of	
	HIV-positive new and relapsed	
	registered TB cases on ART during	100 %
	TB treatment	
	The number of registered new and	
	relapse TB cases with documented	
	HIV-positive status who are on	50
	ART during TB treatment during	00
TB_ART_TA	the reporting period	
	The number of registered new and	
	relapse TB cases with documented	
	HIV-positive status during TB	50
	treatment during the reporting	50
	period	
	Age/Sex: <1 (Numerator: The	
	number of registered new and	



relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: 1-9 (Numerator: The	
number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 10-14 (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 15-19 (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 20-24 (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 25-49 (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 50+ (Numerator:	
The number of registered new and	



relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 10-14	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 15-19	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 20-24	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 25-49	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 50+ (Numerator:	
The number of registered new and	
The number of registered new and relapse TB cases with documented	
relapse TB cases with documented HIV-positive status who are on	



ART during TB treatment during the reporting period) Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented 0 HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented 46 HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented 0 HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented 0 HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented 4 HIV-positive status who are on ART during TB treatment during the reporting period) On ART: Already on ART On ART: New on ART On ART: New on ART On ART: New on ART Age/Sex: <1 (Denominator: The number of registered new and		
Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented 0 HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented 46 HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented 0 HIV-positive status who are on are registered new and relapse TB cases with documented 0 HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented 4 HIV-positive status who are on are registered new and relapse TB cases with documented 4 HIV-positive status who are on ART during TB treatment during the reporting period) On ART: Already on ART On ART: New on ART Age/Sex: <1 (Denominator: The		
(Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented of registered new and relapse TB cases with documented Of HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented Of HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented Of registered new and relapse TB cases with documented Of registered new and relapse TB cases with documented Of registered new and relapse TB cases with documented Of registered new and relapse TB cases with documented Of registered new and relapse TB cases with documented Of registered new and relapse TB cases with documented Of registered new and relapse TB cases with documented Of registered new and relapse TB cases with documented Of registered new and relapse TB cases with documented Of registered new and relapse TB cases with documented Of registered new and relapse TB cases with documented Of registered new and relapse TB cases with documented Of registered new and relapse TB cases with documented Of registered new and relapse TB cases of registered new and relaps	the reporting period)	
registered new and relapse TB cases with documented 46 HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented 0 HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented 4 HIV-positive status who are on ART during TB treatment during the reporting period) On ART: Already on ART On ART: New on ART Age/Sex: <1 (Denominator: The	(Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Male 15+	0
(Numerator: The number of registered new and relapse TB cases with documented 0 HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented 4 HIV-positive status who are on ART during TB treatment during the reporting period) On ART: Already on ART On ART: New on ART Age/Sex: <1 (Denominator: The	registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during	46
(Numerator: The number of registered new and relapse TB cases with documented 4 HIV-positive status who are on ART during TB treatment during the reporting period) On ART: Already on ART On ART: New on ART Age/Sex: <1 (Denominator: The	(Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during	0
On ART: New on ART Age/Sex: <1 (Denominator: The	(Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during	4
Age/Sex: <1 (Denominator: The	On ART: Already on ART	
	On ART: New on ART	
relapse TB cases with documented HIV-positive status during TB	number of registered new and relapse TB cases with documented	



treatment during the reporting
period)
Age/Sex: 1-9 (Denominator: The
number of registered new and
relapse TB cases with documented
HIV-positive status during TB
treatment during the reporting
period)
Age/Sex: Male 10-14
(Denominator: The number of
registered new and relapse TB
cases with documented
HIV-positive status during TB
treatment during the reporting
period)
Age/Sex: Male 15-19
(Denominator: The number of
registered new and relapse TB
cases with documented
HIV-positive status during TB
treatment during the reporting
period)
Age/Sex: Male 20-24
(Denominator: The number of
registered new and relapse TB
cases with documented
HIV-positive status during TB
treatment during the reporting
period)
Age/Sex: Male 25-49 (Denominator: The number of
,
registered new and relapse TB
cases with documented
HIV-positive status during TB
treatment during the reporting
period)



Age/Sex: Male 50+ (Denominator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Female 10-14	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Female 15-19	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Female 20-24	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Female 25-49	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Female 50+	
(Denominator: The number of	



	registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Aggregated Age/Sex: Male <15	
	(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	0
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	46
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	0
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	4
	TB_PREV_DSD TB_PREV_DSD	84 %
TB_PREV_DSD	The number of ART patients who completed a course of TB	82,115



preventive therapy or at least 6	
months of Isoniazid Preventive	
Therapy (IPT) during the reporting	
period	
e number of ART patients who	
ere newly started on TB	
preventive therapy (including those	
who newly started on TB	
preventive therapy in this reporting	97,201
period and those who started in the	97,201
previous reporting period but had	
not been reported as they did not	
fulfill the minimum requirements for	
the previous reporting period).	
By Age/Sex (Denominator): <15,	2 000
Female	3,928
By Age/Sex (Denominator): <15,	2.45
Male	3,421
By Age/Sex (Denominator): 15+,	
-emale	57,889
By Age/Sex (Denominator): 15+,	04.000
Male	31,963
By Therapy type (Denominator):	00
6-12 Month IPT	89,560
By Therapy type (Denominator):	_
Alternative Regimen	3,811
By Therapy type (Denominator):	
Continuous IPT	3,830
By Age/Sex (Numerator): <15,	
Female	3,337
By Age/Sex (Numerator): <15,	
Male	2,912
By Age/Sex (Numerator): 15+,	
emale	48,797
	27.060
By Age/Sex (Numerator): 15+,	27,069



	Male	
	By Therapy type (Numerator): 6-12 Month IPT	75,581
	By Therapy type (Numerator): Alternative Regimen	3,263
	By Therapy type (Numerator): Continuous IPT	3,271
	TB_PREV_TA TB_PREV_TA	84 %
	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	2,390
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	2,838
	By Age/Sex (Denominator): <15, Female	155
	By Age/Sex (Denominator): <15, Male	283
	By Age/Sex (Denominator): 15+, Female	1,155
	By Age/Sex (Denominator): 15+, Male	1,245
	By Therapy type (Denominator): 6-12 Month IPT	2,609
	By Therapy type	114



	(Denominator):Alternative Regimen	
	By Therapy type (Denominator):Continuous IPT	115
	By Age/Sex (Numerator): <15, Female	133
	By Age/Sex (Numerator): <15, Male	239
	By Age/Sex (Numerator): 15+, Female	979
	By Age/Sex (Numerator): 15+, Male	1,039
	By Therapy type (Numerator): 6-12 Month IPT	2,202
	By Therapy type (Numerator): Alternative Regimen	94
	By Therapy type (Numerator): Continuous IPT	94
	TX_TB_DSD The proportion of ART patients who were screened who are receiving TB treatment	2 %
	Number of ART patients who were started on TB treatment during the reporting period.	2,896
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	155,830
	Numerator: By Aggregated Age/Sex: <15, Female	90
	Numerator: By Aggregated Age/Sex: <15, Male	85
	Numerator: By Aggregated Age/Sex: 15+, Female	1,567
	Numerator: By Aggregated Age/Sex: 15+, Male	1,154



	Denominator: By Aggregated	6,096
	Age/Sex: <15, Female	•
	Denominator: By Aggregated Age/Sex: <15, Male	5,413
	Denominator: By Aggregated Age/Sex:15+, Female	91,462
	Denominator: By Aggregated Age/Sex:15+, Male	50,806
	Denominator: By Screen Result: Negative	139,366
	Denominator: By Screen Result: Positive	16,464
	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	16,500
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	148
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	0
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	16,344
	TX_TB_TA The proportion of ART patients who were screened who are receiving TB treatment	2 %
TX_TB_TA	Number of ART patients who were started on TB treatment during the reporting period.	65
	Number of ART patients who were screened for TB at least once during the reporting period	3,477
	Numerator: By Aggregated	4



		1
	Age/Sex: <15, Female	
	Numerator: By Aggregated Age/Sex: <15, Male	5
	Numerator: By Aggregated Age/Sex: 15+, Female	17
	Numerator: By Aggregated Age/Sex: 15+, Male	39
	Denominator: By Aggregated Age/Sex: <15, Female	145
	Denominator: By Aggregated Age/Sex: <15, Male	373
	Denominator: By Aggregated Age/Sex: 15+, Female	1,253
	Denominator: By Aggregated Age/Sex: 15+, Male	1,706
	Denominator: By Screen Result: Negative	3,183
	Denominator: By Screen Result: Positive	294
	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	294
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	4
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	0
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	290
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women	n/a



that receive a virological HIV test	
within 12 months of birth (DSD)	
Number of infants who had a	
virologic HIV test within 12 months	8,904
of birth during the reporting period	
Number of HIV- positive pregnant	
women identified during the	
reporting period (include known	
HIV-positive women at entry into	
PMTCT)	
By infants who received a virologic	
test within 2 months of birth	
By infants who received their first	
virologic HIV test between 2 and 12	
months of age	
Sum of Infant Age disaggregates	
By infants with a positive virologic	
test result within 12 months of birth	
Number of infants with a positive	
virological test result within 2	259
months of birth	
Number of infants with a positive	
virological test result within 12	
months of birth	
Unknown, <= 2 months	513
Unknown, 2 - 12 months	14
Number of infants with a negative	
virological test result within 2	7,293
months of birth	
Number of infants with a positive	
virological test result between 2	40
and 12 months of birth	
Number of infants with a negative	
virological test result between 2	785
and 12 months of birth	



PMTCT_EID_TA Percent of infants born to HIV-positive women that n/a receive a virological HIV test within 12 months of birth (TA) Number of infants who had a virologic HIV test within 12 months 439 of birth during the reporting period Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) By infants who received a virologic test within 2 months of birth By infants who received their first virologic HIV test between 2 and 12 months of age Sum of Infant Age disaggregates PMTCT_EID_TA By infants with a positive virologic test result within 12 months of birth Unknown, <= 2 months 21 Unknown, 2 - 12 months 0 Number of infants with a positive virological test result within 2 12 months of birth Number of infants with a negative virological test result within 2 364 months of birth Number of infants with a positive virological test result between 2 0 and 12 months of birth Number of infants with a negative virological test result between 2 42 and 12 months of birth Number of infants with a positive



	virological test result within 12 months of birth	
	Number of adults and children receiving antiretroviral therapy (ART)	168,230
	Age/Sex: 15-19 Male	2,502
	Age/Sex: 15-19 Female	4,925
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	36
	Aggregated Age/Sex: 15+ Male	1,700
	Aggregated Age/Sex: <15 Female	61
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	1,779
	Sum of Aggregated Age/Sex <15	97
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	3,479
	Sum of Aggregated Age/Sex disaggregates	3,576
	Age/Sex: <1	1,392
	Age/Sex: <1-9	5,121
	Age/Sex: 10-14 Male	1,588
	Age/Sex: 10-14 Female	1,763
	Aggregated Age/Sex: 1-14 Male	
	Age/Sex: 20-24 Male	6,548
	Age/Sex: 25-49 Male	38,411
	Age/Sex: 50+ Male	10,430
	Age/Sex: 20-24 Female	15,562
	Age/Sex: 25-49 Female	65,273
	Age/Sex: 50+ Female	11,139
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	2,693



Age/Sex: <1 Male	
Age/Sex: 1-4 Male	
Age/Sex: 5-14 Male	
Age/Sex: 15-19 Male	30
Age/Sex: 20+ Male	
Age/Sex: <1 Female	
Age/Sex: 1-4 Female	
Age/Sex: 5-14 Female	
Age/Sex: 15-19 Female	72
Age/Sex: 20+ Female	
Sum of Age/Sex disaggregations	102
Aggregated Age/Sex: <1 Male	
Aggregated Age/Sex: <1 Female	
Aggregated Age/Sex: <15 Male	
Aggregated Age/Sex: 1-14 Male	
Aggregated Age/Sex: 15+ Male	
Aggregated Age/Sex: <15 Female	
Aggregated Age/Sex: 1-14 Female	
Aggregated Age/Sex: 15+ Female	
Sum of Aggregated Age/Sex <15	
Sum of Aggregated Age/Sex 15+	
Sum of Aggregated Age/Sex	
disaggregates	
Age/Sex: <1	67
Age/Sex: 1-9	261
Age/Sex: 10-14 Male	216
Age/Sex: 10-14 Female	55
Sum of Aggregated Age/Sex (<1	
and 1-14) <15	
Age/Sex: 20-24 Male	89
Age/Sex: 25-49 Male	1,387
Age/Sex: 50+ Male	219



	Age/Sex: 20-24 Female	201
	Age/Sex: 25-49 Female	989
	Age/Sex: 50+ Female	65
	Number of adults and children newly enrolled on antiretroviral therapy (ART)	33,485
	By Age/Sex: <1	222
	By Age/Sex: 1-9	474
	By Age/Sex: 10-14 Male	773
	By Age/Sex: 15-19 Male	1,685
	By Age/Sex: 20-24 Male	4,081
	By Age/Sex: 25-49 Male	11,214
	By Age/Sex: 50+ Male	2,808
	By Age/Sex: 10-14 Female	550
	By Age/Sex: 15-19 Female	1,103
	By Age/Sex: 20-24 Female	1,488
	By Age/Sex: 25-49 Female	5,816
TX_NEW_DSD	By Age/Sex: 50+ Female	1,974
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	8
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	678
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	8
	Aggregated Grouping by Age/Sex: 15+ Female	603



	Pregnancy status	1,382
	Breastfeeding status	223
	FSW	
	MSM	
	People in prisons and other enclosed settings	
	TG	
	Aggregated Grouping by Age/Sex: 1-14 Female	
	By Key populations: People who inject drugs (PWID)	
	Number of adults and children newly enrolled on antiretroviral therapy (ART)	601
	By Age/Sex: <1	22
	By Age/Sex: 1-9	60
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	126
	By Age/Sex: 15-19 Male	37
TX_NEW_TA	By Age/Sex: 20-24 Male	111
	By Age/Sex: 25-49 Male	647
	By Age/Sex: 50+ Male	94
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	17
	By Age/Sex: 15-19 Female	23
	By Age/Sex: 20-24 Female	26
	By Age/Sex: 25-49 Female	99
	By Age/Sex: 50+ Female	24



	Sum of Age/Sex disaggregates	1,204
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	
	Sum of Aggregated Age/Sex disaggregates	
	Pregnancy status	24
	Breastfeeding status	3
	FSW	
	MSM	
	People in prisons and other enclosed settings	
	TG	
	By Key populations: People who inject drugs (PWID)	
	TX_PVLS_DSD Percentage of	
	ART patients with a viral load result	
TX_PVLS_DSD	documented in the medical record and/or laboratory information	90 %
	systems (LIS) within the past 12	



	months with a suppressed viral	
	load (<1000 copies/ml)	
	Number of adults and pediatric	
	patients on ART with suppressed	
vi	ral load results (<1,000 copies/ml)	132,010
	documented in the medical records	132,010
	and /or supporting laboratory	
1	results within the past 12 months.	
ľ	Number of adult and pediatric ART	
(patients with a viral load result	
ŀ	documented in the patient medical	146,669
	record and /or laboratory records	
l	in the past 12 months.	
	Numerator: Indication: Routine	126,003
	Numerator: Indication: Targeted	2,006
	Numerator: Preg/BF by Indication:	0.050
l	Pregnant Routine	6,053
	Numerator: Preg/BF by Indication:	1.000
	Breastfeeding Routine	1,688
	Numerator: Preg/BF by Indication:	400
	Pregnant Targeted	120
	Numerator: Preg/BF by Indication:	
ı	Breastfeeding Targeted	57
Ī	Numerator: Age/Sex by Indication:	
	<1 Routine	
Ī	Numerator: Age/Sex by Indication:	
	1-9 Routine	
	Numerator: Age/Sex by Indication:	
ı	10-14 Male Routine	
	Numerator: Age/Sex by Indication:	
	15-19 Male Routine	
	Numerator: Age/Sex by Indication:	
	20-24 Male Routine	
	umerator: Age/Sex by Indication:	
_	Traincrator. Ago, och by malcation.	



25-49 Male Routine Numerator: Age/Sex by Indication: 50+ Male Routine Numerator: Age/Sex by Indication: 10-14 Female Routine Numerator: Age/Sex by Indication: 15-19 Female Routine Numerator: Age/Sex by Indication: 20-24 Female Routine Numerator: Age/Sex by Indication: 25-49 Female Routine Numerator: Age/Sex by Indication: 50+ Female Routine Numerator: Age/Sex by Indication: <1 Targeted Numerator: Age/Sex by Indication: 1-9 Targeted Numerator: Age/Sex by Indication: 10-14 Male Targeted Numerator: Age/Sex by Indication: 15-19 Male Targeted Numerator: Age/Sex by Indication: 20-24 Male Targeted Numerator: Age/Sex by Indication: 25-49 Male Targeted Numerator: Age/Sex by Indication: 25-49 Male Targeted Numerator: Age/Sex by Indication: 25-49 Female Targeted Numerator: Age/Sex by Indication: 50+ Male Targeted Numerator: Age/Sex by Indication: 10-14 Female Targeted Numerator: Age/Sex by Indication: 15-19 Female Targeted Numerator: Age/Sex by Indication: 20-24 Female Targeted Numerator: Age/Sex by Indication:		
Numerator: Age/Sex by Indication: 10-14 Female Routine Numerator: Age/Sex by Indication: 15-19 Female Routine Numerator: Age/Sex by Indication: 20-24 Female Routine Numerator: Age/Sex by Indication: 25-49 Female Routine Numerator: Age/Sex by Indication: 50+ Female Routine Numerator: Age/Sex by Indication: 50+ Female Routine Numerator: Age/Sex by Indication:	25-49 Male Routine	
Numerator: Age/Sex by Indication: 10-14 Female Routine Numerator: Age/Sex by Indication: 15-19 Female Routine Numerator: Age/Sex by Indication: 20-24 Female Routine Numerator: Age/Sex by Indication: 25-49 Female Routine Numerator: Age/Sex by Indication: 50+ Female Routine Numerator: Age/Sex by Indication: <1 Targeted Numerator: Age/Sex by Indication: 1-9 Targeted Numerator: Age/Sex by Indication: 10-14 Male Targeted Numerator: Age/Sex by Indication: 15-19 Male Targeted Numerator: Age/Sex by Indication: 20-24 Male Targeted Numerator: Age/Sex by Indication: 25-49 Male Targeted Numerator: Age/Sex by Indication: 50+ Male Targeted Numerator: Age/Sex by Indication: 50+ Male Targeted Numerator: Age/Sex by Indication: 10-14 Female Targeted Numerator: Age/Sex by Indication: 10-15-19 Female Targeted Numerator: Age/Sex by Indication:		
10-14 Female Routine Numerator: Age/Sex by Indication: 15-19 Female Routine Numerator: Age/Sex by Indication: 20-24 Female Routine Numerator: Age/Sex by Indication: 25-49 Female Routine Numerator: Age/Sex by Indication: 50+ Female Routine Numerator: Age/Sex by Indication: <1 Targeted Numerator: Age/Sex by Indication: 1-9 Targeted Numerator: Age/Sex by Indication: 10-14 Male Targeted Numerator: Age/Sex by Indication: 15-19 Male Targeted Numerator: Age/Sex by Indication: 20-24 Male Targeted Numerator: Age/Sex by Indication: 25-49 Male Targeted Numerator: Age/Sex by Indication: 50+ Male Targeted Numerator: Age/Sex by Indication: 50+ Male Targeted Numerator: Age/Sex by Indication: 10-14 Female Targeted Numerator: Age/Sex by Indication: 10-15-19 Female Targeted Numerator: Age/Sex by Indication: 15-19 Female Targeted Numerator: Age/Sex by Indication:	50+ Male Routine	
Numerator: Age/Sex by Indication: 15-19 Female Routine Numerator: Age/Sex by Indication: 20-24 Female Routine Numerator: Age/Sex by Indication: 25-49 Female Routine Numerator: Age/Sex by Indication: 50+ Female Routine Numerator: Age/Sex by Indication: <1 Targeted Numerator: Age/Sex by Indication: 1-9 Targeted Numerator: Age/Sex by Indication: 10-14 Male Targeted Numerator: Age/Sex by Indication: 15-19 Male Targeted Numerator: Age/Sex by Indication: 20-24 Male Targeted Numerator: Age/Sex by Indication: 25-49 Male Targeted Numerator: Age/Sex by Indication: 25-49 Male Targeted Numerator: Age/Sex by Indication: 50+ Male Targeted Numerator: Age/Sex by Indication: 10-14 Female Targeted Numerator: Age/Sex by Indication: 10-19 Female Targeted Numerator: Age/Sex by Indication:	,	
Numerator: Age/Sex by Indication: 20-24 Female Routine Numerator: Age/Sex by Indication: 25-49 Female Routine Numerator: Age/Sex by Indication: 50+ Female Routine Numerator: Age/Sex by Indication: 50+ Female Routine Numerator: Age/Sex by Indication: <1 Targeted Numerator: Age/Sex by Indication: 1-9 Targeted Numerator: Age/Sex by Indication: 10-14 Male Targeted Numerator: Age/Sex by Indication: 15-19 Male Targeted Numerator: Age/Sex by Indication: 20-24 Male Targeted Numerator: Age/Sex by Indication: 25-49 Male Targeted Numerator: Age/Sex by Indication: 50+ Male Targeted Numerator: Age/Sex by Indication: 10-14 Female Targeted Numerator: Age/Sex by Indication: 10-15-19 Female Targeted Numerator: Age/Sex by Indication: 15-19 Female Targeted Numerator: Age/Sex by Indication:		
20-24 Female Routine Numerator: Age/Sex by Indication: 25-49 Female Routine Numerator: Age/Sex by Indication: 50+ Female Routine Numerator: Age/Sex by Indication: <1 Targeted Numerator: Age/Sex by Indication: 1-9 Targeted Numerator: Age/Sex by Indication: 10-14 Male Targeted Numerator: Age/Sex by Indication: 15-19 Male Targeted Numerator: Age/Sex by Indication: 20-24 Male Targeted Numerator: Age/Sex by Indication: 25-49 Male Targeted Numerator: Age/Sex by Indication: 50+ Male Targeted Numerator: Age/Sex by Indication: 10-14 Female Targeted Numerator: Age/Sex by Indication: 10-15-19 Female Targeted Numerator: Age/Sex by Indication: 15-19 Female Targeted Numerator: Age/Sex by Indication:	,	
25-49 Female Routine Numerator: Age/Sex by Indication: 50+ Female Routine Numerator: Age/Sex by Indication: <1 Targeted Numerator: Age/Sex by Indication: 1-9 Targeted Numerator: Age/Sex by Indication: 10-14 Male Targeted Numerator: Age/Sex by Indication: 15-19 Male Targeted Numerator: Age/Sex by Indication: 20-24 Male Targeted Numerator: Age/Sex by Indication: 25-49 Male Targeted Numerator: Age/Sex by Indication: 50+ Male Targeted Numerator: Age/Sex by Indication: 50+ Male Targeted Numerator: Age/Sex by Indication: 10-14 Female Targeted Numerator: Age/Sex by Indication: 15-19 Female Targeted Numerator: Age/Sex by Indication: 20-24 Female Targeted	•	
S0+ Female Routine Numerator: Age/Sex by Indication: <1 Targeted Numerator: Age/Sex by Indication: 1-9 Targeted Numerator: Age/Sex by Indication: 10-14 Male Targeted Numerator: Age/Sex by Indication: 15-19 Male Targeted Numerator: Age/Sex by Indication: 20-24 Male Targeted Numerator: Age/Sex by Indication: 25-49 Male Targeted Numerator: Age/Sex by Indication: 50+ Male Targeted Numerator: Age/Sex by Indication: 10-14 Female Targeted Numerator: Age/Sex by Indication: 15-19 Female Targeted Numerator: Age/Sex by Indication: 15-19 Female Targeted Numerator: Age/Sex by Indication: 20-24 Female Targeted	,	
<1 Targeted Numerator: Age/Sex by Indication: 1-9 Targeted Numerator: Age/Sex by Indication: 10-14 Male Targeted Numerator: Age/Sex by Indication: 15-19 Male Targeted Numerator: Age/Sex by Indication: 20-24 Male Targeted Numerator: Age/Sex by Indication: 25-49 Male Targeted Numerator: Age/Sex by Indication: 50+ Male Targeted Numerator: Age/Sex by Indication: 10-14 Female Targeted Numerator: Age/Sex by Indication: 15-19 Female Targeted Numerator: Age/Sex by Indication: 15-19 Female Targeted Numerator: Age/Sex by Indication: 20-24 Female Targeted Numerator: Age/Sex by Indication: 20-24 Female Targeted	,	
1-9 Targeted Numerator: Age/Sex by Indication: 10-14 Male Targeted Numerator: Age/Sex by Indication: 15-19 Male Targeted Numerator: Age/Sex by Indication: 20-24 Male Targeted Numerator: Age/Sex by Indication: 25-49 Male Targeted Numerator: Age/Sex by Indication: 50+ Male Targeted Numerator: Age/Sex by Indication: 10-14 Female Targeted Numerator: Age/Sex by Indication: 15-19 Female Targeted Numerator: Age/Sex by Indication: 20-24 Female Targeted		
Numerator: Age/Sex by Indication: 15-19 Male Targeted Numerator: Age/Sex by Indication: 20-24 Male Targeted Numerator: Age/Sex by Indication: 25-49 Male Targeted Numerator: Age/Sex by Indication: 25-49 Male Targeted Numerator: Age/Sex by Indication: 50+ Male Targeted Numerator: Age/Sex by Indication: 10-14 Female Targeted Numerator: Age/Sex by Indication: 15-19 Female Targeted Numerator: Age/Sex by Indication: 20-24 Female Targeted	,	
Numerator: Age/Sex by Indication: 20-24 Male Targeted Numerator: Age/Sex by Indication: 25-49 Male Targeted Numerator: Age/Sex by Indication: 50+ Male Targeted Numerator: Age/Sex by Indication: 10-14 Female Targeted Numerator: Age/Sex by Indication: 15-19 Female Targeted Numerator: Age/Sex by Indication: 20-24 Female Targeted	<u> </u>	
20-24 Male Targeted Numerator: Age/Sex by Indication: 25-49 Male Targeted Numerator: Age/Sex by Indication: 50+ Male Targeted Numerator: Age/Sex by Indication: 10-14 Female Targeted Numerator: Age/Sex by Indication: 15-19 Female Targeted Numerator: Age/Sex by Indication: 20-24 Female Targeted		
25-49 Male Targeted Numerator: Age/Sex by Indication: 50+ Male Targeted Numerator: Age/Sex by Indication: 10-14 Female Targeted Numerator: Age/Sex by Indication: 15-19 Female Targeted Numerator: Age/Sex by Indication: 20-24 Female Targeted		
50+ Male Targeted Numerator: Age/Sex by Indication: 10-14 Female Targeted Numerator: Age/Sex by Indication: 15-19 Female Targeted Numerator: Age/Sex by Indication: 20-24 Female Targeted	<u> </u>	
10-14 Female Targeted Numerator: Age/Sex by Indication: 15-19 Female Targeted Numerator: Age/Sex by Indication: 20-24 Female Targeted		
15-19 Female Targeted Numerator: Age/Sex by Indication: 20-24 Female Targeted		
20-24 Female Targeted	•	
Numerator: Age/Sex by Indication:		
	Numerator: Age/Sex by Indication:	



25-49 Female Targeted	
Numerator: Age/Sex by Indication:	
50+ Female Targeted	
Numerator: Aggregate Age/Sex by	45
Indication: <15 Male Targeted	
Numerator: Aggregate Age/Sex by	758
Indication: 15+ Male Targeted	700
Numerator: Aggregate Age/Sex by	67
Indication: <15 Female Targeted	
Numerator: Aggregate Age/Sex by	1,136
Indication: 15+ Female Targeted	.,
Numerator: Aggregate Age/Sex by	3,599
Indication: <15 Male Routine	
Numerator: Aggregate Age/Sex by	42,152
Indication: 15+ Male Routine	
Numerator: Aggregate Age/Sex by	4,685
Indication: <15 Female Routine	
Numerator: Aggregate Age/Sex by	75,567
Indication: 15+ Female Routine	
Denominator: Indication: Routine	139,825
Denominator: Indication: Targeted	2,206
Denominator: Preg/BF by	6,691
Indication: Pregnant Routine	•
Denominator: Preg/BF by	1,852
Indication: Breastfeeding Routine	
Denominator: Preg/BF by	136
Indication: Pregnant Targeted	
Denominator: Preg/BF by	61
Indication: Breastfeeding Targeted	
Denominator: Age/Sex by	
Indication: <1 Routine	
Denominator: Age/Sex by	
Indication: 1-9 Routine	
Denominator: Age/Sex by	



Indication: 10-14 Male Routine
Denominator: Age/Sex by
Indication: 15-19 Male Routine
Denominator: Age/Sex by
Indication: 20-24 Male Routine
Denominator: Age/Sex by
Indication: 25-49 Male Routine
Denominator: Age/Sex by
Indication: 50+ Male Routine
Denominator: Age/Sex by
Indication: 10-14 Female Routine
Denominator: Age/Sex by
Indication: 15-19 Female Routine
Denominator: Age/Sex by
Indication: 20-24 Female Routine
Denominator: Age/Sex by
Indication: 25-49 Female Routine
Denominator: Age/Sex by
Indication: 50+ Female Routine
Denominator: Age/Sex by
Indication: <1 Targeted
Denominator: Age/Sex by
Indication: 1-9 Targeted
Denominator: Age/Sex by
Indication: 10-14 Male Targeted
Denominator: Age/Sex by
Indication: 15-19 Male Targeted
Denominator: Age/Sex by
Indication: 20-24 Male Targeted
Denominator: Age/Sex by
Indication: 25-49 Male Targeted
Denominator: Age/Sex by
Indication: 50+ Male Targeted
Denominator: Age/Sex by



Indication: 10-14 Female Targeted	
Denominator: Age/Sex by	
Indication: 15-19 Female Targeted	
Denominator: Age/Sex by	
Indication: 20-24 Female Targeted	
Denominator: Age/Sex by	
Indication: 25-49 Female Targeted	
Denominator: Age/Sex by	
Indication: 50+ Female Targeted	
Denominator: Aggregate Age/Sex	40
by Indication: <15 Male Targeted	48
Denominator: Aggregate Age/Sex	831
by Indication: 15+ Male Targeted	831
Denominator: Aggregate Age/Sex	90
by Indication: <15 Female Targeted	80
Denominator: Aggregate Age/Sex	1 0 1 7
by Indication: 15+ Female Targeted	1,247
Denominator: Aggregate Age/Sex	4,012
by Indication: <15 Male Routine	4,012
Denominator: Aggregate Age/Sex	46,775
by Indication: 15+ Male Routine	40,773
Denominator: Aggregate Age/Sex	5,173
by Indication: <15 Female Routine	3,173
Denominator: Aggregate Age/Sex	83,865
by Indication: 15+ Female Routine	00,000
Numerator Aggregated Age/Sex:	
<15 Male	
Numerator Aggregated Age/Sex:	
15+ Male	
Numerator Aggregated Age/Sex:	
<15 Female	
Numerator Aggregated Age/Sex:	
15+ Female	
Denominator Aggregated Age/Sex:	



<15 Male	
Denominator Aggregated Age/Sex: 15+ Male	
Denominator Aggregated Age/Sex: <15 Female	
Denominator Aggregated Age/Sex: 15+ Female	
<15, Routine, Unknown Sex	0
<15, Targeted, Unknown Sex	0
<15, Undocumented Test Indication, Female	118
<15, Undocumented Test Indication, Male	67
<15, Undocumented Test Indication, Unknown Sex	0
15+, Routine, Unknown Sex	0
15+, Targeted, Unknown Sex	0
15+, Undocumented Test Indication, Female	2,552
15+, Undocumented Test Indication, Male	1,901
15+, Undocumented Test Indication, Unknown Sex	0
Unknown Age, Routine, Female	0
Unknown Age, Routine, Male	0
Unknown Age, Routine, Unknown Sex	0
Unknown Age, Targeted, Female	0
Unknown Age, Targeted, Male	0
Unknown Age, Targeted, Unknown Sex	0
Unknown Age, Undocumented Test Indication, Female	0



Unknown Age, Undocumented Test Indication, Male	0
Unknown Age, Undocumented Test Indication, Unknown Sex	0
Breastfeeding, Undocumented Test Indication	61
Pregnant, Undocumented Test Indication	136
Undocumented Test Indication	4,638
<15, Routine, Unknown Sex	0
<15, Targeted, Unknown Sex	0
<15, Undocumented Test Indication, Female	98
<15, Undocumented Test Indication, Male	61
<15, Undocumented Test Indication, Unknown Sex	0
15+, Routine, Unknown Sex	0
15+, Targeted, Unknown Sex	0
15+, Undocumented Test Indication, Female	2,207
15+, Undocumented Test Indication, Male	1,635
15+, Undocumented Test Indication, Unknown Sex	0
Unknown Age, Routine, Female	0
Unknown Age, Routine, Male	0
Unknown Age, Routine, Unknown Sex	0
Unknown Age, Targeted, Female	0
Unknown Age, Targeted, Male	0
Unknown Age, Targeted, Unknown Sex	0



	Unknown Age, Undocumented Test Indication, Female	0
	Unknown Age, Undocumented Test Indication, Male	0
	Unknown Age, Undocumented Test Indication, Unknown Sex	0
	Breastfeeding, Undocumented Test Indication	57
	Pregnant, Undocumented Test Indication	120
	Undocumented Test Indication	4,001
	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	104 %
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	5,991
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	5,734
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	



Numerator: Age/Sex by Indication:	
1-9 Targeted Numerator: Age/Sex by Indication: 10-14 Female Routine	
Numerator: Age/Sex by Indication: 10-14 Female Targeted	
Numerator: Age/Sex by Indication: 10-14 Male Routine	
Numerator: Age/Sex by Indication: 10-14 Male Targeted	
Numerator: Age/Sex by Indication: 15-19 Female Routine	
Numerator: Age/Sex by Indication: 15-19 Female Targeted	
Numerator: Age/Sex by Indication: 15-19 Male Routine	
Numerator: Age/Sex by Indication: 15-19 Male Targeted	
Numerator: Age/Sex by Indication: 20-24 Female Routine	
Numerator: Age/Sex by Indication: 20-24 Female Targeted	
Numerator: Age/Sex by Indication: 20-24 Male Routine	
Numerator: Age/Sex by Indication: 20-24 Male Targeted	
Numerator: Age/Sex by Indication: 25-49 Female Routine	
Numerator: Age/Sex by Indication: 25-49 Female Targeted	
Numerator: Age/Sex by Indication: 25-49 Male Routine	
Numerator: Age/Sex by Indication: 25-49 Male Targeted	



Numerator: Age/Sex by Indication:	
50+ Female Routine	
Numerator: Age/Sex by Indication: 50+ Female Targeted	
Numerator: Age/Sex by Indication: 50+ Male Routine	
Numerator: Age/Sex by Indication: 50+ Male Targeted	
Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	246
Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	2
Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	261
Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	1
Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	3,444
Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	30
Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	1,934
Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	20
Numerator: Indication: Routine	5,885
Numerator: Indication: Targeted	53
Numerator: Preg/BF by Indication: Breastfeeding Routine	30
Numerator: Preg/BF by Indication: Breastfeeding Targeted	1
Numerator: Preg/BF by Indication: Pregnant Routine	83
Numerator: Preg/BF by Indication: Pregnant Targeted	3



Denominator: Indication: Routine	6,520
Denominator: Indication: Targeted	58
Denominator: Age/Sex by	
Indication: <1 Routine	
Denominator: Age/Sex by	
Indication: <1 Targeted	
Denominator: Age/Sex by	
Indication: 1-9 Routine	
Denominator: Age/Sex by	
Indication: 1-9 Targeted	
Denominator: Age/Sex by	
Indication: 10-14 Female Routine	
Denominator: Age/Sex by	
Indication: 10-14 Female Targeted	
Denominator: Age/Sex by	
Indication: 10-14 Male Routine	
Denominator: Age/Sex by	
Indication: 10-14 Male Targeted	
Denominator: Age/Sex by	
Indication: 15-19 Female Routine	
Denominator: Age/Sex by	
Indication: 15-19 Female Targeted	
Denominator: Age/Sex by	
Indication: 15-19 Male Routine	
Denominator: Age/Sex by	
Indication: 15-19 Male Targeted	
Denominator: Age/Sex by	
Indication: 20-24 Female Routine	
Denominator: Age/Sex by	
Indication: 20-24 Female Targeted	
Denominator: Age/Sex by	
Indication: 20-24 Male Routine	
Denominator: Age/Sex by	
Indication: 20-24 Male Targeted	



	Denominator: Age/Sex by	
	Indication: 25-49 Female Routine	
	Denominator: Age/Sex by	
	Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by	
	Indication: 25-49 Male Routine	
	Denominator: Age/Sex by	
	Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by	
	Indication: 50+ Female Routine	
	Denominator: Age/Sex by	
	Indication: 50+ Female Targeted	
	Denominator: Age/Sex by	
	Indication: 50+ Male Routine	
	Denominator: Age/Sex by	
	Indication: 50+ Male Targeted	
	Denominator: Aggregate Age/Sex	271
	by Indication: <15 Female Routine	211
	Denominator: Aggregate Age/Sex	2
	by Indication: <15 Female Targeted	2
	Denominator: Aggregate Age/Sex	286
	by Indication: <15 Male Routine	200
	Denominator: Aggregate Age/Sex	1
	by Indication: <15 Male Targeted	· ·
	Denominator: Aggregate Age/Sex	3,818
	by Indication: 15+ Female Routine	3,010
	Denominator: Aggregate Age/Sex	33
	by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex	2,145
	by Indication: 15+ Male Routine	2,145
	Denominator: Aggregate Age/Sex	22
	by Indication: 15+ Male Targeted	
	Denominator: Preg/BF by	32
	Indication: Breastfeeding Routine	3Z



Denominator: Preg/BF by Indication: Breastfeeding Targeted Denominator: Preg/BF by Indication: Pregnant Routine Denominator: Preg/BF by Indication: Pregnant Targeted Numerator Aggregated Age/Sex: <15 Male
Denominator: Preg/BF by Indication: Pregnant Routine Denominator: Preg/BF by Indication: Pregnant Targeted Numerator Aggregated Age/Sex:
Denominator: Preg/BF by Indication: Pregnant Targeted Numerator Aggregated Age/Sex:
Numerator Aggregated Age/Sex:
Numerator Aggregated Age/Sex: 15+ Male
Numerator Aggregated Age/Sex: <15 Female
Numerator Aggregated Age/Sex: 15+ Female
Denominator Aggregated Age/Sex: <15 Male
Denominator Aggregated Age/Sex: 15+ Male
Denominator Aggregated Age/Sex: <15 Female
Denominator Aggregated Age/Sex: 15+ Female
<15, Routine, Unknown Sex 0
<15, Targeted, Unknown Sex 0
<15, Undocumented Test Indication, Female
<15, Undocumented Test Indication, Male
<15, Undocumented Test Indication, Unknown Sex
15+, Routine, Unknown Sex 0
15+, Targeted, Unknown Sex 0
15+, Undocumented Test Indication, Female



15+, Undocumented Test Indication, Male	22
15+, Undocumented Test Indication, Unknown Sex	0
Unknown Age, Routine, Female	0
Unknown Age, Routine, Male	0
Unknown Age, Routine, Unknown Sex	0
Unknown Age, Targeted, Female	0
Unknown Age, Targeted, Male	0
Unknown Age, Targeted, Unknown Sex	0
Unknown Age, Undocumented Test Indication, Female	0
Unknown Age, Undocumented Test Indication, Male	0
Unknown Age, Undocumented Test Indication, Unknown Sex	0
Breastfeeding, Undocumented Test Indication	1
Pregnant, Undocumented Test Indication	4
Undocumented Test Indication	58
<15, Routine, Unknown Sex	0
<15, Targeted, Unknown Sex	0
<15, Undocumented Test Indication, Female	2
<15, Undocumented Test Indication, Male	1
<15, Undocumented Test Indication, Unknown Sex	0
15+, Routine, Unknown Sex	0
15+, Targeted, Unknown Sex	0



	15+, Undocumented Test Indication, Female	30
	15+, Undocumented Test Indication, Male	20
	15+, Undocumented Test	0
Indication, Unknown Sex		
	Unknown Age, Routine, Female	0
	Unknown Age, Routine, Male	0
	Unknown Age, Routine, Unknown Sex	0
	Unknown Age, Targeted, Female	0
	Unknown Age, Targeted, Male	0
	Unknown Age, Targeted, Unknown Sex	0
Unknown Age, Undocumented Te Indication, Female Unknown Age, Undocumented Te Indication, Male		0
		0
	Unknown Age, Undocumented Test Indication, Unknown Sex	0
	Breastfeeding, Undocumented Test Indication	1
	Pregnant, Undocumented Test Indication	3
	Undocumented Test Indication	53
	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	93 %
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	24,445
	Total number of adults and children who initiated ART in the 12 months	26,152



prior to the beginning of the	
reporting period, including those	
who have died, those who have	
stopped ART, and those lost to	
follow-up	
Age/Sex: <1 (Numerator: Number	
of adults and children who are still	
alive and on treatment at 12	
months after initiating ART	
Age/Sex: 1-9 (Numerator: Number	
of adults and children who are still	
alive and on treatment at 12	
months after initiating ART	
Age/Sex: 10-14 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART	
Age/Sex: 15-19 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART	
Age/Sed: 20-24 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART	
Age/Sex: 25-49 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART	
Age/Sex: 50+ Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART	
Age/Sex: 10-14 Female	
(Numerator: Number of adults and	



children who are still alive and on treatment at 12 months after
treatment at 12 months after
treatment at 12 months after
initiating ART
Age/Sex: 15-19 Female
(Numerator: Number of adults and
children who are still alive and on
treatment at 12 months after
initiating ART
Age/Sex: 20-24 Female
(Numerator: Number of adults and
children who are still alive and on
treatment at 12 months after
initiating ART
Age/Sex: 25-49 Female
(Numerator: Number of adults and
children who are still alive and on
treatment at 12 months after
initiating ART
Age/Sex: 50+ Female (Numerator:
Number of adults and children who
are still alive and on treatment at
12 months after initiating ART
Age/Sex: >1 (Denominator: Total
number of adults and children who
initiated ART in the 12 months prior
to the beginning of the reporting
period, including those who have
died, those who have stopped
ART, and those lost to follow-up)
Age/Sex: 1-9 (Denominator: Total
number of adults and children who
initiated ART in the 12 months prior
to the beginning of the reporting
period, including those who have
died, those who have stopped
ART, and those lost to follow-up)



Age/Sex: 10-14 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 15-19 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 20-24 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 25-49 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 50+ Male (Denominator:	
Total number of adults and children	
who initiated ART in the 12 months	
prior to the beginning of the	



reporting period, including those	
who have died, those who have	
stopped ART, and those lost to	
follow-up)	
Age/Sex: 10-14 Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 15-19 Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 20-24 Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 25-49 Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	



Age/Sex: 50+ Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Aggregated Age: <15 (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Aggregated Age: 15+ (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Aggregated Age: <15	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Aggregated Age: 15+	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Numerator by Status: Pregnant	1,334
Numerator by Status:	100
Breastfeeding	163
Denominator by Status: Pregnant	1,490



Denominator by Status: Breastfeeding	174
Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	701
Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7,405
Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	806
Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	15,587
Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	743
Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	7,913



	those who have stopped ART, and	
	those lost to follow-up)	
	Aggregated Age/Sex: <15 Female	
	(Denominator: Total number of	
	adults and children who initiated	
	ART in the 12 months prior to the	007
	beginning of the reporting period,	837
	including those who have died,	
	those who have stopped ART, and	
	those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female	
	(Denominator: Total number of	
	adults and children who initiated	
	ART in the 12 months prior to the	
	beginning of the reporting period,	16,719
	including those who have died,	
	those who have stopped ART, and	
	those lost to follow-up)	
	TX_RET_TA Percent of adults and	
	children known to be alive and on	
	treatment 12 months after initiation	92 %
	of antiretroviral therapy	
	Number of adults and children who	
	are still alive and on treatment at	941
	12 months after initiating ART	
	Total number of adults and children	
	who initiated ART in the 12 months	
TX_RET_TA	prior to the beginning of the	
	reporting period, including those	1,018
	who have died, those who have	•
	stopped ART, and those lost to	
	follow-up	
	Age/Sex: <1 (Numerator: Number	
	of adults and children who are still	
	alive and on treatment at 12	
	months after initiating ART)	



Age/Sex: 1-9 (Numerator: Number	
of adults and children who are still	
alive and on treatment at 12	
months after initiating ART)	
Age/Sex: 10-14 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Age/Sex: 15-19 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Age/Sex: 20-24 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Age/Sex: 25-49 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Age/Sex: 50+ Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Age/Sex: 10-14 Female	
(Numerator: Number of adults and	
children who are still alive and on	
treatment at 12 months after	
initiating ART)	
Age/Sex: 15-19 Female	
(Numerator: Number of adults and	
children who are still alive and on	
treatment at 12 months after	
initiating ART)	
Age/Sex: 20-24 Female	
-	



(Numerator: Number of adults and	
children who are still alive and on	
treatment at 12 months after	
initiating ART)	
Age/Sex: 25-49 Female	
(Numerator: Number of adults and	
children who are still alive and on	
treatment at 12 months after	
initiating ART)	
Age/Sex: 50+ Female (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Age/Sex: <1 (Denominator: Total	
number of adults and children who	
initiated ART in the 12 months prior	
to the beginning of the reporting	
period, including those who have	
died, those who have stopped	
ART, and those lost to follow-up)	
Age/Sex: 1-9 (Denominator: Total	
number of adults and children who	
initiated ART in the 12 months prior	
to the beginning of the reporting	
period, including those who have	
died, those who have stopped	
ART, and those lost to follow-up)	
Age/Sex: 10-14 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 15-19 Male	



(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 20-24 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 25-49 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 50+ Male (Denominator:	
Total number of adults and children	
who initiated ART in the 12 months	
prior to the beginning of the	
reporting period, including those	
who have died, those who have	
stopped ART, and those lost to	
follow-up)	
Age/Sex: 10-14 Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	



including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 15-19 Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 20-24 Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 25-49 Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 50+ Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Aggregated Age: <15 (Numerator:	



Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Aggregated Age: 15+ (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Aggregated Age: <15	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Aggregated Age: 15+	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Numerator by Status: Pregnant	25
Numerator by Status:	,
Breastfeeding	4
Denominator by Status: Pregnant	28
Denominator by Status:	
Breastfeeding	4
Aggregated Age/Sex: <15 Male	
(Numerator: Number of adults and	
children who are still alive and on	68
treatment at 12 months after	
initiating ART)	
Aggregated Age/Sex: 15+ Male	553



(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14
Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	307
Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	63
Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	597
Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	14



	those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	345
	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	440
	By Graduates: Doctors	0
 HRH_PRE	By Graduates: Nurses	267
	By Graduates: Midwives	9
	By Graduates: Social service workers	0
	By Graduates: Laboratory professionals	72
	By Graduates: Other	92
	Sum of Graduates disaggreagtes	440



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
10703	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	1,496,392
14201	Mothers 2 Mothers	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	286,356
17389	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	75,000
17454	Centre for HIV and AIDS Prevention Studies Swaziland	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	3,077,830
17458	International Center for AIDS Care and Treatment Programs, Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	400,000
17460	University Research Corporation, LLC	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,216,191
17461	International Center for AIDS	University	U.S. Department of Health and	GHP-State	1,538,047



	Care and		Human		
	Treatment		Services/Centers		
	Programs,		for Disease		
	Columbia		Control and		
	University		Prevention		
			U.S. Department		
			of Health and		
	Ministry of Health	Host Country	Human		
17462	and Social	Government	Services/Centers	GHP-State	662,580
	Welfare,	Agency	for Disease		
	Swaziland		Control and		
			Prevention		
	International		U.S. Department		
	Center for AIDS		of Health and		
	Care and		Human		
17463	Treatment	University	Services/Centers	GHP-State	3,886,818
	Programs,	,	for Disease		
	Columbia		Control and		
	University		Prevention		
			U.S. Agency for		
17464	Pact	Multi-lateral	International	GHP-State	5,679,130
17404	Pact	Agency	Development	Orn Otate	3,073,130
			-		
47405	Jaha Caass Jaa	Drivete Centre etc.	U.S. Agency for	OLID Otata	0.400.700
17465	John Snow, Inc.	Private Contractor		GHP-State	3,460,768
			Development		
	Catholic Relief		U.S. Agency for		
17965	Services	FBO		GHP-State	234,933
			Development		
	Population		U.S. Agency for	GHP-State,	
17966	Services	NGO	International	GHP-USAID	1,928,828
	International		Development	GITF-USAID	
	The Luise		U.S. Agency for		
17967	The Luke	FBO	International	GHP-State	2,188,588
	Commission		Development		
17972	University of North	University	U.S. Agency for	GHP-State	250,000



	1	i	1	1	<u> </u>
	Carolina at Chapel Hill, Carolina Population Center		International Development		
18169	TBD	TBD	Redacted	Redacted	Redacted
18250	WHO/AFRO	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	250,000
18272	TBD	TBD	Redacted	Redacted	Redacted
18329	Institute for Health Measurement	NGO	U.S. Agency for International Development	GHP-State	1,763,500
18331	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	6,121,278
18387	FHI 360	NGO	U.S. Agency for International Development	GHP-State	2,047,187
18598	Population Council	NGO	U.S. Agency for International Development	GHP-State	250,000
18599	TBD	TBD	Redacted	Redacted	Redacted
18600	TBD	TBD	Redacted	Redacted	Redacted
18601	TBD	TBD	Redacted	Redacted	Redacted
18602	TBD	TBD	Redacted	Redacted	Redacted



Implementing Mechanism(s)

Implementing Mechanism Details

	Mechanism Name: Systems for Improved			
Mechanism ID: 10703	Access to Pharmaceuticals and Services			
	Program (SIAPS)			
Funding Agency: USAID	Procurement Type: Cooperative Agreement			
Prime Partner Name: Management Sciences for Hea	alth			
Agreement Start Date: Redacted	Agreement End Date: Redacted			
TBD: No	New Mechanism: No			
Global Fund / Multilateral Engagement: N/A				
G2G: No	Managing Agency:			

Total All Funding Sources: 1,496,392	Total Mechanism Pipeline: N/A				
Applied Pipeline Amount: 389,228	Applied Pipeline Amount: 389,228				
Total All Funding Sources and Applied Pipeline Amount: 1,885,620					
Funding Source Funding Amount					
GHP-State	1,496,392				

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: Mechanism Name:	Systems for Improved Access to Pharmaceuticals and Services Program (SIARS)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HBHC	600,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	121,392	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	775,000	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14201	Mechanism Name: Reducing Infection through Support & Eduation (RISE)			
Funding Agency: USAID	Procurement Type: Contract			
Prime Partner Name: Mothers 2 Mothers				
Agreement Start Date: Redacted	Agreement End Date: Redacted			
TBD: No	New Mechanism: No			
Global Fund / Multilateral Engagement: N/A				
G2G: No	Managing Agency:			

Total All Funding Sources: 286,356	Total Mechanism Pipeline: N/A				
Applied Pipeline Amount: 27,920	Applied Pipeline Amount: 27,920				
Total All Funding Sources and Applied Pi	Total All Funding Sources and Applied Pipeline Amount: 314,276				
Funding Source	Funding Amount				
GHP-State	286,356				
GHP-USAID	0				

Cross-Cutting Budget Attribution(s)

(No data provided.)



Mechanism ID:	Reducing Infection through Support & Eduation (RISE)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	НВНС	81,825	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	HKID	23,157	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	PDCS	92,650	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	MTCT	83,922	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Treatment	PDTX	4,802	0	

Indicator Number	Label	2018
	Number of HIV-positive pregnant women who received	
PMTCT_ART_DSD	ART to reduce risk of mother-to-child-transmission	1,546
	(MTCT) during pregnancy	
	Number of pregnant women with known HIV status	
PMTCT_ART_DSD	(includes women who were tested for HIV and received	4,584
	their results)	
PMTCT_ART_DSD	New on ART	757



PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	789
	Number of pregnant women with known HIV status	
PMTCT_STAT_DSD	(includes women who were tested for HIV and received their results)	4,584
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	45
PMTCT_STAT_DSD	By Age (Denominator): <15-19	627
PMTCT_STAT_DSD	By Age (Denominator): 20-24	1,591
PMTCT_STAT_DSD	By Age (Denominator): 25-49	2,553
PMTCT_STAT_DSD	By Age (Denominator): 50+	0
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	3
PMTCT_STAT_DSD	By Number of known positives: 15-19	137
PMTCT_STAT_DSD	By Number of known positives: 20-24	351
PMTCT_STAT_DSD	By Number of known positives: 25-49	564
PMTCT_STAT_DSD	By Number of known positives: 50+	0
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	0
PMTCT_STAT_DSD	By Number of new positives: 15-19	59
PMTCT_STAT_DSD	By Number of new positives: 20-24	149
PMTCT_STAT_DSD	By Number of new positives: 25-49	245
PMTCT_STAT_DSD	By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	0
PMTCT_STAT_DSD	By Number of new negative: <10	0
PMTCT_STAT_DSD	By Number of new negative: 10-14	39
PMTCT_STAT_DSD	By Number of new negative: 15-19	402
PMTCT_STAT_DSD	By Number of new negative: 20-24	1,009
PMTCT_STAT_DSD	By Number of new negative: 25-49	1,626
PMTCT_STAT_DSD	By Number of new negative: 50+	0



PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Numerator): <10	0
PMTCT_STAT_DSD	By Age (Numerator): 10-14	42
PMTCT_STAT_DSD	By Age (Numerator): 15-19	598
PMTCT_STAT_DSD	By Age (Numerator): 20-24	1,509
PMTCT_STAT_DSD	By Age (Numerator): 25-49	2,435
PMTCT_STAT_DSD	By Age (Numerator): 50+	0
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	2,920
OVC_SERV_DSD	Age/Sex: 10-14 Male	23
OVC_SERV_DSD	Age/Sex: 15-17 Male	10
OVC_SERV_DSD	By: Age/sex: Male 18-24	10
OVC_SERV_DSD	By: Age/sex: Male 25+	34
OVC_SERV_DSD	Age/Sex: 10-14 Female	24
OVC_SERV_DSD	Age/Sex: 15-17 Female	91
OVC_SERV_DSD	By: Age/sex: 18-24 Female	576
OVC_SERV_DSD	By: Age/sex: 25+ Female	732
OVC_SERV_DSD	Sum of Age/Sex disaggregates	148
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	24
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	88
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	560
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	716
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	23
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	10
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	10



1		
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	34
OVC_SERV_DSD	Age/Sex: <1	603
OVC_SERV_DSD	Age/Sex: 1-9	817
OVC_SERV_DSD	Program Completion: Active	2,920
OVC_SERV_DSD	Program Completion: Graduation	0
OVC_SERV_DSD	Program Completion: Transferred	0
OVC_SERV_DSD	Program Completion: Exited without graduation	0
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,520
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	27
PMTCT_EID_DSD	Unknown, <= 2 months	33
PMTCT_EID_DSD	Unknown, 2 - 12 months	2
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	1,344
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	5
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	109

Mechanism ID: 17389	Mechanism Name: Vast Grants	
Funding Agency: PC	Procurement Type: Grant	
Prime Partner Name: U.S. Peace Corps		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 75,000	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 75,000		



Funding Source	Funding Amount
GHP-State	75,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Duaget Code Illioning	ation		
Mechanism ID:	17389		
Mechanism Name:	Vast Grants		
Prime Partner Name:	U.S. Peace Corps		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	75,000	0

Indicator Number	Label	2018
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	5,474
OVC_SERV_DSD	Age/Sex: 10-14 Male	562
OVC_SERV_DSD	Age/Sex: 15-17 Male	900
OVC_SERV_DSD	By: Age/sex: Male 18-24	413
OVC_SERV_DSD	By: Age/sex: Male 25+	36
OVC_SERV_DSD	Age/Sex: 10-14 Female	881
OVC_SERV_DSD	Age/Sex: 15-17 Female	1,007
OVC_SERV_DSD	By: Age/sex: 18-24 Female	413
OVC_SERV_DSD	By: Age/sex: 25+ Female	98
OVC_SERV_DSD	Sum of Age/Sex disaggregates	3,350



OVC_SERV_DSD	Age/Sex: <1	0
OVC_SERV_DSD	Age/Sex: 1-9	1,164
OVC_SERV_DSD	Program Completion: Active	4,734
OVC_SERV_DSD	Program Completion: Graduation	303
OVC_SERV_DSD	Program Completion: Transferred	9
OVC_SERV_DSD	Program Completion: Exited without graduation	428

Mechanism ID: 17454	Mechanism Name: CHAPS VMMC	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Centre for HIV and AIDS Prevention Studies Swaziland		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 3,077,830	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pip	eline Amount: 3,077,830	
Funding Source	Funding Amount	
GHP-State	3,077,830	
GHP-USAID	o	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17454
Mechanism Name:	CHAPS VMMC
Prime Partner Name:	Centre for HIV and AIDS Prevention Studies Swaziland



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	29,472	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	3,048,358	0

Indicator Number	Label	2018
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention	18,813
VIVIIVIO_GITTO_DGD	program within the reporting period	10,010
VMMC_CIRC_DSD	By Age: 0-60 days	0
VMMC_CIRC_DSD	By Age: 2 months - 9 years	0
VMMC_CIRC_DSD	By Age: 10-14	6,962
VMMC_CIRC_DSD	By Age: 15-19	9,408
VMMC_CIRC_DSD	By Age: 20-24	1,317
VMMC_CIRC_DSD	By Age: 25-29	565
VMMC_CIRC_DSD	By Age: 30-49	561
VMMC_CIRC_DSD	By Age: 50+	0
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	17,687
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	18,813
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	18,813
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	12,701
HTC_TST_DSD	By Test Result: Positive	346
HTC_TST_DSD	Sum of Test Result disaggregates	346
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: <1, Positive	0



HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	3,186
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	90
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	4,308
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	123
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	604
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Negative	516
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: <15, Negative	1,384
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: <15, Positive	38
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Negative	2,359
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Positive	64
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: Unknown Age, Positive	0

Mechanism ID: 17458	Mechanism Name: ICAP – Epi-Research TA



Funding Agency: HHS/CDC Procurement Type: Cooperative Agreement	
Prime Partner Name: International Center for AIDS C	Care and Treatment Programs, Columbia University
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 400,000	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 500,000		
Total All Funding Sources and Applied Pipeline Amount: 900,000		
Funding Source Funding Amount		
GHP-State	400,000	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: Mechanism Name: Prime Partner Name:	ICAP – Epi-Research TA International Center for AIDS Care and Treatment Programs, Columbia		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	400,000	0

Implementing Mechanism Indicator Information

(No data provided.)



Mechanism ID: 17460 Mechanism Name: URC - Lubombo	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation	on, LLC
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 5,216,191	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 600,000		
Total All Funding Sources and Applied Pip	eline Amount: 5,816,191	
Funding Source	Funding Amount	
GHP-State	5,216,191	

Cross-Cutting Budget Attribution(s)

Gender: GBV	116,323
Focus Area:	Post GBV Care
Sub Area:	Capacity building
Water	45,000

Budget Code Information

Mechanism ID:	17460		
Mechanism Name:	URC - Lubombo		
Prime Partner Name:	University Research Co	rporation, LLC	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	1,309,443	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	901,680	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	554,016	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	8,806	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	453,667	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	70,826	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,770,553	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	147,200	0

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	1,889
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	5,494
PMTCT_ART_DSD	New on ART	718
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,171



	Number of HIV-positive pregnant women who received	
PMTCT_ART_TA	ART to reduce risk of mother-to-child-transmission	208
	(MTCT) during pregnancy	
	Number of pregnant women with known HIV status	
PMTCT_ART_TA	(includes women who were tested for HIV and received	267
	their results)	
PMTCT_ART_TA	New on ART	79
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	129
	Number of pregnant women with known HIV status	
PMTCT_STAT_DSD	(includes women who were tested for HIV and received	5,494
	their results)	
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	0
PMTCT_STAT_DSD	By Age (Denominator): <15-19	979
PMTCT_STAT_DSD	By Age (Denominator): 20-24	1,700
PMTCT_STAT_DSD	By Age (Denominator): 25-49	3,081
PMTCT_STAT_DSD	By Age (Denominator): 50+	0
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	0
PMTCT_STAT_DSD	By Number of known positives: 15-19	302
PMTCT_STAT_DSD	By Number of known positives: 20-24	421
PMTCT_STAT_DSD	By Number of known positives: 25-49	680
PMTCT_STAT_DSD	By Number of known positives: 50+	0
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	0
PMTCT_STAT_DSD	By Number of new positives: 15-19	116
PMTCT_STAT_DSD	By Number of new positives: 20-24	159
PMTCT_STAT_DSD	By Number of new positives: 25-49	279
PMTCT_STAT_DSD	By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	0



	·	
PMTCT_STAT_DSD	By Number of new negative: <10	0
PMTCT_STAT_DSD	By Number of new negative: 10-14	0
PMTCT_STAT_DSD	By Number of new negative: 15-19	711
PMTCT_STAT_DSD	By Number of new negative: 20-24	1,001
PMTCT_STAT_DSD	By Number of new negative: 25-49	1,825
PMTCT_STAT_DSD	By Number of new negative: 50+	0
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Numerator): <10	0
PMTCT_STAT_DSD	By Age (Numerator): 10-14	0
PMTCT_STAT_DSD	By Age (Numerator): 15-19	1,121
PMTCT_STAT_DSD	By Age (Numerator): 20-24	1,604
PMTCT_STAT_DSD	By Age (Numerator): 25-49	2,769
PMTCT_STAT_DSD	By Age (Numerator): 50+	0
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	267
PMTCT_STAT_TA	By Age (Denominator): Unknown Age	0
PMTCT_STAT_TA	By Age (Denominator): <10	0
PMTCT_STAT_TA	By Age (Denominator): 10-14	0
PMTCT_STAT_TA	By Age (Denominator): 15-19	39
PMTCT_STAT_TA	By Age (Denominator): 20-24	104
PMTCT_STAT_TA	By Age (Denominator): 25-49	141
PMTCT_STAT_TA	By Age (Denominator): 50+	0
PMTCT_STAT_TA	By known positives: <unknown age<="" td=""><td>0</td></unknown>	0
PMTCT_STAT_TA	By known positives: <10	0
PMTCT_STAT_TA	By known positives: 10-14	0
PMTCT_STAT_TA	By known positives: 15-19	8
PMTCT_STAT_TA	By known positives: 20-24	22
PMTCT_STAT_TA	By known positives: 25-49	38
PMTCT_STAT_TA	By known positives: 50+	0
PMTCT_STAT_TA	By new positives: Unknown Age	0
PMTCT_STAT_TA	By new positives: <10	0



PMTCT_STAT_TA	By new positives: 10-14	0
PMTCT_STAT_TA	By new positives: 15-19	3
PMTCT_STAT_TA	By new positives: 20-24	9
PMTCT_STAT_TA	By new positives: 25-49	14
PMTCT_STAT_TA	By new positives: 50+	0
PMTCT_STAT_TA	By new negatives: Unknown Age	0
PMTCT_STAT_TA	By new negatives: <10	0
PMTCT_STAT_TA	By new negatives: 10-14	0
PMTCT_STAT_TA	By new negatives: 15-19	23
PMTCT_STAT_TA	By new negatives: 20-24	53
PMTCT_STAT_TA	By new negatives: 25-49	96
PMTCT_STAT_TA	By new negatives: 50+	0
PMTCT_STAT_TA	By Age (Numerator): Unknown Age	0
PMTCT_STAT_TA	By Age (Numerator): <10	0
PMTCT_STAT_TA	By Age (Numerator): 10-14	0
PMTCT_STAT_TA	By Age (Numerator): : 15-19	35
PMTCT_STAT_TA	By Age (Numerator): 20-24	84
PMTCT_STAT_TA	By Age (Numerator): 25-49	148
PMTCT_STAT_TA	By Age (Numerator): 50+	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	67,133
HTC_TST_DSD	By Test Result: Positive	8,368
HTC_TST_DSD	Sum of Test Result disaggregates	8,368
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	24
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19,	1



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	28
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	50
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	406
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	495
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	47
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	199
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	36
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown	0



	Age, Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	126
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	689
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	37
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	218
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	791
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	41
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	505
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	49
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	1,702
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	138
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49,	10,978



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	550
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	13,265
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	643
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	5,044
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	234
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	1,010
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	53
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility)Other PITC: <1, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	116
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	605
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	129
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female,	1



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	24
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	214
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	262
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	37
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	109
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female,	13



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	91
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	296
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	76
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	102
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	331
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	92
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	567



HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	161
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	699
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	275
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	3,153
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	1,395
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	3,867
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	1,716
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	1,369
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	522
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	291
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	107
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	48
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	10



HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	76
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	1,679
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	216
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	3,127
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	375
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	23
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	107
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male,	127



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	28
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	263
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	62
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	1,843
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	362
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	2,254
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	455
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	907
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	161
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	180
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT:	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	0



HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	29
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	5
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,395
HTC_TST_TA	By Test Result: Positive	379
HTC_TST_TA	Sum of Test Result disaggregates	379
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49,	0



	Female, Negative	
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Malnutrition: Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Malnutrition: Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	6
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14,	32



	Male, Negative	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	34
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	61
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	405
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	30
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	524
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	41
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	246
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	14
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	45
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male,	5



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	5
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	38
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	13
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male,	0



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Negative	4
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Positive	0



HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	7
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	54
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	8
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	24
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	70
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Female, Negative	116
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Female, Positive	76
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Male, Negative	114
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Male, Positive	93



HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	43
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Positive	36
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	10
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) ANC: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 10-14, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 10-14, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 1-9, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 1-9, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	30
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) ANC: 25-49, Negative	76
HTC_TST_TA	Service Delivery Point (Facility) ANC: 25-49, Positive	15
HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Negative	1



HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: Unknown Age, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: Unknown Age, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	14
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	10
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	19
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	20
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	33
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	43
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	42
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Male,	58



	Nogativa	
	Negative	
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	49
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Negative	35
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Negative	15
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Positive	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	659
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	686
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	23
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	392
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number	23



	1	
	of registered new and relapsed TB cases with	
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: Number	
TB_STAT_DSD	of registered new and relapsed TB cases with	221
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	23
	during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	407
	during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	23
TB_OTAT_BOB	during the reporting period)	25
TD STAT DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total	233
TB_STAT_DSD	number of registered new and relapsed TB cases,	233
	during the reporting period)	
TB_STAT_TA	Number of registered new and relapsed TB cases with	48
	documented HIV status, during the reporting period.	
TB_STAT_TA	Total number of registered new and relapsed TB cases,	48
	during the reporting period.	
	Aggregated Age/Sex: Female <15 (Denominator: Total	
TB_STAT_TA	number of registered new and relapsed TB cases,	0
	during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: Total	
TB_STAT_TA	number of registered new and relapsed TB cases,	0
	during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: Total	
TB_STAT_TA	number of registered new and relapsed TB cases,	0
	during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total	
TB_STAT_TA	number of registered new and relapsed TB cases,	48
	during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of	
TB_STAT_TA	, ,	0
TB_STAT_TA	registered new and relapsed TB cases with	0



	decimand IIIV states at 1 to 1	
	documented HIV status, during the reporting period)	
TD 0747 74	Aggregated Age/Sex: Male 15+ (Numerator: Number of	40
TB_STAT_TA	registered new and relapsed TB cases with	48
	documented HIV status, during the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with	0
IB_STAT_TA	documented HIV status, during the reporting period)	U
	Aggregated Age/Sex: Female 15+ (Numerator: Number	
TB_STAT_TA	of registered new and relapsed TB cases with	0
	documented HIV status, during the reporting period)	·
GEND_GBV_DSD	Number of people receiving post-GBV care	361
	By type of service: Physical and/or Emotional Violence	_
GEND_GBV_DSD	(Other Post-GBV Care)	311
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	50
OEND ODV DOD	By PEP service provision (related to sexual violence	50
GEND_GBV_DSD	services provided)	50
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	3
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	14
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	39
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	4
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	32
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	4
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	31
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	35
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	14
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	2
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	115



GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	15
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	28
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	22
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	2
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	Number of people receiving post-GBV care	25
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	20
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	5
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	5
GEND_GBV_TA	<10, Female, Physical and/or Emotional Violence	0
GEND_GBV_TA	<10, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	<10, Male, Physical and/or Emotional Violence	0
GEND_GBV_TA	<10, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	10-14, Female, Physical and/or Emotional Violence	0
GEND_GBV_TA	10-14, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_TA	10-14, Male, Physical and/or Emotional Violence	5
GEND_GBV_TA	10-14, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	15-19, Female, Physical and/or Emotional Violence	1
GEND_GBV_TA	15-19, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_TA	15-19, Male, Physical and/or Emotional Violence	0
GEND_GBV_TA	15-19, Male, Sexual Violence (Post-Rape Care)	0



GEND_GBV_TA	20-24, Female, Physical and/or Emotional Violence	4
GEND_GBV_TA	20-24, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	20-24, Male, Physical and/or Emotional Violence	0
GEND_GBV_TA	20-24, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	25-49, Female, Physical and/or Emotional Violence	10
GEND_GBV_TA	25-49, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_TA	25-49, Male, Physical and/or Emotional Violence	0
GEND_GBV_TA	25-49, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	50+, Female, Physical and/or Emotional Violence	0
GEND_GBV_TA	50+, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	50+, Male, Physical and/or Emotional Violence	0
GEND_GBV_TA	50+, Male, Sexual Violence (Post-Rape Care)	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	418
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	418
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	13
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	254
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	7
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	144



Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period The number of registered new and relapse TB cases with documented HIV-positive status during TB TB_ART_TA TB_TE attended the Tase of the total period the positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)		,	
TB_ART_DSD number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) TB_ART_DSD Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	TB_ART_DSD	number of registered new and relapse TB cases with documented HIV-positive status during TB treatment	13
TB_ART_DSD number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period The number of registered new and relapse TB cases with documented HIV-positive status during TB seases with documented HIV-positive status during TB aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	TB_ART_DSD	number of registered new and relapse TB cases with documented HIV-positive status during TB treatment	254
TB_ART_DSD number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period The number of registered new and relapse TB cases with documented HIV-positive status during TB as 39 treatment during the reporting period Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during 10 Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during 10 Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during 10 Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during 10 Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during 10 Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during 10 Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HI	TB_ART_DSD	number of registered new and relapse TB cases with documented HIV-positive status during TB treatment	7
TB_ART_TA with documented HIV-positive status who are on ART during TB treatment during the reporting period The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	TB_ART_DSD	number of registered new and relapse TB cases with documented HIV-positive status during TB treatment	144
TB_ART_TA with documented HIV-positive status during TB treatment during the reporting period Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB_ART_TA O O O O O O O O O O O O O	TB_ART_TA	with documented HIV-positive status who are on ART	39
TB_ART_TA number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during O O O O O O O O O O O O O	TB_ART_TA	with documented HIV-positive status during TB	39
TB_ART_TA number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during 0	TB_ART_TA	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	0
TB_ART_TA number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	TB_ART_TA	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	38
12 trouting the reporting period)	TB_ART_TA	number of registered new and relapse TB cases with	0
TB_ART_TA Aggregated Age/Sex: Female 15+ (Numerator: The 1	TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The	1



	number of registered new and relapse TB cases with	
	documented HIV-positive status who are on ART during	
	TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The	
TB_ART_TA	number of registered new and relapse TB cases with	0
ID_AKI_IA	documented HIV-positive status during TB treatment	Ü
	during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The	
TD ADT TA	number of registered new and relapse TB cases with	38
TB_ART_TA	documented HIV-positive status during TB treatment	30
	during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The	
TD 4.DT T4	number of registered new and relapse TB cases with	•
TB_ART_TA	documented HIV-positive status during TB treatment	0
	during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The	
	number of registered new and relapse TB cases with	
TB_ART_TA	documented HIV-positive status during TB treatment	1
	during the reporting period)	
	Number of infants who had a virologic HIV test within	
PMTCT_EID_DSD	12 months of birth during the reporting period	1,889
	Number of infants with a positive virological test result	
PMTCT_EID_DSD	within 2 months of birth	48
PMTCT_EID_DSD	Unknown, <= 2 months	0
PMTCT_EID_DSD	Unknown, 2 - 12 months	0
	Number of infants with a negative virological test result	
PMTCT_EID_DSD	within 2 months of birth	1,596
	Number of infants with a positive virological test result	
PMTCT_EID_DSD	between 2 and 12 months of birth	9
	Number of infants with a negative virological test result	
PMTCT_EID_DSD	between 2 and 12 months of birth	236
	Number of infants who had a virologic HIV test within	
PMTCT_EID_TA	12 months of birth during the reporting period	52
DMTOT EID TA		
PMTCT_EID_TA	Unknown, <= 2 months	0



PMTCT_EID_TA	Unknown, 2 - 12 months	0
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	1
PMTCT_EID_TA	Number of infants with a negative virological test result within 2 months of birth	45
PMTCT_EID_TA	Number of infants with a positive virological test result between 2 and 12 months of birth	0
PMTCT_EID_TA	Number of infants with a negative virological test result between 2 and 12 months of birth	6
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	44,155
TX_CURR_DSD	Age/Sex: 15-19 Male	1,512
TX_CURR_DSD	Age/Sex: 15-19 Female	2,047
TX_CURR_DSD	Sum of age/sex disaggregates	3,559
TX_CURR_DSD	Age/Sex: <1	599
TX_CURR_DSD	Age/Sex: <1-9	1,128
TX_CURR_DSD	Age/Sex: 10-14 Male	379
TX_CURR_DSD	Age/Sex: 10-14 Female	560
TX_CURR_DSD	Age/Sex: 20-24 Male	4,614
TX_CURR_DSD	Age/Sex: 25-49 Male	8,597
TX_CURR_DSD	Age/Sex: 50+ Male	2,843
TX_CURR_DSD	Age/Sex: 20-24 Female	6,218
TX_CURR_DSD	Age/Sex: 25-49 Female	11,691
TX_CURR_DSD	Age/Sex: 50+ Female	3,967
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	267
TX_CURR_TA	Age/Sex: 15-19 Male	9
TX_CURR_TA	Age/Sex: 15-19 Female	5
TX_CURR_TA	Sum of Age/Sex disaggregations	14
TX_CURR_TA	Age/Sex: <1	2
TX_CURR_TA	Age/Sex: 1-9	5
TX_CURR_TA	Age/Sex: 10-14 Male	1
TX_CURR_TA	Age/Sex: 10-14 Female	1



TX_CURR_TA	Age/Sex: 20-24 Male	58
TX_CURR_TA	Age/Sex: 25-49 Male	108
TX_CURR_TA	Age/Sex: 50+ Male	24
TX_CURR_TA	Age/Sex: 20-24 Female	15
TX_CURR_TA	Age/Sex: 25-49 Female	30
TX_CURR_TA	Age/Sex: 50+ Female	9
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	10,802
TX_NEW_DSD	By Age/Sex: <1	35
TX_NEW_DSD	By Age/Sex: 1-9	59
TX_NEW_DSD	By Age/Sex: 10-14 Male	103
TX_NEW_DSD	By Age/Sex: 15-19 Male	441
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,343
TX_NEW_DSD	By Age/Sex: 25-49 Male	2,603
TX_NEW_DSD	By Age/Sex: 50+ Male	830
TX_NEW_DSD	By Age/Sex: 10-14 Female	96
TX_NEW_DSD	By Age/Sex: 15-19 Female	414
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,364
TX_NEW_DSD	By Age/Sex: 25-49 Female	2,627
TX_NEW_DSD	By Age/Sex: 50+ Female	887
TX_NEW_DSD	Sum of Age/Sex disaggregates	10,708
TX_NEW_DSD	Pregnancy status	1,374
TX_NEW_DSD	Breastfeeding status	209
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	236
TX_NEW_TA	By Age/Sex: <1	1
TX_NEW_TA	By Age/Sex: 1-9	4
TX_NEW_TA	By Age/Sex: 10-14 Male	2
TX_NEW_TA	By Age/Sex: 15-19 Male	10
TX_NEW_TA	By Age/Sex: 20-24 Male	39
TX_NEW_TA	By Age/Sex: 25-49 Male	70
TX_NEW_TA	By Age/Sex: 50+ Male	19



TX_NEW_TA	By Age/Sex: 10-14 Female	1
TX_NEW_TA	By Age/Sex: 15-19 Female	6
TX_NEW_TA	By Age/Sex: 20-24 Female	25
TX_NEW_TA	By Age/Sex: 25-49 Female	45
TX_NEW_TA	By Age/Sex: 50+ Female	14
TX_NEW_TA	Sum of Age/Sex disaggregates	231
TX_NEW_TA	Pregnancy status	24
TX_NEW_TA	Breastfeeding status	3
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	29,658
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	33,181
TX_PVLS_DSD	Numerator: Indication: Routine	29,658
TX_PVLS_DSD	Numerator: Indication: Targeted	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	3,879
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	596
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Targeted	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Targeted	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	1,109



TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	9,416
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	1,548
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	17,585
TX_PVLS_DSD	Denominator: Indication: Routine	33,181
TX_PVLS_DSD	Denominator: Indication: Targeted	0
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	4,307
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	658
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	0
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,252
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	10,560
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,701
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	19,668
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0



TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0



TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	185
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	205
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	3
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	0
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	12
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	0
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	56
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	0
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	114
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	0
TX_PVLS_TA	Numerator: Indication: Routine	185



TX_PVLS_TA	Numerator: Indication: Targeted	0
TX_PVLS_TA	Numerator: Preg/BF by Indication: Breastfeeding Routine	1
TX_PVLS_TA	Numerator: Preg/BF by Indication: Breastfeeding Targeted	0
TX_PVLS_TA	Numerator: Preg/BF by Indication: Pregnant Routine	26
TX_PVLS_TA	Numerator: Preg/BF by Indication: Pregnant Targeted	0
TX_PVLS_TA	Denominator: Indication: Routine	205
TX_PVLS_TA	Denominator: Indication: Targeted	0
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	3
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	0
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	13
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	0
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	61
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	0
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	128
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	0
TX_PVLS_TA	Denominator: Preg/BF by Indication: Breastfeeding Routine	1
TX_PVLS_TA	Denominator: Preg/BF by Indication: Breastfeeding Targeted	0
TX_PVLS_TA	Denominator: Preg/BF by Indication: Pregnant Routine	12
TX_PVLS_TA	Denominator: Preg/BF by Indication: Pregnant Targeted	0
TX_PVLS_TA	<15, Routine, Unknown Sex	0
TX_PVLS_TA	<15, Targeted, Unknown Sex	0



TX_PVLS_TA	<15, Undocumented Test Indication, Female	0
TX_PVLS_TA	<15, Undocumented Test Indication, Male	0
TX_PVLS_TA	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_TA	15+, Routine, Unknown Sex	0
TX_PVLS_TA	15+, Targeted, Unknown Sex	0
TX_PVLS_TA	15+, Undocumented Test Indication, Female	0
TX_PVLS_TA	15+, Undocumented Test Indication, Male	0
TX_PVLS_TA	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_TA	Unknown Age, Routine, Female	0
TX_PVLS_TA	Unknown Age, Routine, Male	0
TX_PVLS_TA	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_TA	Unknown Age, Targeted, Female	0
TX_PVLS_TA	Unknown Age, Targeted, Male	0
TX_PVLS_TA	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_TA	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_TA	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_TA	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_TA	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_TA	Pregnant, Undocumented Test Indication	0
TX_PVLS_TA	Undocumented Test Indication	0
TX_PVLS_TA	<15, Routine, Unknown Sex	0
TX_PVLS_TA	<15, Targeted, Unknown Sex	0
TX_PVLS_TA	<15, Undocumented Test Indication, Female	0
TX_PVLS_TA	<15, Undocumented Test Indication, Male	0
TX_PVLS_TA	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_TA	15+, Routine, Unknown Sex	0
TX_PVLS_TA	15+, Targeted, Unknown Sex	0
TX_PVLS_TA	15+, Undocumented Test Indication, Female	0
TX_PVLS_TA	15+, Undocumented Test Indication, Male	0
TX_PVLS_TA	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_TA	Unknown Age, Routine, Female	0
		·



TX_PVLS_TA	Unknown Age, Routine, Male	0
TX PVLS TA	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_TA	Unknown Age, Targeted, Female	0
TX_PVLS_TA	Unknown Age, Targeted, Male	0
TX_PVLS_TA	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_TA	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_TA	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_TA	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_TA	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_TA	Pregnant, Undocumented Test Indication	0
TX_PVLS_TA	Undocumented Test Indication	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	6,815
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	7,182
TX_RET_DSD	Numerator by Status: Pregnant	885
TX_RET_DSD	Numerator by Status: Breastfeeding	136
TX_RET_DSD	Denominator by Status: Pregnant	933
TX_RET_DSD	Denominator by Status: Breastfeeding	145
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	237
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,066
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	301
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,211



TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	255
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,176
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	310
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,441
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	194
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	206
TX_RET_TA	Numerator by Status: Pregnant	18
TX_RET_TA	Numerator by Status: Breastfeeding	3
TX_RET_TA	Denominator by Status: Pregnant	20
TX_RET_TA	Denominator by Status: Breastfeeding	3
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment	90



	at 12 months after initiating ART)	
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	88
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	89
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	101
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	8,152
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period	9,266



	but had not been reported as they did not fulfill the		
	minimum requirements for the previous reporting		
	period).		
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	1,203	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	1,017	
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	3,715	
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	3,331	
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	8,155	
TB_PREV_DSD	By Therapy type (Denominator): Alternative Regimen	546	
TB_PREV_DSD	By Therapy type (Denominator): Continuous IPT	565	
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	1,055	
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	897	
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	3,265	
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	2,935	
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	7,172	
TB_PREV_DSD	By Therapy type (Numerator): Alternative Regimen	486	
TB_PREV_DSD	By Therapy type (Numerator): Continuous IPT	494	
	The number of ART patients who completed a course		
TD DDE\/ TA	of TB preventive therapy or at least 6 months of	184	
TB_PREV_TA	Isoniazid Preventive Therapy (IPT) during the reporting	104	
	period		
	The number of ART patients who were newly started on		
	TB preventive therapy (including those who newly		
	started on TB preventive therapy in this reporting period		
TB_PREV_TA	and those who started in the previous reporting period	209	
	but had not been reported as they did not fulfill the		
	minimum requirements for the previous reporting		
	period).		
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	17	
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	14	
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	51	
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	127	
TB_PREV_TA	By Therapy type (Denominator): 6-12 Month IPT	184	



TB_PREV_TA	By Therapy type (Denominator):Alternative Regimen	12
TB_PREV_TA	By Therapy type (Denominator):Continuous IPT	13
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	15
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	12
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	46
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	111
TB_PREV_TA	By Therapy type (Numerator): 6-12 Month IPT	164
TB_PREV_TA	By Therapy type (Numerator): Alternative Regimen	10
TB_PREV_TA	By Therapy type (Numerator): Continuous IPT	10
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	302
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	42,000
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	5
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	6
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	109
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	182
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	2,594
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	2,245
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	23,359
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	13,802
TX_TB_DSD	Denominator: By Screen Result: Negative	33,604
TX_TB_DSD	Denominator: By Screen Result: Positive	8,396
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	8,381
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	0
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	0
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	8,381
TX_TB_TA	Number of ART patients who were started on TB	27



Г		T
	treatment during the reporting period.	
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	260
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Female	0
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Male	1
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Female	0
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Male	26
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	6
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	26
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	172
TX_TB_TA	Denominator: By Screen Result: Negative	
TX_TB_TA	Denominator: By Screen Result: Positive	58
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	58
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	0
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	58

Implementing Mechanism Details

Mechanism ID: 17461	Mechanism Name: ICAP Lab	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: International Center for AIDS Care and Treatment Programs, Columbia University		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources	s: 1,538,047	Total Mechanism Pipeline: N/A



Applied Pipeline Amount: 1,100,000 Total All Funding Sources and Applied Pipeline Amount: 2,638,047		
Funding Source Funding Amount		
GHP-State	1,538,047	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: Mechanism Name: Prime Partner Name:	17461 ICAP Lab International Center for AIDS Care and Treatment Programs, Columbia		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	1,045,825	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	93,765	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	13,265	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	85,192	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	300,000	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2018
	Number of new HCW who graduated from a pre-service	
HRH_PRE	training institution or program as a result of	26
	PEPFAR-supported strengthening efforts, within the	26
	reporting period, by select cadre	
HRH_PRE	By Graduates: Laboratory professionals	26
HRH_PRE	Sum of Graduates disaggreagtes	26

Implementing Mechanism Details

Mechanism ID: 17462	Mechanism Name: Strengthening MOH Leadership, Governance & Quality Management	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Ministry of Health and Social Welfare, Swaziland		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 662,580	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 500,000			
Total All Funding Sources and Applied Pipeline Amount: 1,162,580			
Funding Source Funding Amount			
GHP-State	662,580		

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	94,400
---------------------------	--------



Budget Code Information

Budget Code Illiormation			
Mechanism ID:	17462		
Mechanism Name:	Strengthening MOH Leadership, Governance & Quality Management		
Prime Partner Name:	Ministry of Health and Social Welfare, Swaziland		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	632,230	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	30,350	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17463	Mechanism Name: ICAP-Manzini		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: International Center for AIDS Care and Treatment Programs, Columbia University			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: N/A			
G2G: No	Managing Agency:		

Total All Funding Sources: 3,886,818	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 800,000			
Total All Funding Sources and Applied Pipeline Amount: 4,686,818			
Funding Source Funding Amount			
GHP-State	3,886,818		



Cross-Cutting Budget Attribution(s)

Water	45,000
Focus Area:	Post GBV Care
Sub Area:	Capacity building
Gender: GBV	93,736

Budget Code Information

Budget Code Information			
	Mechanism ID: Mechanism Name: Mechanism Name: Prime Partner Name: University		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	1,118,712	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	342,149	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	217,269	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	44,957	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	633,042	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	99,731	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	1,339,233	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	3,489
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	10,583
PMTCT_ART_DSD	New on ART	1,142
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,347
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	43
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	122
PMTCT_ART_TA	New on ART	13
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	30
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	10,583
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	13
PMTCT_STAT_DSD	By Age (Denominator): <15-19	1,485
PMTCT_STAT_DSD	By Age (Denominator): 20-24	2,421



By Age (Denominator): 25-49	6,590
By Age (Denominator): 50+	0
By Number of known positives: Unknown Age	0
By Number of known positives: <10	0
By Number of known positives: 10-14	0
By Number of known positives: 15-19	47
By Number of known positives: 20-24	421
By Number of known positives: 25-49	1,821
By Number of known positives: 50+	0
By Number of new positives: Unknown Age	0
By Number of new positives: <10	0
By Number of new positives: 10-14	6
By Number of new positives: 15-19	154
By Number of new positives: 20-24	339
By Number of new positives: 25-49	738
By Number of new positives: 50+	0
By Number of new negative: Unknown Age	0
By Number of new negative: <10	0
By Number of new negative: 10-14	14
By Number of new negative: 15-19	1,302
By Number of new negative: 20-24	1,731
By Number of new negative: 25-49	3,398
By Number of new negative: 50+	0
By Age (Numerator): Unknown Age	0
By Age (Numerator): <10	0
By Age (Numerator): 10-14	14
By Age (Numerator): 15-19	1,494
By Age (Numerator): 20-24	2,467
By Age (Numerator): 25-49	5,996
By Age (Numerator): 50+	0
Number of pregnant women with known HIV status (includes women who were tested for HIV and received	122
	By Age (Denominator): 50+ By Number of known positives: Unknown Age By Number of known positives: 410 By Number of known positives: 10-14 By Number of known positives: 15-19 By Number of known positives: 20-24 By Number of known positives: 25-49 By Number of known positives: 50+ By Number of new positives: Unknown Age By Number of new positives: 10-14 By Number of new positives: 15-19 By Number of new positives: 25-49 By Number of new positives: 20-24 By Number of new positives: 25-49 By Number of new positives: 25-49 By Number of new positives: 25-49 By Number of new negative: Unknown Age By Number of new negative: 10-14 By Number of new negative: 20-24 By Number of new negative: 20-24 By Number of new negative: 25-49 By Number of new negative: 50+ By Age (Numerator): Unknown Age By Age (Numerator): 10-14 By Age (Numerator): 15-19 By Age (Numerator): 20-24 By Age (Numerator): 20-24 By Age (Numerator): 25-49 By Age (Numerator): 25-49



	their results)	
PMTCT_STAT_TA	By Age (Denominator): Unknown Age	0
PMTCT_STAT_TA	By Age (Denominator): <10	0
PMTCT_STAT_TA	By Age (Denominator): 10-14	0
PMTCT_STAT_TA	By Age (Denominator): 15-19	17
PMTCT_STAT_TA	By Age (Denominator): 20-24	29
PMTCT_STAT_TA	By Age (Denominator): 25-49	77
PMTCT_STAT_TA	By Age (Denominator): 50+	0
PMTCT_STAT_TA	By known positives: <unknown age<="" td=""><td>0</td></unknown>	0
PMTCT_STAT_TA	By known positives: <10	0
PMTCT_STAT_TA	By known positives: 10-14	0
PMTCT_STAT_TA	By known positives: 15-19	0
PMTCT_STAT_TA	By known positives: 20-24	4
PMTCT_STAT_TA	By known positives: 25-49	16
PMTCT_STAT_TA	By known positives: 50+	0
PMTCT_STAT_TA	By new positives: Unknown Age	0
PMTCT_STAT_TA	By new positives: <10	0
PMTCT_STAT_TA	By new positives: 10-14	0
PMTCT_STAT_TA	By new positives: 15-19	3
PMTCT_STAT_TA	By new positives: 20-24	6
PMTCT_STAT_TA	By new positives: 25-49	15
PMTCT_STAT_TA	By new positives: 50+	0
PMTCT_STAT_TA	By new negatives: Unknown Age	0
PMTCT_STAT_TA	By new negatives: <10	0
PMTCT_STAT_TA	By new negatives: 10-14	0
PMTCT_STAT_TA	By new negatives: 15-19	15
PMTCT_STAT_TA	By new negatives: 20-24	20
PMTCT_STAT_TA	By new negatives: 25-49	43
PMTCT_STAT_TA	By new negatives: 50+	0
PMTCT_STAT_TA	By Age (Numerator): Unknown Age	0
PMTCT_STAT_TA	By Age (Numerator): <10	0
PMTCT_STAT_TA	By Age (Numerator): 10-14	0



	T	
PMTCT_STAT_TA	By Age (Numerator): : 15-19	18
PMTCT_STAT_TA	By Age (Numerator): 20-24	30
PMTCT_STAT_TA	By Age (Numerator): 25-49	74
PMTCT_STAT_TA	By Age (Numerator): 50+	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	71,710
HTC_TST_DSD	By Test Result: Positive	7,239
HTC_TST_DSD	Sum of Test Result disaggregates	7,239
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	57
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	33
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	15
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	67
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49,	193



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	227
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	67
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	126
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	157
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	263
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	276
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	264
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	48
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	896
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14,	218



	Male, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	1,355
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	1,100
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	323
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	2,691
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	87
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	4,476
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	103
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	12,819
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	248
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	2,964
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	56
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	5,463
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	171
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown	0



	Age, Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility)Other PITC: <1, Negative	365
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	916
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	34
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	29
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female,	8



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	70
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	123
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	332
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	73
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	79
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	149
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	24
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	3



HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	91
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	290
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	82
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	446
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	120
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	364
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	97
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	108
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	883
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	251
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	1,460
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	418
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	4,198
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	1,202
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	965



HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	262
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	1,787
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	508
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	122
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	307
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	75
HTC_TST_DSD	By Key Population: FSW, Negative	0
HTC_TST_DSD	By Key Population: FSW, Positive	0
HTC_TST_DSD	By Key Population: MSM, Negative	0
HTC_TST_DSD	By Key Population: MSM, Positive	0
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	0
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	0
HTC_TST_DSD	By Key Population: PWID, Negative	0
HTC_TST_DSD	By Key Population: PWID, Positive	0
HTC_TST_DSD	By Key Population: TG, Negative	0
HTC_TST_DSD	By Key Population: TG, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Negative	0



HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	216
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	629
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	87
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	938
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	295
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	4,532
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	827
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	85
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	296
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	451
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	58
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	365
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	47



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	105
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	896
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	124
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	1,490
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	208
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	4,273
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	596
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	981
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	135
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	1,802
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	251
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT:	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	127
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	306



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	38
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,005
HTC_TST_TA	By Test Result: Positive	116
HTC_TST_TA	Sum of Test Result disaggregates	116
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	0



HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	15
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	17



HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	24
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	44
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	52
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	217
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	13
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	34
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	99
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	0



_		
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Negative	6
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	14
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	0



HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male,	6



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	7
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	7
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	13
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Female, Negative	22
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Female, Positive	9
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Male, Negative	61
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Male, Positive	30
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	14
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	27
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male,	10



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	6
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 10-14, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) ANC: 10-14, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	7
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 1-9, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 1-9, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	9
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) ANC: 25-49, Negative	49
HTC_TST_TA	Service Delivery Point (Facility) ANC: 25-49, Positive	15
HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: Unknown Age, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: Unknown Age, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	1



HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	5
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	4
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	11
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	17
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	52
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Negative	11
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Positive	0



HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Negative	22
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Positive	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,701
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,736
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	20
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	243
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	63
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,375
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases,	20



	1	
	during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	247
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	63
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,406
GEND_GBV_DSD	Number of people receiving post-GBV care	199
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	125
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	74
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	74
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	4
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	18
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	2
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	5
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	20
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	7
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	17
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	17
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	18
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	16



GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	15
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	60
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	Number of people receiving post-GBV care	12
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	12
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	0
GEND_GBV_TA	<10, Female, Physical and/or Emotional Violence	0
GEND_GBV_TA	<10, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	<10, Male, Physical and/or Emotional Violence	0
GEND_GBV_TA	<10, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	10-14, Female, Physical and/or Emotional Violence	0
GEND_GBV_TA	10-14, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	10-14, Male, Physical and/or Emotional Violence	0
GEND_GBV_TA	10-14, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	15-19, Female, Physical and/or Emotional Violence	0
GEND_GBV_TA	15-19, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	15-19, Male, Physical and/or Emotional Violence	0
GEND_GBV_TA	15-19, Male, Sexual Violence (Post-Rape Care)	0



GEND_GBV_TA	20-24, Female, Physical and/or Emotional Violence	0
GEND_GBV_TA	20-24, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	20-24, Male, Physical and/or Emotional Violence	1
GEND_GBV_TA	20-24, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	25-49, Female, Physical and/or Emotional Violence	5
GEND_GBV_TA	25-49, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	25-49, Male, Physical and/or Emotional Violence	6
GEND_GBV_TA	25-49, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	50+, Female, Physical and/or Emotional Violence	0
GEND_GBV_TA	50+, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	50+, Male, Physical and/or Emotional Violence	0
GEND_GBV_TA	50+, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	Unknown Age, Female, Physical and/or Emotional Violence	0
GEND_GBV_TA	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	Unknown Age, Male, Physical and/or Emotional Violence	0
GEND_GBV_TA	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,191
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,191
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	13
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	170



TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	40
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	968
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	13
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	170
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	40
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	968
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	3,489
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	98
PMTCT_EID_DSD	Unknown, <= 2 months	340
PMTCT_EID_DSD	Unknown, 2 - 12 months	4
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	2,898
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	10
PMTCT_EID_DSD	Number of infants with a negative virological test result	139



	between 2 and 12 months of birth	
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	43
PMTCT_EID_TA	Unknown, <= 2 months	4
PMTCT_EID_TA	Unknown, 2 - 12 months	0
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	1
PMTCT_EID_TA	Number of infants with a negative virological test result within 2 months of birth	36
PMTCT_EID_TA	Number of infants with a positive virological test result between 2 and 12 months of birth	0
PMTCT_EID_TA	Number of infants with a negative virological test result between 2 and 12 months of birth	2
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	50,405
TX_CURR_DSD	Age/Sex: 15-19 Male	644
TX_CURR_DSD	Age/Sex: 15-19 Female	1,090
TX_CURR_DSD	Sum of age/sex disaggregates	1,734
TX_CURR_DSD	Age/Sex: <1	166
TX_CURR_DSD	Age/Sex: <1-9	1,652
TX_CURR_DSD	Age/Sex: 10-14 Male	746
TX_CURR_DSD	Age/Sex: 10-14 Female	645
TX_CURR_DSD	Age/Sex: 20-24 Male	1,027
TX_CURR_DSD	Age/Sex: 25-49 Male	12,410
TX_CURR_DSD	Age/Sex: 50+ Male	4,056
TX_CURR_DSD	Age/Sex: 20-24 Female	2,176
TX_CURR_DSD	Age/Sex: 25-49 Female	21,392
TX_CURR_DSD	Age/Sex: 50+ Female	4,401
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	1,726
TX_CURR_TA	Age/Sex: 15-19 Male	101
TX_CURR_TA	Age/Sex: 15-19 Female	19
TX_CURR_TA	Sum of Age/Sex disaggregations	120



TX_CURR_TA	Age/Sex: <1	28
TX_CURR_TA	Age/Sex: 1-9	88
TX_CURR_TA	Age/Sex: 10-14 Male	147
TX_CURR_TA	Age/Sex: 10-14 Female	2
TX_CURR_TA	Age/Sex: 20-24 Male	129
TX_CURR_TA	Age/Sex: 25-49 Male	687
TX_CURR_TA	Age/Sex: 50+ Male	334
TX_CURR_TA	Age/Sex: 20-24 Female	36
TX_CURR_TA	Age/Sex: 25-49 Female	141
TX_CURR_TA	Age/Sex: 50+ Female	14
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	8,569
TX_NEW_DSD	By Age/Sex: <1	85
TX_NEW_DSD	By Age/Sex: 1-9	196
TX_NEW_DSD	By Age/Sex: 10-14 Male	199
TX_NEW_DSD	By Age/Sex: 15-19 Male	244
TX_NEW_DSD	By Age/Sex: 20-24 Male	681
TX_NEW_DSD	By Age/Sex: 25-49 Male	3,173
TX_NEW_DSD	By Age/Sex: 50+ Male	1,335
TX_NEW_DSD	By Age/Sex: 10-14 Female	80
TX_NEW_DSD	By Age/Sex: 15-19 Female	379
TX_NEW_DSD	By Age/Sex: 20-24 Female	92
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,263
TX_NEW_DSD	By Age/Sex: 50+ Female	842
TX_NEW_DSD	Sum of Age/Sex disaggregates	8,288
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,118
TX_NEW_TA	By Age/Sex: <1	20
TX_NEW_TA	By Age/Sex: 1-9	63
TX_NEW_TA	By Age/Sex: 10-14 Male	107
TX_NEW_TA	By Age/Sex: 15-19 Male	72
TX_NEW_TA	By Age/Sex: 20-24 Male	92



TX_NEW_TA	By Age/Sex: 25-49 Male	482
TX_NEW_TA	By Age/Sex: 50+ Male	238
TX_NEW_TA	By Age/Sex: 10-14 Female	1
TX_NEW_TA	By Age/Sex: 15-19 Female	10
TX_NEW_TA	By Age/Sex: 20-24 Female	1
TX_NEW_TA	By Age/Sex: 25-49 Female	22
TX_NEW_TA	By Age/Sex: 50+ Female	10
TX_NEW_TA	Sum of Age/Sex disaggregates	1,035
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	40,094
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	44,101
TX_PVLS_DSD	Numerator: Indication: Routine	36,082
TX_PVLS_DSD	Numerator: Indication: Targeted	2,006
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	2,172
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	1,090
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Targeted	120
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Targeted	57
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	45
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	758
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	67
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	1,136
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	865



TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	13,571
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	1,299
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	20,347
TX_PVLS_DSD	Denominator: Indication: Routine	39,690
TX_PVLS_DSD	Denominator: Indication: Targeted	2,206
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	2,382
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	1,192
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	136
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Targeted	61
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	48
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	831
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	80
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	1,247
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	954
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	14,923
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,430
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	22,383
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	80
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	48



	T	
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	1,246
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	831
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	61
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	136
TX_PVLS_DSD	Undocumented Test Indication	2,205
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	67
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	45
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	1,136
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	758
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0



TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	57
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	120
TX_PVLS_DSD	Undocumented Test Indication	2,006
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,066
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,172
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	35
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	2
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	23
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	1
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	541
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	30
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	361
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	20
TX_PVLS_TA	Numerator: Indication: Routine	960



TX_PVLS_TA	Numerator: Indication: Targeted	53
TX_PVLS_TA	Numerator: Preg/BF by Indication: Breastfeeding Routine	29
TX_PVLS_TA	Numerator: Preg/BF by Indication: Breastfeeding Targeted	1
TX_PVLS_TA	Numerator: Preg/BF by Indication: Pregnant Routine	57
TX_PVLS_TA	Numerator: Preg/BF by Indication: Pregnant Targeted	3
TX_PVLS_TA	Denominator: Indication: Routine	1,056
TX_PVLS_TA	Denominator: Indication: Targeted	58
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	38
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	2
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	25
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	1
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	596
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	33
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	397
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	22
TX_PVLS_TA	Denominator: Preg/BF by Indication: Breastfeeding Routine	31
TX_PVLS_TA	Denominator: Preg/BF by Indication: Breastfeeding Targeted	1
TX_PVLS_TA	Denominator: Preg/BF by Indication: Pregnant Routine	64
TX_PVLS_TA	Denominator: Preg/BF by Indication: Pregnant Targeted	4
TX_PVLS_TA	<15, Routine, Unknown Sex	0
TX_PVLS_TA	<15, Targeted, Unknown Sex	0



T		
TX_PVLS_TA	<15, Undocumented Test Indication, Female	2
TX_PVLS_TA	<15, Undocumented Test Indication, Male	1
TX_PVLS_TA	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_TA	15+, Routine, Unknown Sex	0
TX_PVLS_TA	15+, Targeted, Unknown Sex	0
TX_PVLS_TA	15+, Undocumented Test Indication, Female	33
TX_PVLS_TA	15+, Undocumented Test Indication, Male	22
TX_PVLS_TA	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_TA	Unknown Age, Routine, Female	0
TX_PVLS_TA	Unknown Age, Routine, Male	0
TX_PVLS_TA	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_TA	Unknown Age, Targeted, Female	0
TX_PVLS_TA	Unknown Age, Targeted, Male	0
TX_PVLS_TA	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_TA	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_TA	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_TA	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_TA	Breastfeeding, Undocumented Test Indication	1
TX_PVLS_TA	Pregnant, Undocumented Test Indication	4
TX_PVLS_TA	Undocumented Test Indication	58
TX_PVLS_TA	<15, Routine, Unknown Sex	0
TX_PVLS_TA	<15, Targeted, Unknown Sex	0
TX_PVLS_TA	<15, Undocumented Test Indication, Female	2
TX_PVLS_TA	<15, Undocumented Test Indication, Male	1
TX_PVLS_TA	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_TA	15+, Routine, Unknown Sex	0
TX_PVLS_TA	15+, Targeted, Unknown Sex	0
TX_PVLS_TA	15+, Undocumented Test Indication, Female	30
TX_PVLS_TA	15+, Undocumented Test Indication, Male	20
TX_PVLS_TA	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_TA	Unknown Age, Routine, Female	0



TX_PVLS_TA	Unknown Age, Routine, Male	0
TX_PVLS_TA	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_TA	Unknown Age, Targeted, Female	0
TX_PVLS_TA	Unknown Age, Targeted, Male	0
TX_PVLS_TA	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_TA	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_TA	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_TA	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_TA	Breastfeeding, Undocumented Test Indication	1
TX_PVLS_TA	Pregnant, Undocumented Test Indication	3
TX_PVLS_TA	Undocumented Test Indication	53
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	8,825
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	9,687
TX_RET_DSD	Numerator by Status: Pregnant	447
TX_RET_DSD	Numerator by Status: Breastfeeding	25
TX_RET_DSD	Denominator by Status: Pregnant	555
TX_RET_DSD	Denominator by Status: Breastfeeding	27
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	290
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,545
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	279
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,711



TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	310
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,782
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	297
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,298
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	556
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	615
TX_RET_TA	Numerator by Status: Pregnant	14
TX_RET_TA	Numerator by Status: Breastfeeding	1
TX_RET_TA	Denominator by Status: Pregnant	17
TX_RET_TA	Denominator by Status: Breastfeeding	1
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	46
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment	342



	at 12 months after initiating ART)	
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	166
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	50
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	380
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	183
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	16,743
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period	20,931



T		
	but had not been reported as they did not fulfill the	
	minimum requirements for the previous reporting	
	period).	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	694
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	653
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	12,063
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	7,521
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	20,931
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	555
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	524
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	9,647
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	6,017
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	16,743
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	490
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	613
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	2
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	81
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	97
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	433
TB_PREV_TA	By Therapy type (Denominator): 6-12 Month IPT	613
TB_PREV_TA	By Therapy type (Denominator):Alternative Regimen	0
TB_PREV_TA	By Therapy type (Denominator):Continuous IPT	0
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	2
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	65
	•	



	<u>'</u>	
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	77
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	346
TB_PREV_TA	By Therapy type (Numerator): 6-12 Month IPT	490
TB_PREV_TA	By Therapy type (Numerator): Alternative Regimen	0
TB_PREV_TA	By Therapy type (Numerator): Continuous IPT	0
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	1,191
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	45,401
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	43
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	44
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	619
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	485
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	1,451
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	1,375
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	26,198
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	16,377
TX_TB_DSD	Denominator: By Screen Result: Negative	44,039
TX_TB_DSD	Denominator: By Screen Result: Positive	1,362
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,362
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	136
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	0
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	1,218
TX_TB_TA	Number of ART patients who were started on TB treatment during the reporting period.	0
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	1,201
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Female	0



TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Male	0
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Female	0
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Male	0
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	3
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	159
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	190
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	849
TX_TB_TA	Denominator: By Screen Result: Negative	1,165
TX_TB_TA	Denominator: By Screen Result: Positive	36
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	36
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	4
TX_TB_TA Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only		0
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	32

Implementing Mechanism Details

Mechanism ID: 17464	Mechanism Name: Rapid and Effective Action for Combating HIV/AIDS III (REACH 3)	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Pact		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 5,679,130	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 5,679,130		
Funding Source	Funding Amount	



GHP-State	5,679,130
orn otato	0,070,100

Cross-Cutting Budget Attribution(s)

Gender: GBV	283,956
Focus Area:	Post GBV Care
Sub Area:	Implementation

Budget Code Information

Budget Code Informa	ation		
Mechanism ID: Mechanism Name: Prime Partner Name:	Rapid and Effective Act	ion for Combating HIV/AI	DS III (REACH 3)
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	519,315	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	3,804,887	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	305,154	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	1,049,774	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
DD DDEV DOD	Number of the target population who completed a	24.574
PP_PREV_DSD	standardized HIV prevention intervention including the	24,574



	1	
	minimum components during the reporting period.	
PP_PREV_DSD	Age/sex: 10-14 Female	5,522
PP_PREV_DSD	Age/sex: 15-19 Female	13,668
PP_PREV_DSD	Age/sex: 20-24 Female	3,230
PP_PREV_DSD	Age/sex: 25-49 Female	2,154
PP_PREV_DSD	Age/sex: 50+ Female	0
PP_PREV_DSD	Sum of Age/Sex disaggregates	24,574
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	45,323
OVC_SERV_DSD	Age/Sex: 10-14 Male	6,496
OVC_SERV_DSD	Age/Sex: 15-17 Male	10,280
OVC_SERV_DSD	By: Age/sex: Male 18-24	1,129
OVC_SERV_DSD	Age/Sex: 10-14 Female	7,275
OVC_SERV_DSD	Age/Sex: 15-17 Female	10,977
OVC_SERV_DSD	By: Age/sex: 18-24 Female	2,365
OVC_SERV_DSD	Sum of Age/Sex disaggregates	35,028
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	5,398
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	1,767
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	681
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	3,437
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	1,631
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	681
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	4,984
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	498



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	599
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	3,190
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	299
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	399
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	1,085
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	238
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	118
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	679
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	115
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	34
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	7,535
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	3,393
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	941
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	3,393
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	2,826
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	753
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	13,224



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	9,970
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	1,948
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	7,198
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	5,998
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	1,650
OVC_SERV_DSD	Age/Sex: 1-9	6,801
OVC_SERV_DSD	Program Completion: Active	0
OVC_SERV_DSD	Program Completion: Graduation	8,190
OVC_SERV_DSD	Program Completion: Transferred	33,621
OVC_SERV_DSD	Program Completion: Exited without graduation	3,512

Implementing Mechanism Details

Mechanism ID: 17465	Mechanism Name: AIDSFree	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: John Snow, Inc.		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 3,460,768	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 2,701,836		
Total All Funding Sources and Applied Pipe	eline Amount: 6,162,604	
Funding Source	Funding Amount	
GHP-State	3,460,768	

Cross-Cutting Budget Attribution(s)



Gender: GBV	123,252
Focus Area:	Post GBV Care
Sub Area:	Capacity building
Water	45,000

Budget Code Inform	ation		
Mechanism ID:	17465		
Mechanism Name:	AIDSFree		
Prime Partner Name:	John Snow, Inc.		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	938,560	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	328,154	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	124,081	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	80,313	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	807,989	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	28,908	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	984,513	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	168,250	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	3,095
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	9,128
PMTCT_ART_DSD	New on ART	921
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,174
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	452
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,434
PMTCT_ART_TA	New on ART	135
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	317
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	9,128
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	410
PMTCT_STAT_DSD	By Age (Denominator): <15-19	1,543
PMTCT_STAT_DSD	By Age (Denominator): 20-24	2,154
PMTCT_STAT_DSD	By Age (Denominator): 25-49	5,449
PMTCT_STAT_DSD	By Age (Denominator): 50+	6



PMTCT_STAT_DSD	By Number of known positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	78
PMTCT_STAT_DSD	By Number of known positives: 15-19	375
PMTCT_STAT_DSD	By Number of known positives: 20-24	499
PMTCT_STAT_DSD	By Number of known positives: 25-49	1,227
PMTCT_STAT_DSD	By Number of known positives: 50+	0
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	0
PMTCT_STAT_DSD	By Number of new positives: 15-19	141
PMTCT_STAT_DSD	By Number of new positives: 20-24	188
PMTCT_STAT_DSD	By Number of new positives: 25-49	567
PMTCT_STAT_DSD	By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	0
PMTCT_STAT_DSD	By Number of new negative: <10	0
PMTCT_STAT_DSD	By Number of new negative: 10-14	313
PMTCT_STAT_DSD	By Number of new negative: 15-19	945
PMTCT_STAT_DSD	By Number of new negative: 20-24	1,370
PMTCT_STAT_DSD	By Number of new negative: 25-49	3,376
PMTCT_STAT_DSD	By Number of new negative: 50+	3
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Numerator): <10	0
PMTCT_STAT_DSD	By Age (Numerator): 10-14	391
PMTCT_STAT_DSD	By Age (Numerator): 15-19	1,466
PMTCT_STAT_DSD	By Age (Numerator): 20-24	2,061
PMTCT_STAT_DSD	By Age (Numerator): 25-49	5,182
PMTCT_STAT_DSD	By Age (Numerator): 50+	5
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,434
PMTCT_STAT_TA	By Age (Denominator): Unknown Age	0



PMTCT_STAT_TA	By Age (Denominator): <10	0
PMTCT_STAT_TA	By Age (Denominator): 10-14	63
PMTCT_STAT_TA	By Age (Denominator): 15-19	232
PMTCT_STAT_TA	By Age (Denominator): 20-24	323
PMTCT_STAT_TA	By Age (Denominator): 25-49	813
PMTCT_STAT_TA	By Age (Denominator): 50+	110
PMTCT_STAT_TA	By known positives: <unknown age<="" td=""><td>0</td></unknown>	0
PMTCT_STAT_TA	By known positives: <10	0
PMTCT_STAT_TA	By known positives: 10-14	9
PMTCT_STAT_TA	By known positives: 15-19	56
PMTCT_STAT_TA	By known positives: 20-24	73
PMTCT_STAT_TA	By known positives: 25-49	191
PMTCT_STAT_TA	By known positives: 50+	16
PMTCT_STAT_TA	By new positives: Unknown Age	0
PMTCT_STAT_TA	By new positives: <10	0
PMTCT_STAT_TA	By new positives: 10-14	1
PMTCT_STAT_TA	By new positives: 15-19	21
PMTCT_STAT_TA	By new positives: 20-24	29
PMTCT_STAT_TA	By new positives: 25-49	85
PMTCT_STAT_TA	By new positives: 50+	7
PMTCT_STAT_TA	By new negatives: Unknown Age	0
PMTCT_STAT_TA	By new negatives: <10	0
PMTCT_STAT_TA	By new negatives: 10-14	46
PMTCT_STAT_TA	By new negatives: 15-19	136
PMTCT_STAT_TA	By new negatives: 20-24	200
PMTCT_STAT_TA	By new negatives: 25-49	435
PMTCT_STAT_TA	By new negatives: 50+	81
PMTCT_STAT_TA	By Age (Numerator): Unknown Age	0
PMTCT_STAT_TA	By Age (Numerator): <10	0
PMTCT_STAT_TA	By Age (Numerator): 10-14	56
PMTCT_STAT_TA	By Age (Numerator): : 15-19	212
PMTCT_STAT_TA	By Age (Numerator): 20-24	354



PMTCT_STAT_TA	By Age (Numerator): 25-49	711
PMTCT_STAT_TA	By Age (Numerator): 50+	100
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	114,394
HTC_TST_DSD	By Test Result: Positive	10,264
HTC_TST_DSD	Sum of Test Result disaggregates	10,264
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	168
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	34
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	77
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	301
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	168
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	689
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	62
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	236
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49,	21



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	1,022
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	92
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	21
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	84
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	3,669
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	248
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	758
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19,	1,804



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	59
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	6,941
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	233
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	3,889
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	134
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	15,949
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	539
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	5,436
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	413
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	23,685
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	1,856
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown	0



	Age, Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility)Other PITC: <1, Negative	504
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	1,862
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	121
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	9,454
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	98
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	184
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	97
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	69
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	83
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	329
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	44
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	184
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female,	22



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	750
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	114
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	255
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	1,117
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	167
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	17
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	88
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	46
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	754



HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	167
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	153
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	354
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	103
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	1,355
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	396
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	757
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	220
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	3,109
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	907
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	1,078
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	320
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	4,614
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	1,385
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	0



HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	99
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	380
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	88
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Negative	61
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	540
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	71
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	1,013
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	144
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Negative	223
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	2,296
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	322
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	3,365
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	471
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age,	0



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	436
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	53
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	88
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	206
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	783
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	108
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	436
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	64
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	1,801
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	240
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	614
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	99
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	2,667
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	364
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female,	0



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT:	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	61
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	217
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	20
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,008
HTC_TST_TA	By Test Result: Positive	259
HTC_TST_TA	Sum of Test Result disaggregates	259
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	143
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	27
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	69
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19,	0



	Famela Danitiva	
	Female, Positive	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	262
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	142
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	598
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	17
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	204
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	891
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	26
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: Unknown	0



	Age, Male, Negative	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Negative	17
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	74
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	305
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Negative	6
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	10
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	6
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male,	26



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Negative	8
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Negative	38
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	21
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Positive	6



HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	5
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	10
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	40
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	21
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	97
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	21
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Female, Negative	31
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Female, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Male, Negative	138
HTC_TST_TA	Service Delivery Point (Facility) Index: 25-49, Male, Positive	32
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	0



Service Delivery Point (Facility) Index: 50+, Male, Positive	0
Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	0
Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0
Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
Service Delivery Point (Facility) Index: <1, Negative	2
Service Delivery Point (Facility) Index: <1, Positive	0
Service Delivery Point (Facility) Index: 1-9, Negative	10
Service Delivery Point (Facility) Index: 1-9, Positive	1
Service Delivery Point (Facility) ANC: <1, Negative	0
Service Delivery Point (Facility) ANC: <1, Positive	0
Service Delivery Point (Facility) ANC: 10-14, Negative	17
Service Delivery Point (Facility) ANC: 10-14, Positive	1
Service Delivery Point (Facility) ANC: 15-19, Negative	31
Service Delivery Point (Facility) ANC: 15-19, Positive	5
Service Delivery Point (Facility) ANC: 1-9, Negative	7
Service Delivery Point (Facility) ANC: 1-9, Positive	0
Service Delivery Point (Facility) ANC: 20-24, Negative	78
Service Delivery Point (Facility) ANC: 20-24, Positive	10
Service Delivery Point (Facility) ANC: 25-49, Negative	118
Service Delivery Point (Facility) ANC: 25-49, Positive	15
Service Delivery Point (Facility) ANC: 50+, Negative	2
Service Delivery Point (Facility) ANC: 50+, Positive	0
Service Delivery Point (Facility) ANC: Unknown Age, Negative	0
Service Delivery Point (Facility) ANC: Unknown Age, Positive	0
Service Delivery Point (Facility) VCT: 10-14, Female,	15
	Positive Service Delivery Point (Facility) Index: Unknown Age, Female, Negative Service Delivery Point (Facility) Index: Unknown Age, Female, Positive Service Delivery Point (Facility) Index: Unknown Age, Male, Negative Service Delivery Point (Facility) Index: Unknown Age, Male, Positive Service Delivery Point (Facility) Index: <1, Negative Service Delivery Point (Facility) Index: <1, Positive Service Delivery Point (Facility) Index: 1-9, Negative Service Delivery Point (Facility) Index: 1-9, Positive Service Delivery Point (Facility) ANC: <1, Negative Service Delivery Point (Facility) ANC: <1, Negative Service Delivery Point (Facility) ANC: 10-14, Negative Service Delivery Point (Facility) ANC: 10-14, Positive Service Delivery Point (Facility) ANC: 15-19, Negative Service Delivery Point (Facility) ANC: 15-19, Negative Service Delivery Point (Facility) ANC: 1-9, Negative Service Delivery Point (Facility) ANC: 1-9, Positive Service Delivery Point (Facility) ANC: 20-24, Negative Service Delivery Point (Facility) ANC: 20-24, Negative Service Delivery Point (Facility) ANC: 25-49, Negative Service Delivery Point (Facility) ANC: 25-49, Negative Service Delivery Point (Facility) ANC: 25-49, Positive Service Delivery Point (Facility) ANC: 50+, Negative Service Delivery Point (Facility) ANC: 50+, Negative Service Delivery Point (Facility) ANC: Unknown Age, Negative Service Delivery Point (Facility) ANC: Unknown Age, Positive



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	7
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	27
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	15
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	69
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	21
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	18
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	106
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	13
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female,	0



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Negative	7
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Positive	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,664
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,714
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	32
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	910
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	40
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	682
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total	32



	<u> </u>	
	number of registered new and relapsed TB cases,	
	during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	938
	during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	41
	during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	703
	during the reporting period)	
TB_STAT_TA	Number of registered new and relapsed TB cases with	24
IB_STAT_TA	documented HIV status, during the reporting period.	24
TD CTAT TA	Total number of registered new and relapsed TB cases,	24
TB_STAT_TA	during the reporting period.	24
	Aggregated Age/Sex: Female <15 (Denominator: Total	
TB_STAT_TA	number of registered new and relapsed TB cases,	0
	during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: Total	
TB_STAT_TA	number of registered new and relapsed TB cases,	0
	during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: Total	
TB_STAT_TA	number of registered new and relapsed TB cases,	5
	during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total	
TB_STAT_TA	number of registered new and relapsed TB cases,	19
	during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of	
TB_STAT_TA	registered new and relapsed TB cases with	0
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Numerator: Number of	
TB_STAT_TA	registered new and relapsed TB cases with	19
	documented HIV status, during the reporting period)	
TR STAT TA	Aggregated Age/Sex: Female <15 (Numerator: Number	0
TB_STAT_TA	of registered new and relapsed TB cases with	<u> </u>
	or registered flow and relapsed 10 cases with	



	1	
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: Number	
TB_STAT_TA	of registered new and relapsed TB cases with	5
	documented HIV status, during the reporting period)	
GEND_GBV_DSD	Number of people receiving post-GBV care	1,905
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,422
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	478
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	427
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	60
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	13
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	9
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	147
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	52
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	18
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	5
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	206
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	70
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	4
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	678
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	240
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	226
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	76
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	47
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	9
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	12
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	1
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	0



GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	Number of people receiving post-GBV care	843
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	631
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	209
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	186
GEND_GBV_TA	<10, Female, Physical and/or Emotional Violence	24
GEND_GBV_TA	<10, Female, Sexual Violence (Post-Rape Care)	4
GEND_GBV_TA	<10, Male, Physical and/or Emotional Violence	2
GEND_GBV_TA	<10, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	10-14, Female, Physical and/or Emotional Violence	60
GEND_GBV_TA	10-14, Female, Sexual Violence (Post-Rape Care)	22
GEND_GBV_TA	10-14, Male, Physical and/or Emotional Violence	8
GEND_GBV_TA	10-14, Male, Sexual Violence (Post-Rape Care)	2
GEND_GBV_TA	15-19, Female, Physical and/or Emotional Violence	85
GEND_GBV_TA	15-19, Female, Sexual Violence (Post-Rape Care)	29
GEND_GBV_TA	15-19, Male, Physical and/or Emotional Violence	0
GEND_GBV_TA	15-19, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	20-24, Female, Physical and/or Emotional Violence	293
GEND_GBV_TA	20-24, Female, Sexual Violence (Post-Rape Care)	106
GEND_GBV_TA	20-24, Male, Physical and/or Emotional Violence	100
GEND_GBV_TA	20-24, Male, Sexual Violence (Post-Rape Care)	31
GEND_GBV_TA	25-49, Female, Physical and/or Emotional Violence	16



GEND_GBV_TA	25-49, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_TA	25-49, Male, Physical and/or Emotional Violence	2
GEND_GBV_TA	25-49, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	50+, Female, Physical and/or Emotional Violence	0
GEND_GBV_TA	50+, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	50+, Male, Physical and/or Emotional Violence	0
GEND_GBV_TA	50+, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	Unknown Age, Female, Physical and/or Emotional Violence	0
GEND_GBV_TA	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	Unknown Age, Male, Physical and/or Emotional Violence	0
GEND_GBV_TA	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,391
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,391
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	11
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	772
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	18
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The	590



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	
	TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	5
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	774
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	18
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	594
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	11
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	11
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	8
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with	0



	1	
	documented HIV-positive status who are on ART during	
	TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_TA	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	0
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	8
TB_ART_TA	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	0
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	3
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	3,144
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	91
PMTCT_EID_DSD	Unknown, <= 2 months	140
PMTCT_EID_DSD	Unknown, 2 - 12 months	8
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	2,608
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	9
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	288
	1	344



	12 months of hirth during the reporting period	
DMTCT FID TA	12 months of birth during the reporting period	47
PMTCT_EID_TA	Unknown, <= 2 months	17
PMTCT_EID_TA	Unknown, 2 - 12 months	0
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	10
PMTCT_EID_TA	Number of infants with a negative virological test result within 2 months of birth	283
PMTCT_EID_TA	Number of infants with a positive virological test result between 2 and 12 months of birth	0
PMTCT_EID_TA	Number of infants with a negative virological test result between 2 and 12 months of birth	34
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	68,675
TX_CURR_DSD	Age/Sex: 15-19 Male	247
TX_CURR_DSD	Age/Sex: 15-19 Female	1,774
TX_CURR_DSD	Sum of age/sex disaggregates	2,021
TX_CURR_DSD	Age/Sex: <1	627
TX_CURR_DSD	Age/Sex: <1-9	2,329
TX_CURR_DSD	Age/Sex: 10-14 Male	449
TX_CURR_DSD	Age/Sex: 10-14 Female	556
TX_CURR_DSD	Age/Sex: 20-24 Male	780
TX_CURR_DSD	Age/Sex: 25-49 Male	16,675
TX_CURR_DSD	Age/Sex: 50+ Male	3,304
TX_CURR_DSD	Age/Sex: 20-24 Female	7,149
TX_CURR_DSD	Age/Sex: 25-49 Female	32,048
TX_CURR_DSD	Age/Sex: 50+ Female	2,737
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	2,119
TX_CURR_TA	Age/Sex: 15-19 Male	19
TX_CURR_TA	Age/Sex: 15-19 Female	48
TX_CURR_TA	Sum of Age/Sex disaggregations	67
TX_CURR_TA	Age/Sex: <1	37
TX_CURR_TA	Age/Sex: 1-9	180



TX_CURR_TA	Age/Sex: 10-14 Male	68
TX_CURR_TA	Age/Sex: 10-14 Female	52
TX_CURR_TA	Age/Sex: 20-24 Male	25
TX_CURR_TA	Age/Sex: 25-49 Male	592
TX_CURR_TA	Age/Sex: 50+ Male	88
TX_CURR_TA	Age/Sex: 20-24 Female	150
TX_CURR_TA	Age/Sex: 25-49 Female	818
TX_CURR_TA	Age/Sex: 50+ Female	42
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	11,798
TX_NEW_DSD	By Age/Sex: <1	102
TX_NEW_DSD	By Age/Sex: 1-9	206
TX_NEW_DSD	By Age/Sex: 10-14 Male	431
TX_NEW_DSD	By Age/Sex: 15-19 Male	929
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,966
TX_NEW_DSD	By Age/Sex: 25-49 Male	5,151
TX_NEW_DSD	By Age/Sex: 50+ Male	480
TX_NEW_DSD	By Age/Sex: 10-14 Female	357
TX_NEW_DSD	By Age/Sex: 15-19 Female	285
TX_NEW_DSD	By Age/Sex: 20-24 Female	0
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,703
TX_NEW_DSD	By Age/Sex: 50+ Female	188
TX_NEW_DSD	Sum of Age/Sex disaggregates	11,490
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	266
TX_NEW_TA	By Age/Sex: <1	1
TX_NEW_TA	By Age/Sex: 1-9	6
TX_NEW_TA	By Age/Sex: 10-14 Male	17
TX_NEW_TA	By Age/Sex: 15-19 Male	26
TX_NEW_TA	By Age/Sex: 20-24 Male	67
TX_NEW_TA	By Age/Sex: 25-49 Male	95
TX_NEW_TA	By Age/Sex: 50+ Male	0



TX_NEW_TA	By Age/Sex: 10-14 Female	15
TX_NEW_TA	By Age/Sex: 15-19 Female	7
TX_NEW_TA	By Age/Sex: 20-24 Female	0
TX_NEW_TA	By Age/Sex: 25-49 Female	32
TX_NEW_TA	By Age/Sex: 50+ Female	0
TX_NEW_TA	Sum of Age/Sex disaggregates	259
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	58,986
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	65,535
TX_PVLS_DSD	Numerator: Indication: Routine	58,986
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	1,604
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	18,101
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	1,834
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	37,447
TX_PVLS_DSD	Denominator: Indication: Routine	65,535
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,782
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	20,110
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,038
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	41,605
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting	4,740



	laboratory results within the past 12 months.	
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	5,259
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	208
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	226
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	2,847
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	1,459
TX_PVLS_TA	Numerator: Indication: Routine	4,740
TX_PVLS_TA	Denominator: Indication: Routine	5,259
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	230
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	248
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	3,161
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	1,620
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	7,951
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	8,362
TX_RET_DSD	Numerator by Status: Pregnant	0
TX_RET_DSD	Numerator by Status: Breastfeeding	0
TX_RET_DSD	Denominator by Status: Pregnant	0
TX_RET_DSD	Denominator by Status: Breastfeeding	0
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment	174



	at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,245
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	225
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,307
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	178
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,362
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	229
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,593
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	306
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	323



	stopped ART, and those lost to follow-up	
TX_RET_TA	Numerator by Status: Pregnant	0
TX_RET_TA	Numerator by Status: Breastfeeding	0
TX_RET_TA	Denominator by Status: Pregnant	0
TX_RET_TA	Denominator by Status: Breastfeeding	0
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	137
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	150
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	145
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	168



	<u> </u>	
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
	The number of ART patients who completed a course	
TB_PREV_DSD	of TB preventive therapy or at least 6 months of	55,466
	Isoniazid Preventive Therapy (IPT) during the reporting	,
	period	
	The number of ART patients who were newly started on	
	TB preventive therapy (including those who newly	
TD DD51/ D05	started on TB preventive therapy in this reporting period	
TB_PREV_DSD	and those who started in the previous reporting period	65,250
	but had not been reported as they did not fulfill the	
	minimum requirements for the previous reporting	
TD DDEV DCD	period).	2.020
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	2,029
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	1,739
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	41,525
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	19,957
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	58,720
TB_PREV_DSD	By Therapy type (Denominator): Alternative Regimen	3,265
TB_PREV_DSD	By Therapy type (Denominator): Continuous IPT	3,265
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	1,725
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	1,479
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	35,299
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	16,963
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	49,912
TB_PREV_DSD	By Therapy type (Numerator): Alternative Regimen	2,777
TB_PREV_DSD	By Therapy type (Numerator): Continuous IPT	2,777
	The number of ART patients who completed a course	
TD DDEV TA	of TB preventive therapy or at least 6 months of	4.740
TB_PREV_TA	Isoniazid Preventive Therapy (IPT) during the reporting	1,716
	period	
	The number of ART patients who were newly started on	
TB_PREV_TA	TB preventive therapy (including those who newly	2,016
	started on TB preventive therapy in this reporting period	



	and those who started in the previous reporting period	
	but had not been reported as they did not fulfill the	
	minimum requirements for the previous reporting	
	period).	
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	136
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	188
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	1,007
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	685
TB_PREV_TA	By Therapy type (Denominator): 6-12 Month IPT	1,812
TB_PREV_TA	By Therapy type (Denominator):Alternative Regimen	102
TB_PREV_TA	By Therapy type (Denominator):Continuous IPT	102
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	116
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	162
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	856
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	582
TB_PREV_TA	By Therapy type (Numerator): 6-12 Month IPT	1,548
TB_PREV_TA	By Therapy type (Numerator): Alternative Regimen	84
TB_PREV_TA	By Therapy type (Numerator): Continuous IPT	84
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	1,245
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	65,250
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	40
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	33
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	787
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	385
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	2,029
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	1,739
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	41,525
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	19,957
TX_TB_DSD	Denominator: By Screen Result: Negative	58,723
TX_TB_DSD	Denominator: By Screen Result: Positive	6,527



TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	6,527
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	0
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	0
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	6,527
TX_TB_TA	Number of ART patients who were started on TB treatment during the reporting period.	38
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	2,016
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Female	4
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Male	4
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Female	17
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Male	13
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	136
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	188
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	1,007
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	685
TX_TB_TA	Denominator: By Screen Result: Negative	1,816
TX_TB_TA	Denominator: By Screen Result: Positive	200
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	200
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	0
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	0
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	200



Mechanism ID: 17965	Mechanism Name: 4Children	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Catholic Relief Services		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 234,933	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 234,933			
Funding Source	Funding Amount		
GHP-State	234,933		

Gender: GBV	211,439
Focus Area:	GBV Prevention
Sub Area:	Implementation

Mechanism ID: Mechanism Name: Prime Partner Name:		.	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	234,933	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	HVSI	0	0



Systems			
---------	--	--	--

Indicator Number	Label	2018
	Number of active beneficiaries served by PEPFAR	
OVC_SERV_DSD	OVC programs for children and families affected by	3,040
	HIV/AIDS	
OVC_SERV_DSD	Age/Sex: 10-14 Male	819
OVC_SERV_DSD	Age/Sex: 15-17 Male	434
OVC_SERV_DSD	Age/Sex: 10-14 Female	846
OVC_SERV_DSD	Age/Sex: 15-17 Female	527
OVC_SERV_DSD	Sum of Age/Sex disaggregates	2,626
OVC_SERV_DSD	Age/Sex: <1	28
OVC_SERV_DSD	Age/Sex: 1-9	386
OVC_SERV_DSD	Program Completion: Active	3,040

	Mechanism Name: Support for International Family Planning and Health Organization 2 (SIFPO 2)	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Population Services Internation	nal	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 1,928,828	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 422,737		
Total All Funding Sources and Applied Pipeline Amount: 2,351,565		
Funding Source	Funding Amount	



GHP-State	1,577,116
GHP-USAID	351,712

(No data provided.)

Budget Code Information

Mechanism ID: Mechanism Name:	Support for International Family Planning and Health Organization 2 (SIFPO 2)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	320,343	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	594,572	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	1,006,079	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	7,834	0

Indicator Number	Label	2018
PP PREV DSD	Number of the target population who completed a	9,949
FF_FKLV_D3D	standardized HIV prevention intervention including the	9,949



	minimum components during the reporting period.	
PP_PREV_DSD	Age/sex: 10-14 Male	0
PP_PREV_DSD	Age/sex: 15-19 Male	0
PP_PREV_DSD	Age/sex: 20-24 Male	0
PP_PREV_DSD	Age/sex: 25-49 Male	0
PP_PREV_DSD	Age/sex: 50+ Male	0
PP_PREV_DSD	Age/sex: 10-14 Female	0
PP_PREV_DSD	Age/sex: 15-19 Female	3,627
PP_PREV_DSD	Age/sex: 20-24 Female	3,676
PP_PREV_DSD	Age/sex: 25-49 Female	2,646
PP_PREV_DSD	Age/sex: 50+ Female	0
PP_PREV_DSD	Sum of Age/Sex disaggregates	9,949
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	5,363
HTC_TST_DSD	By Test Result: Positive	322
HTC_TST_DSD	Sum of Test Result disaggregates	322
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	2,113
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	135
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	2,485
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	161
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	443
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	26

Mechanism ID: 17967	Mechanism Name: Comprehensive Mobile	
Mechanism ib. 17907	Clinical and Prevention Services (CMCPS)	l



Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: The Luke Commission		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 2,188,588	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 2,188,588		
Funding Source Funding Amount		
GHP-State	2,188,588	

(No data provided.)

Machaniam ID.	Mackaniam ID: 47007		
Mechanism ID:	17967		
Mechanism Name:	Comprehensive Mobile Clinical and Prevention Services (CMCPS)		
Prime Partner Name:	The Luke Commission		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	282,583	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	23,098	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	5,354	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HLAB	6,946	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	21,350	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	472,778	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	170,822	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	754,130	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	444,388	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	7,139	0

Indicator Number	Label	2018
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	2,426
VMMC_CIRC_DSD	By Age: 10-14	800
VMMC_CIRC_DSD	By Age: 15-19	874
VMMC_CIRC_DSD	By Age: 20-24	437
VMMC_CIRC_DSD	By Age: 25-29	145



VMMC_CIRC_DSD	By Age: 30-49	90
VMMC_CIRC_DSD	By Age: 50+	80
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	2,191
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	2,426
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	2,426
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	14,583
PP_PREV_DSD	Age/sex: 10-14 Male	200
PP_PREV_DSD	Age/sex: 15-19 Male	1,000
PP_PREV_DSD	Age/sex: 20-24 Male	1,800
PP_PREV_DSD	Age/sex: 25-49 Male	2,200
PP_PREV_DSD	Age/sex: 50+ Male	200
PP_PREV_DSD	Age/sex: 10-14 Female	200
PP_PREV_DSD	Age/sex: 15-19 Female	5,200
PP_PREV_DSD	Age/sex: 20-24 Female	1,800
PP_PREV_DSD	Age/sex: 25-49 Female	1,783
PP_PREV_DSD	Age/sex: 50+ Female	200
PP_PREV_DSD	Sum of Age/Sex disaggregates	14,583
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	7,129
HTC_TST_DSD	By Test Result: Positive	309
HTC_TST_DSD	Sum of Test Result disaggregates	309
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Negative	194
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Positive	10
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Male, Negative	98
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Male, Positive	5
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile	4,756



	Testing: 15+, Female, Negative	
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Positive	220
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Negative	1,772
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Positive	74
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Male, Negative	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	149
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	12
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	35
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	13
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	89
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	25



TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	124
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	149
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	120
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	8
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	31
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	8
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	73
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	120
TX_NEW_DSD	Pregnancy status	5
TX_NEW_DSD	Breastfeeding status	10

Mechanism ID: 17972	Mechanism Name: Measure Evaluation Phase IV	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: University of North Carolina at Chapel Hill, Carolina Population Center		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 250,000	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 250,000		
Funding Source Funding Amount		
GHP-State	250,000	

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Budget Code Information				
Mechanism ID:	17972			
Mechanism Name:	Measure Evaluation Phase IV			
Prime Partner Name:	University of North Card	University of North Carolina at Chapel Hill, Carolina Population Center		
Strategic Area	Budget Code Planned Amount On Hold Amount			
Governance and Systems	HVSI	200,000	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	OHSS	50,000	0	

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18169	TBD: Yes
REDA	CTED

Mechanism ID: 18250	Mechanism Name: WHO/AFRO Disease Control	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: WHO/AFRO		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 250,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 250,000	
Funding Source Funding Amount	
GHP-State	250,000

(No data provided.)

Budget Code Information

Baaget Geae IIII eiii			
Mechanism ID:	18250		
Mechanism Name:	WHO/AFRO Disease Control		
Prime Partner Name:	WHO/AFRO		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	250,000	0

Indicator Number	Label	2018
	Number of new HCW who graduated from a pre-service	
HRH PRE	training institution or program as a result of	414
HKH_FKE	PEPFAR-supported strengthening efforts, within the	414
	reporting period, by select cadre	
HRH_PRE	By Graduates: Doctors	0
HRH_PRE	By Graduates: Nurses	267
HRH_PRE	By Graduates: Midwives	9
HRH_PRE	By Graduates: Social service workers	0
HRH_PRE	By Graduates: Laboratory professionals	46
HRH_PRE	By Graduates: Other	92



HRH_PRE	Sum of Graduates disaggreagtes	414
---------	--------------------------------	-----

Mechanism ID: 18272	TBD: Yes
REDA	CTED

Implementing Mechanism Details

Mechanism ID: 18329	Mechanism Name: Strengthening Health Information Systems (SHIS)	
	Procurement Type: Cooperative Agreement	
Prime Partner Name: Institute for Health Measurement		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 1,763,500	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 1,763,500		
Funding Source Funding Amount		
GHP-State	1,763,500	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID:	18329
Mechanism Name:	Strengthening Health Information Systems (SHIS)
Prime Partner Name:	Institute for Health Measurement



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	1,048,250	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	715,250	0

(No data provided.)

Implementing Mechanism Details

implementing mechanism betans		
Mechanism ID: 18331	Mechanism Name: Global Health Supply Chain - Procurement and Supply Chain Management (GHSC-PSM)	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Global Health Supply Chain Program		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 6,121,278	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 532		
Total All Funding Sources and Applied Pipeline Amount: 6,121,810		
Funding Source	Funding Amount	
GHP-State	6,121,278	

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: Mechanism Name:	18331 Global Health Supply Chain - Procurement and Supply Chain Management (GHSC-PSM)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	440,468	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	175,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	5,505,810	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 18387	Mechanism Name: FHI 360 Linkages for Care	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: FHI 360		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 2,047,187	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 2,047,187		
Funding Source	Funding Amount	
GHP-State	2,047,187	



(No data provided.)

Budget Code Information			
Mechanism ID: Mechanism Name: Prime Partner Name:	FHI 360 Linkages for Ca	ıre	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	486,608	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	350,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	175,705	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	984,874	0

Indicator Number	Label	2018
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on	1,300



	oral antiretroviral pre-exposure prophylaxis (PrEP) in	
	the reporting period to prevent HIV infection	
PrEP_NEW_DSD	Male 15-19	22
PrEP_NEW_DSD	Male 20-24	66
PrEP_NEW_DSD	Male 25-49	132
PrEP_NEW_DSD	Male 50+	0
PrEP_NEW_DSD	Female 15-19	140
PrEP_NEW_DSD	Female 20-24	282
PrEP_NEW_DSD	Female 25-49	658
PrEP_NEW_DSD	Female 50+	0
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	10,777
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,432
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	7,345
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	3,144
HTC_TST_DSD	By Test Result: Positive	345
HTC_TST_DSD	Sum of Test Result disaggregates	345
HTC_TST_DSD	By Key Population: FSW, Negative	2,061
HTC_TST_DSD	By Key Population: FSW, Positive	267
HTC_TST_DSD	By Key Population: MSM, Negative	899
HTC_TST_DSD	By Key Population: MSM, Positive	119
HTC_TST_DSD	By Key Population: People in prisons and other	0



	enclosed settings, Negative	
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	0
HTC_TST_DSD	By Key Population: PWID, Negative	0
HTC_TST_DSD	By Key Population: PWID, Positive	0
HTC_TST_DSD	By Key Population: TG, Negative	0
HTC_TST_DSD	By Key Population: TG, Positive	0

implementing incondition. Detaile				
Mechanism ID: 18598	Mechanism Name: Project SOAR			
Funding Agency: USAID	Procurement Type: Cooperative Agreement			
Prime Partner Name: Population Council				
Agreement Start Date: Redacted	Agreement End Date: Redacted			
TBD: No	New Mechanism: Yes			
Global Fund / Multilateral Engagement: N/A				
G2G: No	Managing Agency:			

Total All Funding Sources: 250,000 Total Mechanism Pipeline: N/A					
Applied Pipeline Amount: 0					
Total All Funding Sources and Applied Pipeline Amount: 250,000					
Funding Source Funding Amount					
GHP-State	250,000				

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID:	18598
Mechanism Name:	Project SOAR
Prime Partner Name:	Population Council



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	250,000	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18599	TBD: Yes	
	REDACTED	

Implementing Mechanism Details

Mechanism ID: 18600	TBD: Yes
REDA	CTED

Implementing Mechanism Details

Mechanism ID: 18601	TBD: Yes
REDA	CTED

Mechanism ID: 18602	TBD: Yes
RE	DACTED



Agency Information - Costs of Doing Business

U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Capital Security Cost Sharing			135,718	135,718	0	135,718
Computers/IT Services			51,236	51,236	0	51,236
ICASS			595,404	595,404	0	595,404
Institutional Contractors			250,000	250,000	0	250,000
Management Meetings/Profes sional Development			33,532	33,532	0	33,532
Non-ICASS Administrative Costs			149,891	149,891	0	149,891
Staff Program Travel			20,738	20,738	0	20,738
USG Staff Salaries and Benefits - Internationally Recruited				0	0	O
USG Staff Salaries and Benefits -			1,555,703	1,555,703	456,387	2,012,090



Locally						
Recruited						
Total	0	0	2,792,222	2,792,222	456,387	3,248,609

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		0		0	3,500	3,500
ICASS		0		0	46,000	46,000
Management Meetings/Profes sional Development		0		0	8,000	8,000
Non-ICASS Administrative Costs		0		0	433	433
Staff Program Travel				0	19,000	19,000
USG Staff Salaries and Benefits - Locally Recruited				0	70,479	70,479
Total	0	0	0	0	147,412	147,412

U.S. Department of Health and Human Services/Centers for Disease Control and



Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Capital Security Cost Sharing		118,983		118,983	105,789	224,772
Computers/IT Services		31,761		31,761	28,239	60,000
ICASS		243,500		243,500	216,500	460,000
Institutional Contractors		99,168		99,168	88,172	187,340
Management Meetings/Profes sional Development		10,322		10,322	9,178	19,500
Non-ICASS Administrative Costs		12,870		12,870	11,443	24,313
Staff Program Travel		63,446		63,446	56,411	119,857
USG Staff Salaries and Benefits - Internationally Recruited	487,500	21,821		509,321	452,846	962,167
USG Staff Salaries and Benefits - Locally Recruited		351,515		351,515	312,536	664,051
Total	487,500	953,386	0	1,440,886	1,281,114	2,722,000



U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Capital Security Cost Sharing		132,700		132,700	0	132,700
ICASS		154,671		154,671	0	154,671
Management Meetings/Profes sional Development		9,482		9,482	1,518	11,000
Non-ICASS Administrative Costs		16,420		16,420	0	16,420
Staff Program Travel		49,681		49,681	14,436	64,117
USG Staff Salaries and Benefits - Internationally Recruited		3,436		3,436	0	3,436
USG Staff Salaries and Benefits - Locally Recruited		403,252		403,252	253,514	656,766
Total	0	769,642	0	769,642	269,468	1,039,110

U.S. Peace Corps



Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
ICASS		127,278		127,278	0	127,278
Peace Corps Volunteer Costs		677,479		677,479	0	677,479
Staff Program Travel		2,165		2,165	0	2,165
USG Staff Salaries and Benefits - Internationally Recruited				0	0	0
USG Staff Salaries and Benefits - Locally Recruited		238,078		238,078	0	238,078
Total	0	1,045,000	0	1,045,000	0	1,045,000